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Abstract 
This thesis is divided into four chapters presenting distinct research projects that address 
challenges in the fields of functional systems chemistry, chemical biology, and the total 
synthesis of natural products. Experimental details, analytical data and appendices are enclosed 
at the end of this work. 
Chapter 1 introduces the concept of electron-poor catechols as surface binding agents and 
highlights some of the natural role models. The development of a synthetic surface modification 
platform for the controlled release of small molecules is described. Nitrocatechol-based 
anchoring units allowed for the immobilization of a molecular cargo on titanium dioxide 
surfaces and cleavage on demand by UV irradiation. 
 
Chapter 2 expands the application of small catechol binders. The design and synthesis of new 
polar derivatives facilitated the use of boronate esters in dynamic functional systems and led to 
the discovery of the third orthogonal dynamic covalent bond. 
Chapter 3 reports on the preparation of biochemical probes for the investigation of the cellular 
target of rapamycin. An efficient assembly of natural product hybrids from rapamycin was 
achieved without the need for protection of the macrolide. The antiproliferative activity of the 
parent compound was shown to be largely conserved in the novel substances. 
Chapter 4 provides a detailed review of the literature on Securinega alkaloids. The first 
enantioselective total synthesis of secu’amamine E was accomplished in twelve linear synthetic 
steps and 8.5% overall yield. Three examples of an intriguing rearrangement process were 
studied allowing for the direct interconversion of natural products with implications for a new 
biogenetic hypothesis. 
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1 Nitrocatechols for Light-Induced Small Molecule Release 
1.1 Introduction 
1.1.1 Catechols in Nature 
Catechols are ortho-dihydroxyaryl compounds serving a variety of different functions in nature. 
Already from the structure itself a chemist can augur the broad range of catechol chemistry. 
The two vicinal hydroxyl groups may serve as weak acid or be oxidized to a highly reactive 
ortho-quinone. They could engage in hydrogen bonding or act as bidentate ligand for 
coordination chemistry. 
 
Scheme 1: Biogenesis of catecholamine neurotransmitters. 
A prominent example from nature are the catecholamine neurotransmitters, tightly regulated 
signaling molecules within neural networks (Scheme 1). Dopamine (2) is enzymatically derived 
from L-3,4-dihydroxyphenylalanine (L-DOPA, L-1) by DOPA decarboxylase (DDC). Further 
transformation by dopamine β-hydroxylase (DβH) produces norepinephrine (3), which is 
methylated by phenolethanolamine-N-methyltransferase (PNMT) to epinephrine (4).1 In the 
human brain dopamine (2) is closely linked to rewarding and alerting systems, and it serves 
several other roles in the peripheral nervous system.2 Norepinephrine (3) and epinephrine (4) 
also act as hormones and are released under physical and psychological stress.3 The 
catecholamines exhibit their high activities via two G protein-coupled receptors, the adrenergic 
and dopamine receptors.4 Narcotic drugs like amphetamines also act partially via these 
receptors and their strong acute effects as well as the high addiction potential 
(methamphetamine) arise from their interference with catecholamine neurotransmitter 
metabolism in the brain.5  
                                                 
1 G. Eisenhofer, I. J. Kopin, D. S. Goldstein, Pharmacol. Rev. 2004, 56, 331–349. 
2 E. S. Bromberg-Martin, M. Matsumoto, O. Hikosaka, Neuron 2010, 68, 815–834. 
3 D. L. Wong, Cell. Mol. Neurobiol. 2006, 26, 891–900. 
4 O.-E. Brodde, H. Bruck, K. Leineweber, J. Pharmacol. Sci. 2006, 100, 323–337. 
5 D. Sulzer, M. S. Sonders, N. W. Poulson, A. Galli, Prog. Neurobiol. 2005, 75, 406–433. 
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Scheme 2: Oxidative metabolism of dopamine in the human brain producing neurotoxic dopamine 
derivatives and melanin pigments. 
But also, catecholamines themselves are attributed with neurotoxic effects and play a role in 
the development of neurodegenerative diseases, especially in the Parkinson’s disease. While 
dopamine (2), norepinephrine (3) and epinephrine (4) are usually metabolized enzymatically 
by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO), autoxidation of 
dopamine (2) leads to reactive dopamine quinone (5, Scheme 2), which is transformed to 
neurotoxic compounds like 5-S-cysteinyl-dopamine (6) or aminochrome (7).6 Spontaneous 
cyclization and oxidation of dopamine quinone (5) lead to aminochrome (7), which by 
tautomerization (8) and cross-linking of aryl moieties, produces melanin (poly-5,6-
dihydroxyindole, 9–11). Increased formation of neuromelanin pigments together with largely 
reduced amounts of dopamine (2) producing cells has been observed in patients suffering from 
Parkinson’s disease. 
                                                 
6 (a) J. Smythies, L. Galzigna, Biochim. Biophys. Acta 1998, 1380, 159–162; (b) C. Aureli, T. Cassano, 
A. Masci, A. Francioso, S. Martire, A. Cocciolo, S. Chichiarelli, A. Romano, S. Gaetani, P. Mancini, 
M. Fontana, M. d’Erme, L. Mosca, J. Neurosci. Res. 2014, 92, 347–358. 
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Figure 1: Examples of bacterial catechol-containing siderophores and their natural sources. 
Another example of natural catechols are siderophores, iron chelators produced by bacteria, 
fungi and plants. In the extracellular environment, these compounds bind and transport 
inorganic Fe3+ making it bioavailable to the parent organism. Hundreds of siderophores have 
been described in the literature and can be classified by the functional groups complexing the 
ferric ions.7 The siderophores produced by graminaceous plants (phytosiderophores) are usually 
carboxylate siderophores whereas fungi predominantly possess hydroxamate siderophores. The 
largest structural variety is found in bacteria, which, in addition to the afore mentioned, also 
synthesize catecholate siderophores (12–15, Figure 1). Siderophores are only produced and 
secreted under iron starvation conditions to supply the organism with iron from mineral sources. 
Ferric ions are complexed and transported to the membrane where specific receptors recognize 
these complexes and transport them into the cell. Transport of the ferric siderophore complexes 
has been studied to a great extend in Gram-negative bacteria where several homologous TonB-
dependent transporters consisting of 22-stranded transmembrane β barrels have been 
characterized.8 To release the ions, the siderophores are either degraded, or the ferric ions are 
                                                 
7 For general reviews on siderophores, see: (a) H. Drechsel, G. Jung, J. Peptide Sci. 1998, 4, 147–181; 
(b) R. C. Hider, X. Kong, Nat. Prod. Rep. 2010, 27, 637–657. 
8 (a) K. P. Locher, B. Rees, R. Koebnik, A. Mitschler, L. Moulinier, J. P. Rosenbusch, D. Moras, Cell 
1998, 95, 771–778; (b) A. D. Ferguson, E. Hofmann, J. W. Coulton, K. Diederichs, W. Welte, Science 
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reduced to ferrous ions with decreased affinity to the complexing ligand. Many siderophores 
contain peptide building blocks which are synthesized non-ribosomally and the biosyntheses of 
enterobactin (12),9 pyoverdine D (14)10 and others11 have been reported. Their structures can 
be very diverse, containing alkaloid and polyketide fragments as exemplified by the structure 
of anachelin (13).12 
 
Figure 2: Blue mussels, Mytilus edulis, on a rock in Cornwall, UK (left)13 and a drawing of M. edulis 
by Julius Fürst indicating the byssus’ filaments and plaque tips (around 1895, right).14 
The ability to efficiently complex ions and coordinate to solid surfaces is existential for the 
mussels of the genus Mytilus. These bivalve mollusks live stationary in the intertidal zones of 
ocean shores. To brave the constant waves in their habitat, mussels adhere permanently to 
virtually any surface found in the marine environment. Adhesion is accomplished under wet 
conditions by a bundle of filaments reaching out radially. The filaments carry adhesive plaques 
at the tips, which bind to the foreign surface. The plaques secrete a proteinaceous gel, which 
darkens, solidifies, and leads to the strong adhesion. Analyses showed that the secretion 
contains so called mussel foot proteins (Mfps) of which Mfp-3 and Mfp-5 contain up to 
                                                 
1998, 282, 2215–2220; (c) S. K. Buchanan, B. S. Smith, L. Venkatramani, D. Xia, L. Esser, M. Palnitkar, 
R. Chakraborty, D. van der Helm, J. Deisenhofer, Nat. Struct. Biol. 1999, 6, 56–63; (d) D. Cobessi, H. 
Celia, F. Pattus, J. Mol. Biol. 2005, 352, 893–904. 
9 D. P. Frueh, H. Arthanari, A. Koglin, D. A. Vosburg, A. E. Bennett, C. T. Walsh, G. Wagner, Nature 
2008, 454, 903–907. 
10 (a) P. Visca, F. Imperi, I. L. Lamont, Trends Microbiol. 2007, 15, 22–30; (b) I. J. Schalk, L. Guillon, 
Environ. Microbiol. 2013, 15, 1661–1673. 
11 (a) J. J. De Voss, K. Rutter, B. G. Schroeder, C. E. Barry III, J. Bacteriol. 1990, 181, 4443–4451; (b) 
L. E. N. Quadri, Mol. Microbiol. 2000, 37, 1–12. 
12 (a) Y. Itou, S. Okada, M. Murakami, Tetrahedron 2001, 57, 9093–9099; (b) Y. Ito, K. Ishida, S. 
Okada, M. Murakami, Tetrahedron 2004, 60, 9075–9080. 
13 https://commons.wikimedia.org/wiki/File:Blue_mussel_clump.jpg; public domain. 
14 https://commons.wikimedia.org/wiki/File:Miesmuschel_(Mytilus_edulis).jpg; Julius Fürst, public 
domain. 
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30 mol% of L-DOPA (L-1).15 The complex interplay of the Mfps as well as the influence of 
surrounding factors have not yet been fully understood but many studies have been carried out 
to elucidate those details.16 Attractive interactions between specific Mfps and mineral surfaces 
as well as protein-protein binding interactions have been reported.17 Also, the implementation 
of metal ions (Ca2+, Fe3+) into the protein films can enable adhesion through ion bridging of 
proteins.18 Covalent crosslinking between Mfps proceeds through oxidation of the L-DOPA 
(L-1) residues by seawater or redox exchange with Fe3+.19 The extent of crosslinking remains 
unclear and is thought to be closely regulated as oxidation to the quinone results in a much 
reduced binding affinity to mineral surfaces. These crosslinking events enable the protein film 
to also adhere to organic surfaces by the formation of covalent bonds to surface bound 
nucleophiles. Furthermore, the oxidation of catechol groups as well as the incorporation of 
metal ions at sites of film rupture and defect enable self-healing of the macromolecular network. 
  
                                                 
15 (a) J. H. Waite, X. X. Qin, Biochemistry 2001, 40, 2887–2893; (b) H. Zhao, N. B. Robertson, S. A. 
Jewhurst, J. H. Waite, J. Biol. Chem. 2006, 281, 11090–11096. 
16 Review: B. P. Lee, P. B. Messersmith, J. N. Israelachvili, J. H. Waite, Annu. Rev. Mater. Res. 2011, 
41, 99–132. 
17 Q. Lin, D. Gourdon, C. Sun, N. Holten-Andersen, T. H. Anderson, J. H. Waite, J. N. Israelachvili, 
Proc. Natl. Acad. Sci. USA 2007, 104, 3782–3786. 
18 (a) D. S. Hwang, H. Zeng, A. Masic, M. J. Harrington, J. N. Israelachvili, J. H. Waite, J. Biol. Chem. 
2010, 285, 25850–25858; (b) H. Zeng, D. S. Hwang, J. N. Israelachvili, J. H. Waite, Proc. Natl. Acad. 
Sci. USA 2010, 107, 12850–12853. 
19 (a) L. M. McDowell, L. A. Burzio, J. H. Waite, J. Schaefer, J. Biol. Chem. 1999, 274, 20293–20295; 
(b) M. J. Sever, J. T. Weisser, J. Monahan, S. Srinivasan, J. J. Wilker, Angew. Chem. Int. Ed. 2004, 43, 
448–450. 
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1.1.2 Catecholic Surface Coatings 
 
Figure 3: Schematic representation of designs of polymers with catechol residues. 
Inspired by the outstanding adhesive capabilities of Mfps, scientists have developed a wide 
range of biomimetic molecular architectures primarily for medical and materials science 
applications. Several molecular setups have been designed consisting of a linear or branched 
polymer backbone carrying from a single catechol side-chain to up to ca. 30 mol% catechol 
groups (Figure 3).20 While the first examples of such polymers were relatively simple DOPA 
polypeptides produced via common peptide synthesis,21 the field expanded rapidly. Thus 
adhesive proteins have been produced applying DNA recombination for expression by a 
microbial host22 or copolymerization of N-carboxyanhydride amino acid precursors to obtain 
DOPA/lysine co-polypeptides on gram-scale.23 Also, synthetic polymers have been introduced 
as backbone and photocopolymerization of DOPA N-methacrylate and polyethylene glycol 
(PEG) diacrylate monomers produced adhesive hydrogels.24 A very versatile approach for the 
generation of coatings is the deposition of a polydopamine film on a substrate surface in alkaline 
medium, followed by one of several techniques to further modify the layer including 
metallization, thiol self-assembly, and grafting of polymers onto the polydopamine film.25 The 
                                                 
20 Review: E. Faure, C. Falentin-Daudré, C. Jérôme, J. Lyskawa, D. Fournier, P. Woisel, C. Detrembleur, 
Prog. Polym. Sci. 2013, 38, 236–270. 
21 (a) H. Yamamoto, J. Adhes. Sci. Tecnol. 1987, 1, 177–183; (b) H. Yamamoto, S. Yamauchi, S. Ohara, 
Biomimetics 1992, 1, 219–238; (c) H. Yamamoto, K. Ohkawa, Amino Acids 1993, 5, 71–75. 
22 (a) R. L. Strausberg, D. M. Anderson, D. Filpula, M. Finkelman, R. Link, R. McCandliss, S. A. 
Orndorff, S. L. Strausberg, T. Wei, ACS Symp. Ser. 1989, 385, 453–464; (b) D. R. Filpula, S. M. Lee, 
R. P. Link, S. L. Strausberg, R. L. Strausberg, Biotechnol. Prog. 1990, 6, 171–177. 
23 (a) M. Yu, T. J. Deming, Macromolecules 1998, 31, 4739–4745; (b) M. Yu, J. Hwang, T. J. Deming, 
J. Am. Chem. Soc. 1999, 121, 5825–5826. 
24 B. P. Lee, K. Huang, F. N. Nunalee, K. R. Shull, P. B. Messersmith, J. Biomater. Sci. Polym. Ed. 
2004, 15, 449–464. 
25 H. Lee, S. M. Dellatore, W. M. Miller, P. B. Messersmith, Science 2007, 318, 426–430. 
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formation and structure of the polydopamine film are still under investigation.26 
Mechanistically, the oxidation and cross-linking events are thought to parallel those in the 
formation of eumelanin (cf. 12–15, Scheme 2). Analogous films can be generated using 
norepinephrine (3) as initial monomer and the resulting OH groups on the surface may be used 
for further functionalization by surface-initiated ring-opening polymerization.27 
These catecholic polymers are desirable, especially for applications in the medical and clinical 
area. The ability to effectively bind to a large variety of surfaces under wet conditions makes 
these compounds prime candidates as wound sealants and medical adhesives. In solutions of 
branched and linear DOPA-capped PEG, hydrogel formation can be triggered by the addition 
of an oxidant (e.g. periodate, horseradish peroxidase) and, depending on the nature and 
concentration of the oxidant, can be achieved in only 30 seconds.28 Strong tissue adhesion has 
been reported for different catecholic PEG-based polymers and fine tuning of the polymer 
structure allows for further adjustment of properties such as the hydrogel degradation rate.29 
Studies in mice focusing on the biocompatibility of such polymers showed that the applied non-
degradable wound sealant was in place even one year after implantation with an intact tissue 
interface and healthy surrounding tissues.30 A broad variety of further applications has been 
reported including the generation of antifouling, anticorrosion, and hydrophobic coatings or 
chemo- and biosensing applications.16,31 
  
                                                 
26 (a) V. Ball, D. D. Frari, M. Michel, M. J. Buehler, V. Toniazzo, M. K. Singh, J. Gracio, D. Ruch, 
Bionanoscience 2012, 2, 16–34; (b) J. Yang, M. A. Cohen Stuart, M. Kamperman, Chem. Soc. Rev. 
2014, 43, 8271–8298. 
27 S. M. Kang, J. Rho, I. S. Choi, P. B. Messersmith, H. Lee, J. Am. Chem. Soc. 2009, 131, 13224–
13225. 
28 B. P. Lee, J. L. Dalsin, P. B. Messersmith, Biomacromolecules 2002, 3, 1038–1047. 
29 S. A. Burke, M. Ritter-Jones, B. P. Lee, P. B. Messersmith, Biomed. Mater. 2007, 2, 203–210. 
30 C. E. Brubaker, H. Kissler, L.-J. Wang, D. B. Kaufman, P. B. Messersmith, Biomaterials 2010, 31, 
420–427. 
31 Reviews: (a) M. E. Lynge, R. van der Westen, A. Postma, B. Städler, Nanoscale 2011, 3, 4916–4928; 
(b) Q. Ye, F. Zhou, W. Liu, Chem. Soc. Rev. 2011, 40, 4244–4258; (c) S. Sedó, J. Saiz-Poseu, F. Busqué, 
D. Ruiz-Molina, Adv. Mater. 2013, 25, 653–701; (d) S. Moulay, Polym. Rev. 2014, 54, 436–513. 
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Figure 4: Studies on the anachelin chromophore 16 revealed the influence of an EWG attached to the 
catechol. R = L-Ser. 
Based on the strong iron complexing capabilities of the cyanobacterial siderophore anachelin 
(13), its catecholic chromophore has been developed into a surface anchoring unit (anacat, 16) 
for bare metal oxide substrates (Figure 4).32 Studies on the bis-nor derivative 17 lacking the 
two N-methyl groups revealed that the positively charged ammonium group reduces liability 
towards oxidation of the catechol significantly,33 rendering the anchor 16 suitable for the 
generation of self-assembled monolayers (SAMs). This approach avoids the formation of a 
thick and structurally undefined polymer layer. 
 
Figure 5: A series of catechols tested for their anchoring ability on metal oxide surfaces. Numbers in 
brackets represent the first dissociation constant of the catechol hydroxyl groups, pKa1(OH). 
  
                                                 
32 (a) S. Zürcher, D. Wäckerlin, Y. Bethuel, B. Malisova, M. Textor, S. Tosatti, K. Gademann, J. Am. 
Chem. Soc. 2006, 128, 1064–1065; (b) K. Gademann, J. Kobylinska, J.-Y. Wach, T. M. Woods, 
BioMetals 2009, 22, 595–604. 
33 Y. Bethuel, K. Gademann, J. Org. Chem. 2005, 70, 6258–6264. 
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A series of derived biomimetic anchoring units with varying electron density of their catechol 
moieties has been investigated (Figure 5).34 Besides the protection towards oxidation, the 
electron-withdrawing groups (EWGs) also lead to acidification of the catechol OH groups and 
adlayer thickness and stability were found to increase with decreasing pKa. In particular, 
nitrodopamine (19) proved to be a valuable surface anchor as it can be obtained from 
commercial dopamine (2) by nitration in one synthetic step while possessing excellent surface 
binding properties. The SAMs can be generated by operationally simple dip-and-rinse 
procedures using dilute aqueous solutions of catechol in high-salt buffer. Temperature as well 
as pH can be adjusted to the substrate to achieve optimal surface coverage.34 
 
Scheme 3: Different binding modes of catechol derivatives on a titania surface. 
Investigations concerning the structure of catecholic SAMs on metal oxides, especially TiO2, 
have revealed a number of possible binding modes (Scheme 3).31b,35 After physisorption, the 
catechol is bound only by hydrogen bonds (20). A hydroxyl group from the metal oxide is then 
replaced by the catechol forming a monodentate mononuclear complex 21. This intermediate 
then forms one of three possible complexes: a bidentate mononuclear chelate complex 22, a 
monodentate binuclear complex 23 with an adjacent second surface hydroxyl group displaced 
by the catechol and bridging hydrogen bonds, or a bidentate binuclear complex 24. 
                                                 
34 B. Malisova, S. Tosatti, M. Textor, K. Gademann, S. Zürcher, Langmuir 2010, 26, 4018–4026. 
35 S. P. Pujari, L. Scheres, A. T. M. Marcelis, H. Zuilhof, Angew. Chem. Int. Ed. 2014, 53, 6322–6356. 
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Figure 6: Biomimetic catechol anchoring units attached to mPEG for the generation of protein-
resistant surfaces. 
Catecholic SAMs have been used for the generation of protein-resistant surfaces using different 
anchoring units (such as the series shown in Figure 5) attached to the end of methoxy 
polyethylene glycol (mPEG).32a,34 A similar study focused on the identification of structurally 
analogous anchors, which are easier to produce then the anacat (16) reference compound 
(Figure 6).36 The resulting coatings 25–28 significantly reduced protein adsorption compared 
to bare TiO2 when exposed to human serum. Furthermore, it was shown that a positively 
charged ammonium substituent facilitates PEG adlayer formation, but also easily accessible 
bis-dopamine anchoring units are efficient. 
Building on these results, the passively acting antifouling coatings were interfaced with 
antimicrobial agents to generate active functional surfaces. The clinically used glycopeptide 
antibiotic vancomycin was merged with an anacat-capped PEG unit to generate the natural 
product hybrid 29 (Figure 7).37 In addition to strong metal oxide surface anchoring and 
prevention of the nonspecific adsorption of proteins and cells, hybrid 29 acts as an active 
antimicrobial surface coating agent. Due to the high local concentration of the vancomycin unit 
in proximity to the surface, bacterial growth of Bacillus subtilis was inhibited efficiently and 
the attachment of dead cells to the surface was inhibited by the PEG chains. Activity of the 
coating was retained even after five cycles of incubation with bacteria followed by washing. 
Another class of antimicrobial coating agents was designed to interfere with quorum sensing 
(QS),38 bacterial communication pathways based on small chemical signaling agents 
(autoinducers) dependent on the cell density of a population. QS enables a bacterial population 
                                                 
36 J.-Y. Wach, B. Malisova, S. Bonazzi, S. Tosatti, M. Textor, S. Zürcher, K. Gademann, Chem. Eur. J. 
2008, 14, 10579–10584. 
37 J.-Y. Wach, S. Bonazzi, K. Gademann, Angew. Chem. Int. Ed. 2008, 47, 7123–7126. 
38 J. Gomes, A. Grunau, A. K. Lawrence, L. Eberl, K. Gademann, Chem. Commun. 2013, 49, 155–157. 
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to act as one and regulates various mechanisms such as surface attachment or virulence factor 
production.39 Based on N-acyl-l-homoserine lactone (AHL) autoinducers, the hybrids 30 and 
31 have been developed featuring different catechol anchoring units. Titania beads coated with 
hybrid 31 induced QS in the GFP-based reporter strain Pseudomonas putida F117 proving the 
viability of this approach. Even though dialysis experiments with the coated beads revealed 
leakage of the AHL into the surrounding medium, the beads retained their activity upon 
extensive washing (10 cycles). 
 
Figure 7: Natural product hybrids as surface coating agents to actively combat bacterial colonization. 
  
                                                 
39 Reviews: (a) W.-L. Ng, B. L. Bassler, Annu. Rev. Genet. 2009, 43, 197–222; (b) S. Dobretsov, M. 
Teplitski, V. Paul, Biofouling 2009, 25, 413–427. 
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1.2 A Tractable Surface Release System40 
After nitrodopamine (19) had proved to be a valuable molecular surface anchor with strong 
binding and high surface coverage on solid metal oxide supports, we envisioned further 
development of this unit by adding more functionality. It is quite evident that this anchoring 
moiety contains a nitro-aryl core, which has been utilized in photoremovable protecting groups 
(PPGs) for decades. Structurally the simplest representative of these so-called caging groups is 
the o-nitrobenzyl group, the photo-induced cleavage mechanism of which is shown in Scheme 
4.41 
 
Scheme 4: Photolysis mechanism of the o-nitrobenzyl group. 
Excitation of the 2-nitroaryl compound 32 generates the aci-nitro tautomer 33. Presumably the 
neutral nitronic acid cyclizes irreversibly to benzisoxazoline intermediate 34, which then opens 
up to give hemiacetal 35. Fragmentation of the hemiacetal group releases the cargo molecule 
(ROH) along with 2-nitrosobenzaldehyde (36). Additional substituents on the aromatic ring 
allow for tuning of the excitation wavelength applied during cleavage. Furthermore, 
introduction of a methyl group in the benzylic position enhanced cleavage efficiency by 
facilitating the generation of aci-nitro tautomer 33. Among the most prevalent PPGs used today, 
the o-nitrobenzyl group bears almost the entire nitrodopamine (19) framework in its structure. 
While this structural analogy is promising, removal of the methylene bridge to obtain the 
catechol induces electronic changes and thereby might alter cleavage efficiency of the unit. 
Besides the chemical changes, the whole physical setup, with the catechols being directly 
attached to a solid support and the resulting new physical conditions, could form additional 
obstacles. For instance, it was not clear whether the absorption of light by the aromatic moiety 
within a SAM on top of a solid surface remains as efficient as in typical solution phase. In 
                                                 
40 R. Wehlauch, J. Hoecker, K. Gademann, ChemPlusChem 2012, 77, 1071–1074. 
41 A. P. Pelliccioli, J. Wirz, Photochem. Photobiol. Sci. 2002, 1, 441–458. 
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addition, the most common material used as solid support, titanium(IV) oxide, is photo-active 
itself and is commonly used as a photocatalyst, for example in the detoxification of 
wastewaters.42 
 
Scheme 5: Coumarin dyes as proof-of-concept cargos. 
As a proof of concept, we decided to use coumarin dye 37 as a first cargo (Scheme 5). By 
attachment of the catechol anchor to the OH group, caged fluorophores were synthesized — 
non-fluorescent substances which are cleaved upon photoirradiation to yield fluorescent dyes. 
When we tried to synthesize caged fluorophore 38 the final deprotection of the catechol failed 
under various conditions and these observations can be explained as shown in Scheme 6. 
 
Scheme 6: Proposed decomposition of 1st generation photo-labile catechol anchors during 
deprotection. R = H, MOM. 
The electron-withdrawing effect of the nitro group of caged fluorophore 39 results in low pKa 
values of the catechol protons and facilitates the formation of para-quinone methide 40 and 
therefore the release of fluorophore 37. Thus, we moved to another PPG as blueprint for our 
surface anchoring unit, the ortho-nitrophenethyl group 41. This homologous structure does not 
allow for the formation of a quinone methide. The mechanism for cleavage of this PPG is 
different from the mechanism presented for the o-nitrobenzyl group 32 (Scheme 7).43 
  
                                                 
42 I. K. Konstantinou, T. A. Albanis, Appl. Catal., B 2004, 49, 1–14. 
43 S. Walbert, W. Pfleiderer, U. E. Steiner, Helv. Chim. Acta 2001, 84, 1601–1611. 
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Scheme 7: Photolysis mechanism of the o-nitrophenethyl group. 
Photoexcitation induces formation of an analogous aci-nitro tautomer 42 as shown above. At 
this point, however, two different mechanistic pathways are possible. The first and productive 
pathway proceeds via deprotonation to the nitronate anion 43 and leads to an elimination 
reaction and extrusion of the cargo (ROH) giving 2-nitrostyrene (44) as a byproduct. The 
undesired second pathway is unproductive. Analogous to the lower homolog 33 the nitronic 
acid of 42 attacks at the benzyl position to form benzisoxazoline intermediate 45, which then 
opens up again. Alcohol 46 is generated, which cannot fragment to release the cargo, leading 
to a potential loss of material. 
 
Scheme 8: Synthesis of caged fluorophore 52. 
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We designed a synthetic route to caged fluorophore 52 (Scheme 8). Synthesis of the anchor 
commenced with protection of 4-ethylcatechol (47) with an acetonide group under acid 
catalysis. Acetonide 48 was subjected to nitration with half-concentrated nitric acid giving 
compound 49 in very good yield. Homologation with paraformaldehyde in methanolic Triton 
B (benzyltrimethylammonium hydroxide) under heating gave the final anchor precursor 50 in 
low yield. However, a large portion of the starting material was recovered and could be recycled 
in this step. Due to ease of synthesis, precursor 50 was coupled with coumarin 37 via a carbonate 
bridge using a protocol we had already developed during the synthesis of a caged retinoic acid 
analog.44 Deprotection of the catechol moiety was effected by treatment with aqueous TFA and 
followed by purification with preparative reversed-phase HPLC giving the caged fluorophore 
52 in good overall yield. 
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Figure 8: Photocleavage of immobilized caged fluorophore Ti-52 under UV irradiation. 
The compound 52 was then transferred into SAMs on titania microparticles (Ti-52) by a dip-
and-rinse procedure. After washing, the particles were re-suspended in MOPS buffer medium 
and irradiated at 366 nm under a common laboratory UV lamp. Release of the free coumarin 
dye 37 was observed in terms of developing fluorescence as well as detection by reversed-phase 
HPLC-MS (Figure 8). 
  
                                                 
44 J. Hoecker, R. Liffert, P. Burch, R. Wehlauch, K. Gademann, Org. Biomol. Chem. 2013, 11, 3314–
3321. 
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1.3 Results and Discussion 
1.3.1 Improved Synthesis of the Photo-Labile Anchoring Unit 
After a successful proof-of-concept study, our first aim was the optimization of our synthesis 
of the protected anchoring unit 50. While our original route was efficient enough to obtain the 
required amount of material, the synthesis had two major drawbacks. The starting material, 
4-ethylcatechol (47), is expensive (ca. 100 CHF/g) when obtained from commercial suppliers 
and the low yield of the homologation at the end of the sequence required several cycles as the 
isolated amount of product 50 barely exceeded the amount of reisolated starting material 49 
(41%/39%). 
 
Scheme 9: Access to catechol derivatives by oxidation of 4-ethylphenol (53). 
The direct oxidation of phenols to ortho-quinones using 2-iodoxybenzoic acid (IBX, 54) as the 
oxidant has been reported by Pettus and coworkers in 200245 and a simplified procedure 
including in situ reduction to the free catechol by addition of sodium dithionite has been 
reported by Bernini and coworkers in 2011.46 IBX (54) itself is readily available from 2-
iodobenzoic acid (IBA, ca. 0.9 CHF/g) by oxidation with Oxone (2 KHSO5·KHSO4·K2SO4, 
<0.1 CHF/g).47 When a methanolic solution of 4-ethylphenol (53, ca. 0.1 CHF/g) was treated 
with IBX (54) in methanol, full conversion of the starting material 53 was observed within 1.5 
h (Scheme 9). Reduction of the quinone intermediate by sodium dithionite (<0.1 CHF/g) was 
completed within 10 min after addition and crude catechol 47 was isolated as a brown oil. 
Although the texture of the material obtained was contrasting from the commercial substance 
(grey solid), 1H NMR analysis indicated high purity and any attempts of further purification 
either failed (crystallization, sublimation) or were inefficient (activated carbon, flash 
chromatography, size exclusion chromatography). The crude catechol 47 was subjected to our 
previously applied acetonide protection conditions and again the resulting crude product 48 was 
                                                 
45 D. Magdziak, A. A. Rodriguez, R. W. Van De Water, T. R. R. Pettus, Org. Lett. 2002, 4, 285–288. 
46 R. Bernini, F. Crisante, N. Merendino, R. Molinari, M. C. Soldatelli, F. Velotti, Eur. J. Med. Chem. 
2011, 46, 439–446. 
47 M. Frigerio, M. Santagostino, S. Sputore, J. Org. Chem. 1999, 64, 4537–4538. 
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of high purity. While purification by flash chromatography was possible without significant 
loss of substance, the material could simply be carried on to nitration in half-conc. nitric acid. 
After workup, nitroaryl compound 49 was obtained as a pure yellow solid making an additional 
purification step unnecessary. With this improved sequence we could drastically reduce the cost 
of our synthesis. However, in terms of atom economy the oxidation with IBX (54) was not 
satisfying. Even though only a small excess of reagent (1.1 eq.) was used, the oxidant 54 (280 
g/mol) outweighs the substrate 53 (122 g/mol) more than twice. Therefore, IBA was recovered 
from the reaction mixture by acid/base extraction in a model experiment, where out of the 34 
mmol of employed IBX (54) 63% of pure IBA were recovered. 
Table 1: Optimization of the final homologation towards anchor precursor 50. 
 
Entry (CH2O)n 
[eq.] 
Base 
[eq.] 
Solvent Time 
[h] 
Conversion 
(1H NMR) 
1 20 Triton B, 4.5 MeOH 65 45% 
2 10 Triton B, 1.05 MeOH 20 15% 
3 20 KOtBu, 4.5 MeOH 22 22% 
4 20 KOtBu, 5.0 tBuOH (110 °C) 21 16% 
5 2.0 Triton B, 0.50 DMSO/MeOH, 10:1 4.5 96% 
6 2.0 Triton B, 0.25 DMSO/MeOH, 10:1 1.5 70% 
a Reactions were performed in a sealed tube at 85 °C. 
Addressing the second drawback of our original synthesis a series of experiments was 
conducted to optimize the reaction conditions of the final homologation step and selected results 
are shown in Table 1. During our earlier studies (entry 1) we could already observe that the 
reaction stopped at a maximum conversion of 45% and could not be forced to completion by 
addition of more reagents and continued heating. Beside the low yield of this transformation 
the very long reaction time makes recycling of recovered starting material 49 a lengthy 
procedure. Reducing the amount of both base and paraformaldehyde also resulted only in 
reduced conversion of the substrate 49 after 20 h (entry 2). When Triton B was replaced by the 
stronger base potassium tert-butanolate, again only low conversion was detected after 22 h 
(entry 3). In order to be able to reach higher temperatures in our sealed tube system, the solvent 
was switched to tert-butanol and the oil bath temperature was increased to 110 °C (entry 4). 
Despite some solubility issues conversion remained almost unaffected. As this reaction is 
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catalytic in base but even large excess of reagent did not lead to high conversion, we decided 
to boost basicity by the use of aprotic but highly polar DMSO as the solvent. Since we used 
Triton B as a methanolic solution, methanol could not be eliminated completely from the 
reaction mixture. With tremendously reduced amounts of paraformaldehyde (2.0 eq.) and a 
substoichiometric amount of Triton B (0.5 eq.), conversion of 96% of starting material 49 was 
observed by 1H NMR analysis after 4.5 h reaction time (entry 5). After workup and purification 
by flash chromatography, an isolated yield of 85% was obtained. With further reduced amounts 
of base (0.25 eq.) 70% conversion were reached after only 1.5 h, however, the reaction stopped 
at this point and prolonged heating did not lead to completion (entry 6). With these optimized 
conditions in hand, synthesis of the protected anchor precursor 50 could be achieved in four 
synthetic steps from 4-ethylphenol (53) in 51% overall yield (Scheme 10). 
 
Scheme 10: Summary of the improved synthesis of protected anchor precursor 50. 
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1.3.2 Functional Group Evaluation 
In order to investigate the photo release properties of the nitrocatechol system in more detail, a 
series of model analogs was synthesized carrying different functional groups linking the 
anchoring unit with the cargo. The compounds were then photolyzed and a comparison of the 
cleavage efficiency of the various leaving groups was drawn. 
1.3.2.1 Synthesis of Functional Group Analogs 
The most relevant functional groups for caging of small organic molecules are hydroxyl, amino 
and carboxylic acid groups. The utilization of carbonates and carbamates for the mild coupling 
of hydroxyl and amino groups, respectively, has already been demonstrated above and these 
functional groups were also included in this study. In the field of chemical biology, phosphates 
are another important class of functional groups. However, the properties of phosphates and 
thus their chemical behavior differ strongly from the former functional groups and the synthesis 
of phosphate cages is not as general. Although photolysis of the cages can only be induced by 
UV irradiation, the proportion of which is relatively small in artificial room lighting, all 
reactions have been performed in the dark and exposure to light was minimized during workup 
and purification. 
 
Scheme 11: Syntheses of ether and amine analogs. 
Starting from protected anchor precursor 50, ether analog 56 was synthesized via the 
Williamson ether synthesis using sodium hydride as the base and benzyl bromide as the 
electrophile giving the protected ether 55 in good yield (Scheme 11). In a general procedure, 
cleavage of the acetonide protecting group was achieved by treatment with aqueous TFA and 
the free catechol 56 was obtained in good yield after purification by preparative reversed-phase 
HPLC. Synthesis of amine analog 59 was achieved by reductive amination. Anchor precursor 
50 was oxidized to the corresponding aldehyde 57 in excellent yield using Dess-Martin 
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periodinane as the oxidant. Following a protocol developed by Tajbakhsh and coworkers,48 the 
aldehyde 57 was condensed with benzylamine in trifluoroethanol, which could be observed by 
the fast development of an intense red color of the reaction mixture. Reduction by sodium 
borohydride led to amine 58. Final deprotection following our general procedure gave catechol 
59 in very good yield. 
 
Scheme 12: Failed attempts towards acetonide 58. 
Several previous attempts to obtain acetonide 58 had failed (Scheme 12). Our first approach 
was based on the nosyl strategy developed by Fukuyama and coworkers49 and 
benzylnosylamide 60 was obtained via known procedures.50 Subsequent coupling of amide 60 
with anchor precursor 50 under Mitsunobu reaction conditions was not successful in our hands. 
In a second approach, alcohol 50 was first converted to the corresponding bromide 62 in an 
Appel reaction. When known Boc-protected benzylamine 6351 in DMF was treated with sodium 
hydride followed by addition of bromide 62 the desired amine 64 could not be obtained. Instead, 
the bromide 62 underwent an elimination reaction to the corresponding nitrostyrene. 
                                                 
48 M. Tajbakhsh, R. Hosseinzadeh, H. Alinezhad, S. Ghahari, A. Heydari, S. Khaksar, Synthesis 2011, 
490–496. 
49 T. Kann, T. Fukuyama, Chem. Commun. 2004, 353–359. 
50 B. Nyasse, L. Grehn, U. Ragnarsson, H. L. S. Maia, L. S. Monteiro, I. Leito, I. Koppel, J. Koppel, J. 
Chem. Soc., Perkin Trans. 1 1995, 2025–2031. 
51 S. V. Chankeshwara, A. K. Chakraborti, Synthesis 2006, 2784–2788. 
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Scheme 13: Syntheses of carbonate (66) and carbamate (68) analogs. 
The carbonate and carbamate model compounds 66 and 68, respectively, were synthesized 
following our previously developed procedure (Scheme 13). Acetonide 50 was transformed into 
its chloroformate ester using triphosgene in THF in the presence of triethylamine. The mixture 
was evaporated under high vacuum and redissolved in dichloromethane. A solution of either 
benzyl alcohol or benzylamine in pyridine was added giving carbonate 65 or carbamate 67, 
respectively. The crude acetonides 65 and 67 were subjected to the general deprotection method 
and catechols 66 and 68 were obtained in good overall yields. 
 
Scheme 14: Syntheses of ester analogs 70 and 72. 
Ester intermediate 69 was synthesized in good yield by coupling of phenylacetic acid with 
acetonide 50 using EDC·HCl and DMAP as coupling reagents (Scheme 14). When ester 69 was 
treated with aqueous TFA, the ester function was hydrolyzed before the acetonide protecting 
group and catechol 70 could not be obtained. Also, the use of weaker acids such as acetic acid 
or dichloroacetic acid did not lead to the desired deprotection. We therefore changed the acid 
coupling partner in the first step to diphenylacetic acid and intermediate 71 was produced in 
excellent yield. Due to the increased steric bulk in the α-position of the ester function, 
deprotection of ester 71 was successful using the general method resulting in an only slightly 
reduced yield of catechol 72 when compared to the other substrates. 
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1.3.2.2 Photo-Cleavage 
The cleavage efficiency of the different catechols 56, 59, 66 and 68 was studied in a kinetic 
analysis by monitoring of the photo-induced decay of the substances. Aqueous solutions of the 
substrates were irradiated at 366 nm under a common laboratory UV lamp and analyzed by 
reversed-phase UPLC-MS after certain time intervals (Figure 9). The relative amount of 
substrate within each series was determined by integration of its respective peak in the UV 
traces obtained. The released cargos (BnOH, BnNH2) could not be identified in the UV traces 
probably due to their low extinction coefficients compared to the light harvesting catechols. 
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Figure 9: Decay of catechols 56 (A), 59 (B), 66 (C) and 68 (D) in solution quantified by reversed-
phase UPLC-MS. 
Comparing the different kinetic profiles, it became obvious that cleavage of ether 56 was most 
efficient with only 39% of substrate remaining after five minutes of irradiation (Figure 9A). 
After 25 minutes of irradiation no substrate 56 was detected anymore. Decay of amine 59 
(Figure 9B) was significantly slower with more than 12% of the substance 59 intact after 
25 minutes of irradiation. This observation was expected as it is in accord with the fact that 
amides represent worse leaving groups than alcoholates. However, cleavage of carbonate 66 
(Figure 9C) and carbamate 68 (Figure 9D) was surprisingly slow. Since both functions should 
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be good leaving groups comparable to carboxylates, the reaction seemed to be harmed by 
additional factors. While photolysis of carbamate 68 was more efficient than photolysis of 
amine 59 and thus showed a reasonable profile, the line shape of the decrease of carbonate 66 
seemed remarkable. The reaction proceeded fast in the beginning and, with 44% substrate left 
after five minutes, was comparable to that of ether 56. Then, the reaction slowed down and after 
25 minutes still more than 13% of the substrate remained. Since these experiments were 
conducted in buffered aqueous medium at low concentrations, the observed effects cannot be 
addressed to a change in pH. A possibility that seems unlikely but cannot be excluded is the 
formation of an undesired byproduct with a high extinction coefficient. Accumulation of this 
substance would then lead to increased light absorption and progressive inhibition of the 
photolysis reaction. The photocleavage of ester 72 could not be included in the present series 
as the substance proved to be insoluble in water. When a dilute solution of ester 72 in MeCN 
was added to aqueous MOPS buffer solution, the compound precipitated. The substance could 
be photolyzed in a mixture of MeCN/water (1:2), but the reaction proceeded significantly 
slower in less protic medium. This observation was expected and can be explained 
mechanistically (cf. Scheme 7). The aci-nitro tautomer, which is formed after photoexcitation 
of the nitrocatechol, needs to be deprotonated in order to eliminate the cargo, which is then 
neutralized by protonation. These proton transfer steps occur much more efficiently in aqueous 
medium and the reaction can be entirely shut down in an aprotic environment. 
To evaluate the photorelease of cargo from solid support catechols 56, 59, 66 and 68 were 
immobilized as SAMs on titania nanoparticles using a previously developed dip-and-rinse 
procedure.40 While the particles showed a slightly yellow coloration after the immobilization 
procedure, the respective cargos (BnOH or BnNH2) could not be detected after the photolysis 
experiments. Different factors were considered to overcome this problem. The cargos chosen 
for this study were very small, which can complicate detection by UPLC-MS, and relatively 
apolar, which could lead to the precipitation of released molecules on the titania nanoparticles. 
To test these factors 3,4,5-trimethoxybenzylamine (73) was chosen as a cargo and catechol 74 
was prepared analogously to amine 59 (Scheme 15). Unfortunately, after immobilization of 
catechol 74 and release of the cargo by photolysis, the latter could not be detected in the medium 
by means of reversed-phase UPLC-MS. 
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Scheme 15: Synthesis of catechol 74 carrying a heavier and more polar cargo. 
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1.4 Conclusion 
In summary, we have developed a cost-efficient and straightforward synthesis of our protected 
surface anchoring moiety yielding the target 50 in four synthetic steps from cheap 4-ethylphenol 
(53) in 51% overall yield. Furthermore, we synthesized a series of model compounds (56, 59, 
66 and 68) to evaluate photocleavage efficiency with different leaving groups establishing 
experimental procedures that allow for the coupling of various cargo molecules. The fastest 
photolysis reactions were observed using ether and carbamate functions to connect the surface 
anchor and the cargo. While these groups allow for attachment of a broad range of amines and 
alcohols, the application of esters is limited. A hypothetic cargo needs sufficient steric 
encumbrance at the α-carbon atom to prevent hydrolysis of the ester during deprotection of the 
catechol anchor. Further studies need to be carried out focusing on the application of the system 
on solid surfaces giving detailed insights in release kinetics from solid support. Also, a 
determination of the actual surface coverage, that can be reached using such nitrocatechol 
anchors, would yield crucial information to estimate the dosage of a released substance. 
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2 Catecholic Binders for Dynamic Functional Systems 
2.1 Dynamic Covalent Bonds in Functional Systems 
The ability to selectively target one particular bond in a given substrate molecule is of vital 
importance for synthetic organic chemistry. The challenge of finding appropriate conditions 
resulting in a chemo- and site-selective reaction becomes increasingly difficult with higher 
structural complexity of the substrate. Especially when assembling large macro- and 
supramolecular architectures, classic organic transformations fail to target only one specific 
bond within the plethora of bonds present leading to undesired side reactions. For the 
preparation of such architectures, non-covalent interactions like hydrogen bonding and 
hydrophobic interactions are valuable tools and the exploration of less prominent molecular 
interactions such as halogen bonding is of current interest.52 
Table 2: Examples of non-covalent, dynamic covalent and covalent bonds encountered in functional 
systems. 
Non-covalent Dynamic covalent Covalent 
Hydrogen bond Disulfide C-C 
Hydrophobic Hydrazone C-H 
Ionic bond Boronate ester C-O 
π-Stacking Imine C-N 
Cation-π Thioester O-S 
Halogen bond Hemiacetal/acetal O-P 
Anion-π  O-B 
 
The so-called dynamic covalent bonds combine the properties of covalent and non-covalent 
interactions in a unique manner.53 Depending on the conditions, these bonds can either be as 
rigid and stable as covalent bonds or as dynamic and rapidly interchanging as non-covalent 
bonds. A disulfide bond for example is stable under acidic conditions, but exchanges and 
equilibrates rapidly under basic conditions in the presence of thiolates. This definition is kind 
of loose in a sense that many covalent bonds become labile under specific conditions. However, 
for a bond to be classified as “dynamic covalent” these conditions need to be mild enough to 
tolerate other functional groups within the molecular scaffold. This dual nature of dynamic 
covalent bonds makes them very attractive for the generation of molecular structures with 
                                                 
52 (a) P. Politzer, J. S. Murray, ChemPhysChem 2013, 14, 278–294; (b) T. M. Beale, M. G. Chudzinski, 
M. G. Sarwar, M. S. Taylor, Chem. Soc. Rev. 2013, 42, 1667–1680. 
53 (a) J.-M. Lehn, Top. Curr. Chem. 2012, 322, 1–32; (b) S. Otto, Acc. Chem. Res. 2012, 45, 2200–2210; 
(c) F. B. L. Cougnon, J. K. M. Sanders, Acc. Chem. Res. 2012, 45, 2211–2221. 
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specific functions,54 well demonstrated by the example of dynamic covalent libraries.55 In a 
combinatorial fashion a set of building blocks is linked by reversible chemical transformations 
and the distribution of products typically depends on the free-energy landscape presented to the 
system (thermodynamic control).56 Changing the experimental conditions alters this free-
energy landscape and thus product distribution can be influenced, for example by the addition 
of an external template which cannot participate in the reversible covalent binding events. Non-
covalent interactions between library members and the template will energetically favor these 
binders and promote their production. After equilibration of the system, library members can 
be isolated under conditions that do not allow for further exchange of the dynamic covalent 
bonds. If library members are able to intermolecularly bind to copies of themselves, the 
equilibrium shifts towards these self-assembling members. This mechanism represents an 
example of self-replication which plays a central role in origin-of-life theories.55,57 
Systems chemistry focuses on the interfacing of functional components to yield a chemical 
system with emergent properties, which were not present in the individual components and 
which were not necessarily deducible from the characteristics of individual components. The 
combination of several non-covalent interactions is very common in biological and chemical 
systems, for example hydrogen bonding, hydrophobic and π-π interactions in double-stranded 
DNA or in protein secondary and tertiary structures. Also, the combined use of dynamic 
covalent organic bonds with non-covalent interactions such as metal coordination chemistry 
has been established58 and most recently the development of a chemical system able to store, 
recall and erase information has been reported.59 However, the use of several dynamic covalent 
organic bonds within a system remains rare.60 An illustrative example of such a system are 
small molecular walkers (Scheme 16).61 The function of this system is to move a molecular 
                                                 
54 (a) S. J. Rowan, S. J. Cantrill, G. R. L. Cousins, J. K. M. Sanders, J. F. Stoddart, Angew. Chem. Int. 
Ed. 2002, 41, 898–952; (b) J. N. H. Reek, S. Otto (eds.), Dynamic Combinatorial Chemistry, WILEY-
VCH, Weinheim, 2010; (c) Y. Jin, C. Yu, R. J. Denman, W. Zhang, Chem. Soc. Rev. 2013, 42, 6634–
6654. 
55 (a) R. A. R. Hunt, S. Otto, Chem. Commun. 2011, 47, 847–858; (b) J. Li, P. Nowak, S. Otto, J. Am. 
Chem. Soc. 2013, 135, 9222–9239. 
56 (a) Q. Ji, R. C. Lirag, O. Š. Miljanić, Chem. Soc. Rev. 2014, 43, 1873–1884; (b) E. Mattia, S. Otto, 
Nat. Nanotechnol. 2015, 10, 111–119. 
57 (a) V. del Amo, D. Philp, Chem. Eur. J. 2010, 16, 13304–13318; (b) E. Moulin, N. Giuseppone, Top. 
Curr. Chem. 2012, 322, 87–106. 
58 M. L. Saha, S. De, S. Pramanik, M. Schmittel, Chem. Soc. Rev. 2013, 42, 6860–6909. 
59 J. Holub, G. Vantomme, J.-M. Lehn, J. Am. Chem. Soc. 2016, 138, 11783–11791. 
60 A. Wilson, G. Gasparini, S. Matile, Chem. Soc. Rev. 2014, 43, 1948–1962. 
61 M. J. Barrell, A. G. Campaña, M. von Delius, E. M. Geertsema, D. A. Leigh, Angew. Chem. Int. Ed. 
2011, 50, 285–290. 
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fragment, the walker (shown in red), along a molecular track in a predefined direction. To 
achieve this directional movement a sequential combination of basic disulfide exchange, light-
induced cis–trans-isomerization and acidic hydrazone exchange is necessary. While reversing 
the order of events changes the direction of movement, the sequence must remain the same to 
enable directionality. The key to achieving this directional movement lies in the orthogonality 
of the dynamic covalent bonds utilized in the system.60,62  
 
Scheme 16: A molecular walker (red) moving along a molecular track in a defined direction. 
  
                                                 
62 M. von Delius, E. M. Geertsema, D. A. Leigh, A. M. Z. Slawin, Org. Biomol. Chem. 2010, 8, 4617–
4624. 
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An example demonstrating the power of this methodology of orthogonal dynamic covalent 
bonds is the formation of double-channel photosystems,63 functional multicomponent surface 
architectures for the generation of photocurrent (Figure 10). To build such architectures, an 
initiator precursor equipped with diphosphonate anchors was deposited onto an indium-doped 
tin oxide (ITO) surface (75). Naphthalenediimide (NDI) π-stacks were then grown on the 
surface using self-organizing surface-initiated polymerization (SOSIP, 76).64 Two thiolate 
groups generated by reduction of the precursor initiate a ring-opening disulfide-exchange 
polymerization process, which is propagated by two asparagusic acid esters flanking the NDI 
building blocks. Treatment with excess hydroxylamine cleaved the benzaldehyde caps leaving 
free hydrazide groups (77), which were subsequently coupled with porphyrin and 
phthalocyanine derivatives (78). This overall process is called templated stack exchange 
(TSE).65 The parallel π-stacks of this architecture were demonstrated to transport electrons and 
holes in an antiparallel fashion. While NDI stacks transport electrons towards the surface, the 
porphyrin/phthalocyanine stacks move holes away from the surface. An improved system was 
prepared by replacing NDI and porphyrin/phthalocyanine stacks with oligothiophene and 
Bingel fullerene stacks, respectively.66 By introduction of a redox gradient along the π-stacks 
via variation of the electron density of the aryl moieties charge recombination was minimized. 
                                                 
63 G. Sforazzini, R. Turdean, N. Sakai, S. Matile, Chem. Sci. 2013, 4, 1847–1851. 
64 (a) N. Sakai, M. Lista, O. Kel, S. Sakurai, D. Emery, J. Mareda, E. Vauthey, S. Matile, J. Am. Chem. 
Soc. 2011, 133, 15224–15227; (b) M. Lista, J. Areephong, N. Sakai, S. Matile, J. Am. Chem. Soc. 2011, 
133, 15228–15231. 
65 N. Sakai, S. Matile, J. Am. Chem. Soc. 2011, 133, 18542–18545. 
66 H. Hayashi, A. Sobczuk, A. Bolag, N. Sakai, S. Matile, Chem. Sci. 2014, 5, 4610–4614. 
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Figure 10: Schematic representation of a double-channel surface architecture produced by SOSIP and 
TSE and a representative structure of an NDI unit attached to a porphyrin unit (79). 
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Figure 11: Schematic representation of triply dynamic surface architecture including boronate esters 
(left) and two natural products, which could be sensed by incorporation into the scaffold (right). For a 
detailed description of the symbols used, see Figure 10. 
The complexity of architectures accessible by this methodology could be increased dramatically 
by the discovery of additional combinations of three or even more dynamic covalent bonds. A 
few examples have been reported adding boronate esters as a third component.67 Using the 
techniques described above, NDI stacks were grown on an ITO surface using SOSIP (80) and 
different boronic acid derivatives (e.g. 81) were introduced by TSE (82, Figure 11).67a,b It was 
shown that boronate ester formation is feasible and chemosensing of different natural catechols 
and vicinal diols such as riboflavins (83) and anthocyanins (84) was performed using this 
system. While simultaneous formation of boronate esters, hydrazones and disulfides was 
demonstrated,67c complete orthogonality could not be established. The lability of boronate 
esters towards hydrolysis was problematic as hydrazone exchange required strong acids. Due 
to the high binding affinities of electron-poor catechols to metal oxides, a series of catechol 
derivatives was synthesized and boronate ester formation was evaluated in functional surface 
architectures.  
                                                 
67 (a) K.-D. Zhang, S. Matile, Angew. Chem. Int. Ed. 2015, 54, 8980–8983; (b) K.-D. Zhang, N. Sakai, 
S. Matile, Org. Biomol. Chem. 2015, 13, 8687–8694; (c) L. Rocard, A. Berezin, F. De Leo, D. Bonifazi, 
Angew. Chem. Int. Ed. 2015, 54, 15739–15743. 
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2.2 Results and Discussion 
2.2.1 Synthesis of Catechol Derivatives 
The initial synthetic studies towards new electron-poor catechol derivatives built on the 
synthesis we had already developed for a photolabile nitrocatechol anchor. Different 
halogenated catechols were expected to serve as valuable starting point, since aryl halides can 
be further transformed using cross-coupling reactions. Furthermore, reports on natural 
chlorocatechols from the cement of the sandcastle worm Phragmatopoma californica68 and 
derived bio-inspired polymers69 suggest, that the chloro-substituent increases the acidity and 
lowers the oxidation potential of the catechol. Consequently, these chlorocatechols show a 
higher coordination affinity for metal ions, which fueled our interest in these compounds. 
 
Scheme 17: Attempts to functionalize known acetonide intermediate 48. 
Acetonide 48 was prepared following our known route and functionalization of the aryl core 
was explored (Scheme 17). Similar transformations performed on hydroxytyrosol derivatives 
served as a benchmark.70 Chlorination of acetonide 48 using N-chlorosuccinimide (NCS) in the 
presence of catalytic amounts of aluminium trichloride (10 mol%)71 provided the desired 
chloride 85 in moderate yield. The loss of material was attributed to the acidic reaction 
conditions and the possible formation of hydrogen chloride from the catalyst and residual water 
in the reaction flask leading to cleavage of the protecting group. To circumvent these 
drawbacks, instead of simply switching the reagent NCS to N-bromosuccinimide, another 
methodology was chosen avoiding acidic reagents. Bromination of acetonide 48 was achieved 
                                                 
68 C. J. Sun, A. Srivastava, J. R. Reifert, J. H. Waite, J. Adhesion 2009, 85, 126–138. 
69 L. Garcia-Fernández, J. Cui, C. Serrano, Z. Shafiq, R. A. Gropeanu, V. San Miguel, J. Iturri Ramos, 
M. Wang, G. K. Auernhammer, S. Ritz, A. A. Golriz, R. Berger, M. Wagner, A. del Campo, Adv. Mater. 
2013, 25, 529–533. 
70 R. Bernini, S. Cacchi, G. Fabrizi, E. Filisti, Org. Lett. 2008, 10, 3457–3460. 
71 Y. Zhang, K. Shibatomi, H. Yamamoto, Synlett 2005, 2837–2842. 
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using equimolar amounts of Oxone (KHSO5 · 0.5 KHSO4 · 0.5 K2SO4) and potassium bromide 
in aqueous acetone72 to give the desired bromide 86 in good yield. According to the original 
publications Oxone oxidizes acetone to dimethyldioxirane (DMDO), which in turn oxidizes the 
halide anion to a “reactive species”, that transfers a halogen atom to the aryl moiety of the 
substrate. Visual inspection of the present bromination reaction clearly point towards the in situ 
formation of elemental bromine as the reaction mixture develops an intense brown color within 
the first minutes slowly fading back to the initial yellow color of the mixture. In the presence 
of potassium sulfate from the triple salt oxidant Oxone, the reaction mixture is buffered so that 
the hydrogen bromide produced as a byproduct is deprotonated straight away. With the first 
aryl halide derivatives in hand, we immediately moved on to cross-coupling strategies and 
became particularly interested in the synthesis of a trifluoromethylated compound 88. 
Following two procedures involving the formation of “Cu-CF3” as active species either from a 
combination of potassium trifluoroacetate and copper(I) iodide73 or a combination of the 
Ruppert-Prakash reagent (trifluoromethyltrimethylsilane, TMS-CF3
74), silver fluoride and 
copper,75 conversion to the desired product 88 was not observed. After several attempts, only 
starting material was recovered except for a small percentage of the corresponding aryl iodide 
observed by UPLC-MS in the product mixture of the former protocol. This side product was 
formed by copper-mediated halogen exchange at the high temperatures applied (160 °C).76 Also 
a direct electrophilic trifluoromethylation approach using the Togni reagent77 (87, 3,3-di-
methyl-1-trifluoromethyl-1,2-benziodoxole78) was not successful and only starting material 48 
was recovered. 
                                                 
72 (a) P. Bovicelli, E. Mincione, R. Antonioletti, R. Bernini, M. Colombari, Synth. Commun. 2001, 31, 
2955–2963; (b) P. Bovicelli, R. Bernini, R. Antonioletti, E. Mincione, Tetrahedron Lett. 2002, 43, 5563–
5567. 
73 K. Matsui, E. Tobita, M. Ando, K. Kondo, Chem. Lett. 1981, 1719–1720. 
74 (a) I. Ruppert, K. Schlich, W. Volbach, Tetrahedron Lett. 1984, 25, 2195–2198; (b) G. K. S. Prakash, 
R. Krishnamurti, G. A. Olah, J. Am. Chem. Soc. 1989, 111, 393–395. 
75 M. M. Kremlev, A. I. Mushta, W. Tyrra, Y. L. Yagupolskii, D. Naumann, A. Möller, J. Fluor. Chem. 
2012, 133, 67–71. 
76 G. E. Carr, R. D. Chambers, T. F. Holmes, J. Chem. Soc., Perkin Trans. 1 1988, 921–926. 
77 M. S. Wiehn, E. V. Vinogradova, A. Togni, J. Fluor. Chem. 2010, 131, 951–957. 
78 P. Eisenberger, S. Gischig, A. Togni, Chem. Eur. J. 2006, 12, 2579–2586. 
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Scheme 18: Aryl halides did not undergo homologation with paraformaldehyde due to decreased 
acidity of the benzylic protons. 
When either aryl chloride 85 or aryl bromide 86 were subjected to the homologation conditions 
optimized for photoactive nitro derivative 50 (Scheme 18), neither of the two substrates was 
converted to the desired product and only starting materials were detected by 1H NMR analysis 
of the reaction mixtures. The acidity of the benzylic protons of halides 85 and 86 is decreased 
compared to their nitro analog, which can be rationalized by the resonance structures of the 
intermediate anion. While the aryl halide anion 91 can only delocalize the negative charge 
across the phenyl ring, an additional resonance form is possible for nitro anion 92 stabilizing 
the charge as a nitronate 93. Not having found a way to introduce a functional handle into the 
catechol units, which would be essential for the future attachment of additional components, no 
further experiments were conducted on this synthetic approach. 
 
Scheme 19: Synthesis of fully protected DOPAC. 
Our new approach focused on the use of commercially available 3,4-dihydroxyphenylacetic 
acid (DOPAC, 94) as a common precursor, which already possesses the desired catechol 
function as well as the homobenzylic functional handle for attachment of another component 
(Scheme 19). Protection of the free acid 94 was achieved via Fischer esterification in refluxing 
methanol in the presence of a catalytic amount of sulfuric acid giving methyl ester 95 followed 
by acetonide formation on the catechol applying our previously developed procedure yielding 
fully protected DOPAC 96 in excellent yield. The preparation of this compound had been 
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published in the literature before and a similar two step approach applying 2,2-dimethoxy-
propane as the solvent in the second transformation gave only 72% yield.79 An attractive one-
pot procedure reported to produce compound 96 in 94% yield directly from DOPAC using 
2,2-dimethoxypropane and para-toluenesulfonic acid (pTsOH) in refluxing toluene could not 
be reproduced in our laboratory.80 
 
Scheme 20: Halogenation reactions of protected DOPAC. 
Moving on to the functionalization of protected intermediate 96, halogenation reactions came 
into focus again. Application of the procedures described above produced both aryl chloride 97 
and aryl bromide 98 in excellent yields (Scheme 20). The chlorination reaction was monitored 
closely and full conversion of the starting material 96 was observed after only four hours 
allowing for a drastic reduction in reaction time, possibly reducing decomposition of the 
product 97 in the acidic medium. Furthermore, a positive influence of the electron-withdrawing 
ester substituent on both reactions cannot be excluded as both yields were increased compared 
to our earlier studies (cf. Scheme 17). Also, iodination of compound 96 was achieved under 
mild conditions using a combination of iodine and silver sulfate in methanol81 producing the 
desired aryl iodide 99 in excellent yield in only one hour. When ethanol was used as the solvent 
in this transformation, as described in the original procedure, partial exchange of the ester group 
was observed, and a mixture of methyl and ethyl esters was obtained. 
                                                 
79 B. Geiseler, L. Fruk, J. Mater. Chem. 2012, 22, 735–741. 
80 B. Almeida Cotrim, J. Joglar, M. J. L. Rojas, J. M. Decara del Olmo, M. Macias-González, M. R. 
Cuevas, M. Fitó, D. Muñoz-Aguayo, M. I. Covas Planells, M. Farré, F. R. de Fonseca, R. de la Torre, 
J. Agric. Food Chem. 2012, 60, 1067–1074. 
81 W.-W. Sy, B. A. Lodge, A. W. By, Synth. Commun. 1990, 20, 877–880. 
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Scheme 21: Electrophilic trifluoromethylation of protected DOPAC could not be achieved. 
With the three different aryl halides 97–99 in hand, we turned to further coupling reactions and 
explored the synthesis of trifluoromethyl derivative 100. Initial experiments on the direct 
electrophilic trifluoromethylation of protected DOPAC 96 using the Togni reagent 87 did not 
lead to formation of the desired product (Scheme 21) and efforts were focused on the use of 
copper-mediated trifluoromethylation strategies. A classic approach using trifluoroacetate salts 
as the trifluoromethyl source73 showed promising results. This method is attractive due to the 
low cost as well as easy handling of trifluoroacetate salts. An evaluation of different reaction 
conditions was performed (Table 3). 
Table 3: Optimization studies on the trifluoromethylation of aryl halides 98 and 99 using potassium 
trifluoroacetate. 
 
Entry -X CF3CO2K [eq.] CuI [eq.] Yield [%]a 
1 -Br 4 2 62 
2 -Br 6 3 54 
3 -Br 6 6 64 
4 -I 6 6 33 
5 -I 4 0.4 Cu0, 0.4 Ag2O dec. 
a Highest isolated yield obtained under the stated conditions. 
 
Typical procedures use excess amounts of potassium trifluoroacetate as well as copper iodide 
in N-methylpyrrolidone (NMP). Applying 4 eq. of potassium trifluoroacetate and 2 eq. of 
copper iodide transformed aryl bromide 98 to the desired compound 100 in up to 62% yield 
(Entry 1). Since full conversion of the starting material 98 was not always observed within 24 h, 
reagent loadings were increased with no significant influence on the outcome of the reaction 
(Entries 2 and 3). Common side products in all cases were the reduced protected DOPAC 96 as 
well as a pentafluoroethyl homolog of 100, which is formed by repeated coupling of a 
Catecholic Binders for Dynamic Functional Systems 
38 
trifluoromethyl group to the product 100. While the formation of these side products was not 
unexpected, their yield relative to the desired product varied significantly. Attempts to create 
more defined reaction conditions by the use of degassed solvent and pre-dried potassium 
trifluoroacetate did not lead to any change in product distribution. When the substrate was 
changed to the more reactive aryl iodide 99, an overall decrease in yield was observed (Entry 
4). Full conversion of the starting material was observed within less than 17 h. However, 1H 
NMR analysis indicated the formation of several unidentified side products, likely caused by 
the high reaction temperature (160 °C) in combination with the high reactivity of aryl iodides. 
A recent protocol using only catalytic amounts of elemental copper in the presence of silver(I) 
oxide as a promoter82 did not yield the desired product and decomposition of the starting 
material was observed (Entry 5). While initial experiments on aryl bromide 98 provided the 
desired product 100 in acceptable yield, these results could not be reproduced reliably over 
several experiments rendering this approach unpredictable. Thus, the Ruppert-Prakash reagent 
was investigated as a trifluoromethyl source83 generally allowing for milder reaction conditions 
(Table 4). 
Table 4: Studies on the trifluoromethylation of aryl iodide 99 using the Ruppert-Prakash reagent. 
 
Entry TMS-CF3 [eq.] CuI [eq.] KF [eq.] Solvent Yield [%] 
1 1.4 1.8 1.4 DMF/NMPa 81 
2 1.5 1.6 1.5 DMF/NMP 86 
3 2.0 2.2 2.0 DMF/NMP 92 
4 2.0 1.2 2.0 DMF/NMP n.d. 
5 1.5 1.6 1.5 EtCN <20% conv. 
6 2.0 2.1 2.0 NMP 88 
a Solvents were always used in a 1:1 ratio. 
  
                                                 
82 Y. Li, T. Chen, H. Wang, R. Zhang, K. Jin, X. Wang, C. Duan, Synlett 2011, 1713–1716. 
83 H. Urata, T. Fuchikami, Tetrahedron Lett. 1991, 32, 91–94. 
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Initial experiments using 1.4 eq. of the Ruppert-Prakash reagent, 1.8 eq. copper(I) iodide and 
1.4 eq. pre-dried potassium fluoride in a 1:1 mixture of DMF/NMP yielded 81% of the desired 
product 100 containing less than 10% of the pentafluoroethyl homolog, as quantified by 
1H NMR analysis (Entry 1). Gradually increasing the excess of the trifluoromethyl source and 
its activator slightly improved the yield to 92% without causing undesired side reactions 
(Entries 2 and 3). Only when the excess of copper(I) iodide was reduced below the level of the 
other reagents, the formation of additional side products was observed (Entry 4). Under these 
conditions, highly reactive trifluoromethyl anions are generated from the reagents but the 
amount of copper(I) present in the mixture is not sufficient to stabilize the reactive species 
leading to undesired side reactions. A recent report on the use of propionitrile as solvent in these 
transformations reducing the amount of pentafluoroethyl side product75 could not be confirmed 
in our hands (Entry 5). After 48 h reaction time, we did not only observe less than 20% 
conversion of the starting material by 1H NMR analysis, but also the presence of more of the 
pentafluoroethyl compound than of the desired product 100 in the mixture. The use of pure 
NMP as solvent turned out to have no significant influence on the reaction outcome and 88% 
yield were obtained on a 1.3 mmol scale (Entry 6). 
Table 5: Optimization studies on the methylsulfonylation of aryl iodide 99. 
 
Entry Cu salt, eq. MeSO2Na 
[eq.] 
L-Pro 
[eq.] 
Temperature 
[°C] 
Yield 
[%] 
1 CuI, 0.4 1.5 0.4 80 35 
2 Cu(OAc)2, 0.4 1.5 0.4 80 59 
3 Cu(OAc)2, 0.4 1.5 0.4 100 77 
4 Cu(OAc)2, 0.6 1.6 0.6 100 86 
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As a last functionalization, the synthesis of methylsulfonyl derivative 101 from iodide 99 was 
investigated (Table 5). Following a published procedure for the copper-catalyzed and proline-
promoted sulfonylation using sodium methanesulfinate in DMSO at 80 °C84 gave the desired 
product 100 in 35% yield (Entry 1). Although copper(II) acetate was reported to perform 
significantly worse than copper(I) iodide in the original publication, the unusual blue color of 
the reaction mixture indicated the formation of copper(II) during the reaction and prompted us 
to carry out the control experiment. Indeed, copper(II) acetate could efficiently catalyze the 
present transformation with a higher isolated yield of 59% (Entry 2). As the reaction proceeded 
slow and full conversion of the starting material 99 was not always observed after 24 h, the 
reaction temperature was increased to 100 °C resulting in faster conversion and slightly 
increased yields (Entry 3). Optimal results were achieved using 60 mol% instead of 40 mol% 
of proline and copper salt affording the product in 86% yield (Entry 4). 
 
Scheme 22: Saponification of catechol precursors 97–101. 
In order to enable the attachment of cargos to catechol precursors 97–101, saponification of the 
ester moiety was performed on all derivatives (Scheme 22). A solution of substrate in THF was 
treated with 1 M aqueous sodium hydroxide giving a turbid mixture. Within 60 min, the reaction 
mixture turned clear indicating full conversion of the starting material. After acidification, 
carboxylic acids 102–106 were isolated by extraction in good to excellent yields. Another 
strategy considered for the formation of a chemical handle for further modifications, was 
reduction of the ester function to a primary hydroxyl group. An exemplary reduction using 
lithium aluminium hydride in THF was performed on trifluoromethyl derivative 100 producing 
the desired alcohol 107 in excellent yield (Scheme 23). 
 
Scheme 23: Exemplary reduction of ester 100 to primary alcohol 107. 
                                                 
84 W. Zhu, D. Ma, J. Org. Chem. 2005, 70, 2696–2700. 
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Cleavage of the acetonide protecting group was performed on derivatives 98–101 to set up the 
free catechols for further studies (Scheme 24). Neat acetonide was treated with cold 20% 
aqueous TFA and after 2–3 h, a mixture of distinct dark brown color was obtained. The mixture 
was concentrated, and the residue was subjected to preparative reversed-phase HPLC affording 
the catechols 108–111 in moderate to good yields. Since these compounds were designed to 
serve as highly polar binders, flash chromatography over silica gel was not possible due to 
coating of the stationary phase. Catechols 108–110 were obtained as off-white solids, which 
were stable in air at 4 °C over several months. Methylsulfonylcatechol 111 was obtained as a 
hygroscopic orange solid illustrating the high polarity of the compound. 
 
Scheme 24: Acetonide cleavage and formation of free catechols. 
 
2.2.2 Application of Electron-Poor Catechols in Triply Dynamic Functional Systems85 
Functional systems employing three types of dynamic covalent bonds, namely disulfides, 
hydrazones and boronate esters, had been reported before and simultaneous formation of these 
three bonds had been demonstrated.67 A very recent study introduced even a fourth reaction, 
that could be run simultaneously; the 1,4-addition of thiols onto conjugated acceptors.86 In order 
to assess the applicability of bio-inspired electron-poor catechols in functional systems, the 
stability of their corresponding boronate esters with three different phenylboronic acid 
derivatives was investigated. Besides our novel catechols 108–111, the series included 
nitrodopamine (19) and the anachelin chromophore (16), since these catechols are known to 
strongly bind to metal oxides. Furthermore, quercetin (113), alizarin red (114) and coumarin 
derivative 115 were included as positive controls known to form boronate esters in functional 
systems.67a By titration of UV-active catechols with boronic acids and reverse titration of 
alizarin red boronate esters with UV-inactive catechols, the dissociation constants KD were 
                                                 
85 These studies have been performed by Santiago Lascano and Dr. Kang-Da Zhang in the research 
group of Prof. Dr. Stefan Matile at the University of Geneva and have been published: S. Lascano, K.-
D. Zhang, R. Wehlauch, K. Gademann, N. Sakai, S. Matile, Chem. Sci. 2016, 7, 4720–4724. 
86 H. M. Seifert, K. Ramirez Trejo, E. V. Anslyn, J. Am. Chem. Soc. 2016, 138, 1091610924. 
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determined. Benzoxaborole derivative 112 was identified as the best binding partner resulting 
in KD values distributed over a suitable range allowing for the formation of boronate esters of 
markedly different stabilities (Scheme 25). Among the compounds studied, nitrocatechol 19 
and methylsulfonylcatechol 111 gave the best values in the sub-millimolar range. Anachelin 
chromophore 16 showed intermediate stability in between the positive control substances, 
which were closely followed by trifluoromethylcatechol 110 and bromocatechol 108. 
Iodocatechol 109 gave a surprisingly high KD value. 
 
Scheme 25: Series of catechol derivatives investigated in the formation of boronate esters. 
Dissociation constants KD listed below each compound were assessed by titration. Catechols are 
ordered by increasing KD values. 
Exchange reactions of boronate esters, hydrazones and disulfides were studied in solution to 
find conditions that allow for orthogonal exchange of each single function in presence of the 
others (Scheme 26). Boronate ester 116 and bromocatechol 108 were exposed to 2% Hünig’s 
base and 10% D2O in DMSO-d6 and the reaction monitored by 
1H NMR spectroscopy. 
Equilibrium was reached with a half-life of substrates t50 <3 min and the mixture contained 
boronate esters 116 and 117 in a ratio of 1:1.1. Hydrazones and disulfides did not react under 
these conditions. Hydrazone exchange was the main obstacle in this study, since boronate esters 
tend to hydrolyze under acidic conditions. However, the use of methyl 3-amino-4-
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hydroxybenzoate (119) as an organocatalyst87 facilitated hydrazone exchange in only 1.5 mM 
TFA. Equilibration in t50 = 11.9 h produced hydrazones 120 and 122 in a ratio of 1.3:1. At this 
stage it was of key importance that boronate ester 116 remained intact under these conditions 
and also disulfides did not react. Finally, exchange of disulfides 124 and 125 was triggered by 
small amounts of benzylthiol in the presence of triethylamine (both 2.0 mM). Equilibrium was 
reached in t50 = 2.5 h with disulfides 124 and 126 present in a ratio of 1:1.6 and again hydrazones 
and boronate esters were not affected. 
 
Scheme 26: Conditions for orthogonal exchange of boronate esters, hydrazones and disulfides in 
solution. 
In order to demonstrate the applicability of three orthogonal dynamic organic covalent bonds 
in functional systems, the above findings were translated into a multicomponent surface 
architecture 128 (Scheme 27). On an ITO surface, NDI stacks were grown by the SOSIP 
technique (127). Benzoxaborole 129 was incorporated by TSE and boronate ester formation 
was achieved by incubation in a solution of nitrocatechol 19 and Hünig’s base resulting in 
surface architecture 128. While formation of all three bonds had already been achieved, the 
challenge was to carry out hydrazone exchange without cleaving the boronate ester groups. Due 
to the small amount of substance on the surface, several solid supports were incubated in the 
                                                 
87 D. Larsen, M. Pittelkow, S. Karmakar, E. T. Kool, Org. Lett. 2015, 17, 274–277. 
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same sample of hydrazone exchange medium. The accumulated substance in the medium was 
then analyzed by 1H NMR spectroscopy and intact boronate ester 132 was identified along with 
only small amounts of the hydrolyzed benzoxaborole. Additional evidence for the presence of 
boronate ester 132 was obtained by ESI-MS. Thus, surface architecture 128 represents the first 
functional system based on three orthogonal dynamic organic covalent bonds. 
 
Scheme 27: Multicomponent surface architecture containing three orthogonal dynamic covalent 
bonds. 
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2.2.3 New Generation Binders 
In late 2015, Wolkenstein and coworkers have reported the structures of borolithochromes,88 
natural spiroborate pigments isolated from pink-colored calcareous material of the putative 
Jurassic red alga Solenopora jurassica.89 Microgram amounts of 13 different compounds were 
isolated by HPLC and their structures and absolute configurations were assigned mainly using 
microcryoprobe NMR analysis. The fact, that these natural products are of Jurassic age and thus 
survived for more than 150 million years implies a high stability of the spiroborate moiety and 
raises the question, whether 1,8-naphthalenediol-based binders would perform superior 
compared to the catechols 108–111 when applied in orthogonal boronate ester exchange in 
triply dynamic functional systems. Building on our results with nitrocatechol 19 and 
methylsulfonyl catechol 111 (cf. Scheme 25), we investigated the synthesis of similar 
naphthalene-based compounds bearing an electron-withdrawing substituent and a chemical 
handle in the para-positions relative to the hydroxyl groups. 
 
Scheme 28: Synthesis of 1,8-naphthalenediol (134) and direct functionalization attempts. 
Commercially available 1,8-naphthosultone (133) was hydrolyzed under harsh basic conditions 
to afford 1,8-naphthalenediol (134)90 in good yield after recrystallization from chloroform 
(Scheme 28). The possibility to introduce a sulfonic acid substituent without the need for 
protection of the hydroxyl groups was investigated briefly at this stage. The sulfonic acid 
function would be desirable as it is electron-withdrawing and could be used as a chemical 
handle in form of a sulfonamide at the same time. When diol 134 was treated with sulfuric acid, 
                                                 
88 K. Wolkenstein, H. Sun, H. Falk, C. Griesinger, J. Am. Chem. Soc. 2015, 137, 13460–13463. 
89 K. Wolkenstein, J. H. Gross, H. Falk, Proc. Natl. Acad. Sci. USA 2010, 107, 19374–19378. 
90 (a) H. Erdmann, Liebigs Ann. 1888, 247, 306–366; (b) K. A. Parker, T. Iqbal, J. Org. Chem. 1980, 45, 
1149–1151. 
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conversion of the starting material was observed and UPLC-MS analysis showed the expected 
mass (m/z = 241, [M+H]+) of the main constituent of the crude product mixture. However, 1H 
NMR analysis indicated the presence of several different aromatic compounds in the mixture 
and isolation of the highly polar sulfonic acid 135 was not achieved. Also, nitration of the free 
diol 134 was investigated using classic nitration conditions as well as milder conditions 
applying sodium nitrite in the presence of acid. In all cases, only a complex mixture was 
obtained. When the temperature was decreased below 0 °C, no reaction was observed. 
 
Scheme 29: Protection and functionalization of diol 134. 
Due to the complications encountered with direct functionalization, diol 134 was protected as 
an acetonide, a strategy that had proved successful with the catechol derivatives. Applying our 
previously developed conditions, acetonide 137 was obtained in a moderate yield of 47%. 
Introduction of the nitro group was attempted, and surprisingly TLC indicated formation of a 
single product in 10 minutes at 0 °C. However, after purification the material was identified as 
the symmetric dinitro compound 138. Attempts to use milder nitration conditions (cf. Scheme 
28) were not successful. Installation of a chemical handle could be achieved using Friedel-
Crafts acylation conditions91 and afforded ketone 139 in an excellent yield of 96% as a mixture 
of para- and ortho-isomers in a ratio of 5:1. While partial separation of the isomers was possible 
chromatographically, nitration of the mixture followed by chromatography over silica gel gave 
the desired nitroaryl compound 140 as a single isomer in 55% yield. Bromination and iodination 
of ketone 139 were attempted using the protocols applied for the synthesis of catechol 
derivatives (cf. Scheme 20), but 1H NMR and HRMS analyses clearly pointed towards the 
                                                 
91 N. P. Buu-Hoï, D. Lavit, J. Chem. Soc. 1956, 2412. 
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formation of two regioisomers in ca. 1:1 ratio, which could not be improved when reactions 
were performed at low temperatures. 
 
Scheme 30: Attempts to cleave the acetonide protecting group. 
Efforts to cleave the acetonide protecting group to yield either the free diol 141 or a borate such 
as 142 or 143 were unsuccessful. While treatment with methanolic hydrogen chloride at 
elevated temperatures did not lead to conversion of the starting material, forcing conditions like 
heating to 120 °C in a microwave reactor slowly lead to darkening of the mixture without 
formation of a product detectable by 1H NMR analysis. When acetonide 140 was treated with 
boron trichloride, fast conversion of the starting material was observed, but only complex 
mixtures were obtained even when the reaction temperature was reduced to –78 °C. 
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2.3 Conclusion 
The development of an efficient branched synthesis of several electron deficient catechol 
derivatives has been achieved with the potential to use aryl halide intermediates for further 
synthetic studies and extend the portfolio of substrates. The synthetic catechols were used in 
the formation and controlled exchange of boronate esters and were subsequently applied in a 
triply dynamic surface architecture, which represents the first functional system employing 
three orthogonal dynamic organic covalent bonds. Synthetic efforts towards new naphthalene-
derived aromatic diols based on spiroborate natural products have yielded an advanced nitroaryl 
intermediate. Further studies on the deprotection of this intermediate or the use of alternative 
protecting groups need to be performed in order to make the test substrate available. The 
investigation of additional functionalization methods could lead to a broader scope of 
substituents on the aryl core and thus provide a new series of diols to be tested in dynamic 
functional systems. 
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3 Rapamycin-Based Probes for the Structural Investigation of 
TOR Complexes 
3.1 Introduction 
 
Figure 12: Structures of immunosuppressive natural products from Streptomyces species. 
Rapamycin (144), also known under the generic name sirolimus, is a macrocyclic polyketide 
isolated from the bacterium Streptomyces hygroscopicus in 1975 by Sehgal and coworkers at 
Ayerst Pharmaceuticals (Figure 12).92 The bacteria cultures had been isolated from a soil 
sample collected on Easter Island (Rapa Nui), from which the name rapamycin was derived. 
Initially, the compound 144 was recognized for its antifungal activity, especially against several 
species of the Candida genus,92 and its structure was determined by single crystal X-ray 
crystallography93 as well as NMR spectroscopy.94 Although further studies reported potent 
immunosuppressive95 and antitumor activities96 of rapamycin (144), drug development was 
ceased.97 In 1987, FK-506 (145) was isolated from Streptomyces tsukubaensis and reports on 
its immunosuppressive properties triggered a revival in the investigation of rapamycin.98 
                                                 
92 (a) C. Vézina, A. Kudelski, S. N. Sehgal, J. Antibiot. 1975, 28, 721–726; (b) S. N. Sehgal, H. Baker, 
C. Vézina, J. Antibiot. 1975, 28, 727–732. 
93 D. C. N. Swindells, P. S. White, J. A. Findley, Can. J. Chem. 1978, 56, 2491–2492. 
94 J. A. Findlay, L. Radics, Can. J. Chem. 1980, 58, 579–590. 
95 R. R. Martel, J. Klicius, S. Galet, Can. J. Physiol. Pharmacol. 1977, 55, 48–51. 
96 (a) J. Douros, M. Suffness, Cancer Treatment Rev. 1981, 8, 63–87; (b) C. P. Eng, S. N. Sehgal, C. 
Vézina, J. Antibiot. 1984, 37, 1231–1237. 
97 K. Garber, J. Natl. Cancer Inst. 2001, 93, 1517–1519. 
98 (a) H. Tanaka, A. Kuroda, H. Marusawa, H. Hatanaka, T. Kino, T. Goto, M. Hashimoto, T. Taga, J. 
Am. Chem. Soc. 1987, 109, 5031–5033; (b) T. Kino, H. Hatanaka, M. Hashimoto, M. Nishiyama, T. 
Goto, M. Okuhara, M. Kosaka, H. Aoki, H. Imanaka, J. Antibiot. 1987, 40, 1249–1255; (c) T. Kino, H. 
Hatanaka, S. Miyata, N. Inamura, M. Nishiyama, T. Yajima, T. Goto, M. Okuhara, M. Kohsaka, H. 
Aoki, T. Ochiai, J. Antibiot. 1987, 40, 1256–1265. 
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Eventually rapamycin (144) was approved in 1999 for clinical use to prevent organ rejection 
after renal transplantation (marketed as Rapamune©). Additional rapamycin analogs (rapalogs) 
were developed in the following years and received clinical approval (see Section 3.2). 
Extensive biochemical studies led to the discovery of the cellular target or rapamycin (TOR) 
and subsequent investigations established TOR signaling as a central pathway, that is highly 
conserved among most eukaryotes. Many reviews describing TOR signaling in different 
organisms have been published in the past.99 
In the early 1990s, TOR was first discovered in the yeast Saccharomyces cerevisiae using 
rapamycin-resistant mutants.100 Two genes were identified encoding for two essential and 
homologous proteins, TOR1 and TOR2, which belong to the phosphatidylinositol 3-kinase-
related kinase (PIKK) family. This study also showed that an intracellular cofactor, the FK-506-
binding protein 12 (FKBP12), is required for the toxicity of rapamycin. Disruption of the gene 
encoding for FKBP12 had no effect on the viability of the yeast. On the contrary, other known 
inhibitors of FKBP12 were not immunosuppressive.101 Thus, the FKBP12-rapamycin complex 
gained new toxic properties against a target required for viability of the organism. Further 
investigations provided evidence that the FKBP12-rapamycin complex binds directly to TOR1 
and TOR2.102 The yeast S. cerevisiae is a special case as its genome encodes for two TOR 
kinases, whereas most other eukaryotes have only one TOR gene.99e Interestingly, there are no 
reports on FKBP12 being a part of normal TOR signaling and the protein is thought to be 
hijacked by rapamycin (144).99d Investigations of the biological roles of TOR1 and TOR2 
concluded that TOR2 has two essential functions; one is redundant with TOR1 (and thus TOR1 
is not essential) while the other one is unique to TOR2.103 The observation that inhibition of 
TOR signaling induces starvation symptoms led to the assumption that TOR actively controls 
cell growth. It was shown that only the shared TOR1/2 signaling branch is responsive to 
                                                 
99 See for example: (a) M. Laplante, D. M. Sabatini, Cell 2012, 149, 274–293; (b) H. Pópulo, J. M. 
Lopes, P. Soares, Int. J. Mol. Sci. 2012, 13, 1886–1918; (c) R. Zoncu, A. Efeyan, D. M. Sabatini, Nat. 
Rev. Mol. Cell Biol. 2011, 12, 21–35; (d) R. Loewith, M. N. Hall, Genetics 2011, 189, 1177–1201; (e) 
S. Wullschleger, R. Loewith, M. N. Hall, Cell 2006, 124, 471–484. 
100 J. Heitman, N. R. Movva, M. N. Hall, Science 1991, 253, 905–909. 
101 S. L. Schreiber, Science 1991, 251, 283–287. 
102 (a) R. Stan, M. M. McLaughlin, R. Cafferkey, R. K. Johnson, M. Rosenberg, G. P. Livi, J. Biol. 
Chem. 1994, 269, 32027–32030; (b) M. C. Lorenz, J. Heitman, J. Biol. Chem. 1995, 270, 27531–27537; 
(c) Y. Zheng, Y. Jiang, Cell 1995, 82, 121–130. 
103 (a) N. C. Barbet, U. Schneider, S. B. Helliwell, I. Stansfield, M. F. Tuite, M. N. Hall, Mol. Biol. Cell 
1996, 7, 25–42; (b) A. Schmidt, M. Bickle, T. Beck, M. N. Hall, Cell 1997, 88, 531–542; (c) A. Schmidt, 
T. Beck, A. Koller, J. Kunz, M. N. Hall, EMBO J. 1998, 17, 6924–6931; (d) S. B. Helliwell, I. Howald, 
N. Barbet, M. N. Hall, Genetics 1998, 148, 99–112. 
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nutrients and sensitive to rapamycin (144), while the TOR2 unique branch is not. A break-
through was accomplished in 2002, when two large multiprotein complexes, TOR complex 
(TORC) 1 and 2, were isolated from yeast cells.104 Studies on the complexes established two 
separate TOR signaling pathways: TORC1 contains either TOR1 or TOR2, it is rapamycin-
sensitive and involved in the shared TOR1/2 pathway. TORC2 contains exclusively TOR2, it 
is rapamycin-insensitive and involved in the TOR2 unique pathway. Furthermore, it was 
confirmed that not only the TOR kinases but also the TORCs are conserved among other 
eukaryotes.105 
 
Figure 13: General functionality of the TOR complexes. 
To date many upstream regulators and downstream targets of the TOR signaling network have 
been identified and it is recognized as a central signaling pathway.99 TORC1 (~1.2 MDa) 
actively regulates the accumulation of cellular mass in response to the abundance and quality 
of nutrients in the environment. It controls translational processes and thus influences protein 
expression, especially the biogenesis of ribosomes but also permeases for the import of 
                                                 
104 (a) R. Loewith, E. Jacinto, S. Wullschleger, A. Lorberg, J. L. Crespo, D. Bonenfant, W. Oppliger, P. 
Jenoe, M. N. Hall, Mol. Cell 2002, 10, 457–468; (b) K. P. Wedaman, A. Reinke, S. Anderson, J. Yates, 
III, J. M. McCaffery, T. Powers, Mol. Biol. Cell 2003, 14, 1204–1220; (c) A. Reinke, S. Anderson, J. 
M. McCaffery, J. Yates, III, S. Aronova, S. Chu, S. Fairclough, C. Iverson, K. P. Wedaman, T. Powers, 
J. Biol. Chem. 2004, 279, 14752–14762. 
105 (a) K. Hara, Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, K. 
Yonezawa, Cell 2002, 110, 177–189; (b) D.-H. Kim, D. D. Sarbassov, S. M. Ali, J. E. King, R. R. 
Latek, H. Erdjument-Bromage, P. Tempst, D. M. Sabatini, Cell 2002, 110, 163–175; (c) E. Jacinto, R. 
Loewith, A. Schmidt, S. Lin, M. A. Rüegg, A. Hall, M. N. Hall, Nat. Cell Biol. 2004, 6, 1122–1128; 
(d) D. D. Sarbassov, S. M. Ali, D.-H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage, P. 
Tempst, D. M. Sabatini, Curr. Biol. 2004, 14, 1296–1304. 
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nutrients. In addition to promoting anabolism, TORC1 suppresses stress-responsive pathways 
to effect cell growth. Interestingly, TORC1 is involved in aging processes and therefore in the 
regulation of life span. The observation that dietary restriction increases the life span of 
biological systems has been linked to TORC1 and studies involving genetic or chemical 
downregulation of TORC1 led to an increased life span in yeast, worms, flies and mice.106 
Inhibition of TORC1 signaling by rapamycin (144) leads to a marked decrease of protein 
synthesis and induction of catabolic processes like autophagy. The cell exits from the cell cycle 
and enters a G0 state, also known as quiescence. TORC2 (~1.4 MDa) appears to be activated 
by membrane tension107 and ribosomes.108 Since the number of active ribosomes directly 
influences the growth capacity of a cell, TORC2 is only active in growing cells. It controls the 
organization of the actin cytoskeleton as well as endocytosis and is involved in the regulation 
of sphingolipid biosynthesis. In a simplified model, TORC1 regulates the temporal aspects of 
cell growth and TORC2 controls the spatial aspects. These central roles for cell viability make 
the TOR signaling network a target for disease and indeed deregulation is observed especially 
in cancer where rapid cell growth is often characteristic.99a,b,109 
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3.2 Concept of the Project 
 
Figure 14: FRB and FKBP12 binding sites of rapamycin (144) and examples of derived drugs. 
Although many biological aspects of TOR have been discovered and the constitutions of the 
multiprotein TORCs of different organisms have been reported,99 their detailed molecular 
structures were largely unknown until very recently.107 While for example the atomic structures 
of the FKBP12-rapamycin complex110 as well as FKBP12-rapamycin complexed with the 
FKBP12-rapamycin binding domain (FRB) of human TOR111 have been determined via X-ray 
crystallography in the 1990s, the fully assembled TORCs awaited characterization. Thus, 
structural features such as the exact alignment of the different proteins in the complex or the 
exact location of the TOR kinase pocket were uncertain. A low-resolution structure (26 Å) of 
human TORC1 obtained by cryo-electron microscopy (cryo-EM) was reported in 2010. The 
protein complex was obtained in small amounts from genetically modified cells using tandem 
affinity purification (TAP). A high-resolution (5.9 Å) structure of human TORC1, also obtained 
by cryo-EM, was eventually published in 2016 allowing for the complete assignment of the 
folded protein domains.112 A low-resolution cryo-EM structure (26 Å) of yeast TORC2 was 
reported in 2015.113 This study proved that the FRB of TORC2 was blocked by a protein named 
Avo3 and removal of a C-terminal part of Avo3 furnished rapamycin-sensitive TORC2. 
                                                 
110 G. D. Van Duyne, R. F. Standaert, S. L. Schreiber, J. Clardy, J. Am. Chem. Soc. 1991, 113, 7433–
7434. 
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Figure 15: Schematic designs of rapamycin-based probes for the analysis of TORCs. 
In 2014, we initiated our studies on the development of rapamycin-based probes which could 
be used for the structural analysis of TORCs. Considering the two protein binding sites of 
rapamycin (144), two hydroxyl groups at C31 and C42 seemed suitable for synthetic modifi-
cations of the macrolide (Figure 14). Reports on the deactivation of 31-O-alkylated 
compounds114 and a comparison of commercial drugs like compounds 146–148 rendered the 
42-hydroxyl group the function of choice for the introduction of additional molecular 
components. We devised two different molecular architectures for biochemical probes (Figure 
15). The first design featured a rapamycin unit 144 tethered to a biotin molecule. Furthermore, 
the tether should contain a labile functional group, in this case a disulfide group, through which 
the probe could be chemically cleaved on demand. The resulting probe could be used to isolate 
TORC1 by pull-down experiments. The rapamycin moiety would recruit TORC1 from protein 
extract of genetically unmodified cells and the biotin moiety would be exploited for 
immobilization of the complexes via biotin-streptavidin binding. The purified complexes could 
then be collected by cleavage of the functional group in the linker. This technique might allow 
for the isolation of TORC1 on milligram-scale and thus enable X-ray crystallographic analysis 
of the complex. The second design featured a rapamycin unit 144 conjugated to gold 
nanoparticles (AuNPs) via a short linker. This assembly would allow for the tracking of 
FKBP12-rapamycin binding sites in TORCs by cryo-EM. A short linker between the macrolide 
and AuNPs would assure spatial confinement of the resulting probe and thus enable exact 
localization within the protein complex. 
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3.3 Results and Discussion 
3.3.1 Synthesis of Rapamycin-Biotin Hybrids 
At the onset of our studies, a technique allowing the selective modification of rapamycin (144) 
at the desired position 42 was needed. A process involving 31,42-O-disilylation of macrolide 
144 followed by selective deprotection to yield a 31-O-silylated rapamycin derivative had been 
reported in the patent literature and this route had also been used by Wyeth in the production 
of temsirolimus (147).115 However, this synthesis involves many steps and the monoprotected 
rapamycin derivative requires the need for activated coupling partners to react with the 
secondary 42-hydroxyl function. A more efficient procedure for the direct synthesis of 
rapamycin 42-O-esters was reported in 2005 by Wyeth researchers.116 In an enzymatic 
transformation using either Candida antarctica lipase B or Amano lipase PS from Burkholderia 
cepacia, rapamycin (144) was selectively esterified in position 42 by different vinyl ester or 
acid anhydride precursors. 
 
Scheme 31: Synthesis of rapamycin hemisuccinate (150) adopted from Gu et al. 
Using Candida antarctica lipase B immobilized on polymer beads (Immobead 150) and 
succinic anhydride (149) in toluene at 45 °C for 46 h, rapamycin 42-O-hemisuccinate (150) was 
prepared in a single step (Scheme 31). The product 150 was isolated in 86% yield after 
chromatography over silica gel. This approach is very attractive as it circumvents the use of 
protecting groups minimizing the number of synthetic steps performed on the precious natural 
                                                 
115 (a) C.-C. Shaw, J. Sellstedt, R. Noureldin, G. K. Cheal, G. Fortier (American Home Products 
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product 144. Furthermore, a free carboxylic acid group is introduced to the molecule providing 
a functional group that allows for selective targeting through amide coupling reactions. 
 
Scheme 32: Synthesis of rapamycin-biotin hybrid 156. 
With functionalized rapamycin derivative 150 in hands, we investigated the introduction of a 
biotin moiety (Scheme 32). Hexanediamine 151 was chosen as a preliminary test linker to 
investigate the synthesis of our probe architecture. Mono-Boc-protected linker 153 was 
obtained by treatment of excess diamine 151 (5 eq.) with di-tert-butyl dicarbonate (152) in 
chloroform.117 The desired product 153 was obtained in 89% yield calculated from dicarbonate 
152. Linker 153 was then attached to biotin in an amide coupling reaction using EDC 
hydrochloride in pyridine providing compound 154 in 86% yield.118 Boc-deprotection was 
achieved by treatment of the neat substance with TFA affording the biotin-linker fragment 155 
in 81% yield.118 A final peptide coupling reaction with rapamycin hemisuccinate 150 applying 
O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) in the 
presence of Hünig’s base in DMF gave the all-carbon probe 156 in 43% yield after purification 
by preparative reversed-phase HPLC. 
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Scheme 33: Synthesis of rapamycin-biotin hybrid 161. 
For the cleavable rapamycin-based probe we exchanged the 1,6-hexanediamine fragment with 
cystamine. Thus, cystamine dihydrochloride (157) was also protected using di-tert-butyl 
dicarbonate requiring triethylamine to neutralize the starting material in this case. In a statistical 
reaction, mono-Boc cystamine (158) was produced in 51% yield. The following amide coupling 
with biotin was first attempted under same conditions used in the previous synthesis, but the 
desired product was not obtained. During the basic aqueous workup used to remove the urea 
byproduct of the coupling reagent the product 159 decomposed rapidly, most likely due to 
disulfide cleavage. When the mixture was concentrated after complete conversion of the 
substrates and the residue was subjected directly to purification by HPLC, the yield could be 
improved to 40%. The best results were obtained when HBTU was used instead of EDC 
hydrochloride providing compound 159 in 50% yield. Cleavage of the Boc protecting group 
also failed under our previous conditions using TFA and milder conditions were used instead. 
Treatment of compound 159 with hydrochloric acid in a methanol/1,4-dioxane (2:1) mixture 
afforded the desired biotin-linker fragment 160 as a hydrochloride salt in quantitative yield after 
HPLC purification. Peptide coupling with rapamycin hemisuccinate 150 under the same 
conditions used for probe 156 provided the desired rapamycin-based probe 161 in 38% yield 
on a 28 mg-scale following purification via HPLC. 
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Figure 16: Toxicity test of all-carbon probe 156 (bottom) and disulfide probe 161 (middle) in four 
different concentrations against wild-type (WT) Saccharomyces cerevisiae and a rapamycin-resistant 
mutant (TOR1-1). Rapamycin (144) was used as a control (top). 
Both probes 156 and 161 were then evaluated for their toxicity against two strains of S. 
cerevisiae (Figure 16).119 Yeast cells were incubated in the presence of either probe 156 or 161 
and rapamycin (144) was used as a control. All three compounds completely inhibited growth 
of wild-type (WT) S. cerevisiae at concentrations of 200 and 50 nM. Slow growth was observed 
with probes 156 and 161 at 12.5 nM concentration, whereas rapamycin (144) still showed 
complete inhibition. At 3.125 nM concentration, none of the substances displayed growth 
inhibitory effects. A rapamycin-resistant mutant of S. cerevisiae (TOR1-1) was not affected by 
the substances in any of the four concentrations. From these observations, we concluded that 
both compounds 156 and 161 were still active TOR inhibitors. While activity was slightly 
decreased compared to the parent compound 144 itself, the mode of action appeared to be 
unchanged, since rapamycin-resistant yeast was not impaired in the experiments. 
The ability of probes 156 and 161 to recruit TORC1 from a yeast protein extract was evaluated 
next applying two different protocols.119 In the first test, streptavidin beads were loaded with 
one of the probes, then saturated with biotin and washed extensively. The beads were incubated 
in yeast protein extract for 2.5 h at 4 °C and washed again. The isolated protein constituents 
were analyzed using gel electrophoresis with Coomassie brilliant blue staining or Western blot. 
In the second experiment, the individual probes were directly incubated in yeast protein extract, 
which had been partially depleted from biotinylated proteins. The probes were recovered from 
the extract using streptavidin beads and protein constituents were analyzed as mentioned above. 
                                                 
119 Biological tests have been performed by Dr. Manoël Prouteau and Christl Gaubitz in the group of 
Prof. Dr. Robbie Loewith at the University of Geneva. 
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Unfortunately, both pull-down experiments were not successful and neither TORC1 nor any of 
the proteins involved in the complex were pulled down from the yeast protein extracts. Since 
the amount of isolated contaminants from the first experiments seemed to correlate to the 
amount of probe used to coat the streptavidin beads, we concluded that the probes bind to 
streptavidin. In combination with the toxicity observed against yeast cells, both biological 
functions of hybrids 156 and 161 appeared to be intact but were possibly exclusive and could 
not be exploited simultaneously, thus preventing the isolation of TORC1. Another reason for 
our observations could be fast enzyme-mediated hydrolysis of the probes. 
 
Scheme 34: Synthesis of elongated rapamycin-biotin hybrid 165. 
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To test whether the short linking units used to connect the two biologically active moieties of 
hybrids 156 and 161 prevented simultaneous protein binding through steric encumbrance, we 
developed a new probe 165 featuring an extended linking unit (Scheme 34). In order not to 
introduce too many apolar fragments to the probe, which might result in undesired hydrohpobic 
effects and prevent a stretched conformation of the molecule in solution, we chose a polar chain 
fragment. Elongation of the linker was achieved by coupling the disulfide-containing fragment 
160 with commercially available N-Boc-N'-succinyl-4,7,10-trioxa-1,13-tridecanediamine 
(162). Use of HBTU in the presence of Hünig’s base provided the desired product 163 in 74% 
after purification by HPLC. The Boc protecting group was removed by treatment with 
hydrochloric acid in a mixture of methanol/1,4-dioxane (1:1) giving the crude hydrochloride 
salt 164 in about 60% yield. Peptide coupling with rapamycin hemisuccinate 150 under the 
previously developed conditions afforded extended probe 165 in 43% yield following HPLC 
purification. Thus, the yield of the final step assembling hybrids 156, 161 and 165 remained 
very constant throughout the study. The extended rapamycin-biotin hybrid 165 awaits 
biological evaluation. 
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3.3.2 Synthetic Studies towards a Rapamycin-Gold Nanoparticle Conjugate 
 
Scheme 35: Synthetic efforts towards a rapamycin derivative bearing an amino-terminated side chain. 
To generate a rapamycin-AuNP conjugate, we planned to use commercially available AuNPs, 
which are stabilized by phosphine ligands presenting carboxylate groups to the outside of the 
particles. Such AuNPs enable the attachment of additional molecular fragments through peptide 
coupling. Therefore, the synthesis of a rapamycin derivative with a short linker chain bearing a 
terminal amine function was investigated (Scheme 35). Initial attempts focused on the use of 
mono-Boc-protected diamine 153 and peptide coupling with rapamycin hemisuccinate 150 was 
performed using HBTU in the presence of Hünig’s base providing derivative 166 in 95% yield 
after flash chromatography. Unfortunately, cleavage of the Boc protecting group failed under 
various conditions. When solutions of hydrochloric acid in either 1,4-dioxane (commercial) or 
methanol (commercial or prepared by addition of AcCl to methanol) were applied at 0 °C, 
partial formation of a species with the correct mass was indicated by UPLC-MS analysis along 
with side product formation. After quenching with either aqueous sodium bicarbonate or a mild 
basic ion-exchange resin followed by extraction, only complex mixtures were obtained. A 
decrease in temperature slowed down conversion of the starting material while experiments at 
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room temperature resulted in fast decomposition. Treatment of compound 166 TFA in 
dichloromethane at 0 °C also led to decomposition of the substrate. A protocol that had been 
developed to synthesize temsirolimus (147) described a high-yielding reaction of a 
semisynthetic intermediate in a mixture of THF and 2 N sulfuric acid (2:1) for 88 h at 0–5 
°C.115a When compound 166 was reacted under the same conditions, only slow decomposition 
was observed. 
 
Scheme 36: Synthesis of rapamycin derivative 170 bearing an amino-terminated side chain for 
conjugation to AuNPs. 
At this point, the synthetic strategy was changed to the use of a terminal azide instead of the 
Boc-protected amino group. Known 5-azidopentan-1-amine (168) was prepared following 
published procedures to serve as the linker fragment.120 Peptide coupling with rapamycin hemi-
succinate 150 using HBTU and Hünig’s base afforded azido derivative 169 in 87% yield after 
flash chromatography. Transformation of the azide function via the Staudinger reduction was 
investigated first.121 When compound 169 was treated with triphenylphosphine in a mixture of 
                                                 
120 J. W. Lee, S. I. Jun, K. Kim, Tetrahedron Lett. 2001, 42, 2709–2711. 
121 H. Staudinger, J. Meyer, Helv. Chim. Acta 1919, 2, 635–646. 
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THF and water (3:1) at room temperature only very slow conversion of the substrate was 
observed and UPLC-MS analysis indicated decomposition. To avoid the formation of the 
iminophosphorane intermediate involved in the Staudinger reduction we briefly investigated 
hydrogenation of the azide function. A very mild procedure using the Lindlar palladium catalyst 
in methanol under a hydrogen atmosphere (1 atm) at room temperature122 resulted in a clean 
reaction reaching full conversion after 3 h. Analysis of the crude mixture by UPLC-MS 
indicated formation of a single product with the correct mass. Due to the small scale, on which 
this reaction was performed (4 µmol), additional investigations need to be performed. The 
obtained substance decomposed within 48 h at 4 °C suggesting that the primary amino group 
possibly attacks the macrocycle. 
  
                                                 
122 P. G. Reddy, T. V. Pratap, G. D. K. Kumar, S. K. Mohanty, S. Baskaran, Eur. J. Org. Chem. 2002, 
3740–3742. 
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3.4 Conclusion 
The synthesis of three different rapamycin-biotin hybrid probes 156, 161 and 165 was 
accomplished using a strategy that avoids the use of protecting groups on the macrolide natural 
product rapamycin (144) and thus minimizes the number of synthetic steps performed on this 
sensitive compound. While the two first generation hybrids 156 and 161 were shown to be 
active inhibitors of the molecular target of rapamycin (TOR), their application in the isolation 
of target of rapamycin complex 1 (TORC1) from a yeast protein extract of S. cerevisiae failed. 
As a rationale for these observations, we hypothesized the linking unit of the hybrids 156 and 
161 might be too short. Consequently, the synthesis of an elongated rapamycin-biotin hybrid 
165 was developed and the compound awaits biochemical evaluation. Investigations towards 
the synthesis of a rapamycin-gold nanoparticle conjugate established the synthesis of an amino-
rapamycin derivative 170. Further studies on the final formation of this compound and 
subsequent attachment to gold nanoparticles need to be performed. 
  
Rapamycin-Based Probes for the Structural Investigation of TOR Complexes 
67 
  
Rapamycin-Based Probes for the Structural Investigation of TOR Complexes 
68 
  
Synthetic Studies on the Securinega Alkaloids 
69 
4 Synthetic Studies on the Securinega Alkaloids123 
4.1 The Securinega Alkaloids – A Literature Review 
4.1.1 General Overview 
  
Figure 17: S. suffruticosa in Bupyung, Korea (left)124 and F. virosa on Maui, Hawaii (right).125 
The Securinega alkaloids comprise a group of more than 60 known natural products found in 
plants of the Phyllanthaceae family and more precisely in the Flueggea, Margaritaria, 
Phyllanthus and Securinega genera.126 These plants are commonly found in the subtropical 
zones of the Americas, Africa and Asia, and are broadly applied as traditional medicines in 
these regions. For example, the species Securinega suffruticosa and Flueggea virosa (Figure 
17) — two rich and well-studied sources of Securinega alkaloids — have been used in Chinese 
folk medicine to treat a variety of symptoms such as lumbago, indigestion, impotence, 
rheumatism, infantile paralysis or eczema.127 F. virosa was used to treat complications of the 
liver, kidneys, gall bladder, bladder and genitals as well as bilharzia in Senegalese medicine. In 
India, it was used against diabetes.128 Margaritaria discoidea has been used in Guinean folk 
                                                 
123 Parts of this chapter have been published: (a) R. Wehlauch, K. Gademann, Asian J. Org. Chem. 2017, 
6, 1146–1159; (b) R. Wehlauch, S. M. Grendelmeier, H. Miyatake-Ondozabal, A. H. Sandtorv, M. 
Scherer, K. Gademann, Org. Lett. 2017, 19, 548–551. 
124 https://commons.wikimedia.org/wiki/File:Securinega_suffruticosa.JPG; Dalgial, CC BY-SA 3.0 
license, accessed 05.10.2016. 
125 https://commons.wikimedia.org/wiki/File:Starr_070111-3247_Flueggea_virosa.jpg; Forest & Kim 
Starr, CC BY 3.0 license, accessed 05.10.2016. 
126 For a general review on Securinega alkaloids, see: E. Chirkin, W. Atkatlian, F.-H. Porée in The 
Alkaloids, Vol. 74 (Ed.: H.-J. Knölker), Academic Press, London, 2015, pp. 1–120. 
127 (a) B. Li, M. G. Gilbert, G. Fischer, C. A. Meyer in Flora of China, Vol. 11 (Eds.: Z. Y. Wu, P. H. 
Raven, D. Y. Hong), Missouri Botanical Garden Press, St. Louis, 2008, p. 178; (b) S. Qin, J.-Y. Liang, 
Y.-W. Guo, Helv. Chim. Acta 2009, 92, 399–403, and references therein. 
128 B. Oliver-Bever, J. Ethnopharmacol. 1983, 7, 1–93, and references therein. 
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medicine to treat malaria, diabetes and diarrhea among others.129 Phyllanthus niruri has been 
used for the treatment of malaria and other diseases in India and China,130 but also in Central 
Africa.131 In West Africa, it was used as a stomachic.128,132 Several groups have reported on the 
isolation of Securinega alkaloids from samples of P. niruri collected in India133 and Thailand.134 
However, these alkaloids were not found in samples of the same species collected in Brazil.135 
This result might be explained by the different environmental conditions presented to the plants. 
Recently, it was shown that plant growth regulators influence the alkaloid content of S. 
suffruticosa callus cultures, and promotion as well as inhibition of alkaloid production was 
observed.136 To date, no report has been published on the isolation of Securinega alkaloids from 
a plant sample collected in the Americas. Interestingly, Securinega alkaloids have been 
obtained from Zygogynum pauciflorum,137 a species of the Winteraceae family found in New 
Caledonia. Since this family is not related to Phyllanthaceae, the study revealed a rare case of 
metabolic convergence. The Phyllanthaceae family of plants represents one of several 
Euphorbiaceae segregates and was classified in 2006.138 Nevertheless, the Securinega alkaloids 
are often assigned to the Euphorbiaceae in the recent literature. 
                                                 
129 M. S. T. Diallo, M. A. Baldé, A. Camara, M. S. Traoré, M. L. Bah, A. S. Diallo, A. K. Camara, S. 
Laurent, A. Roch, R. N. Muller, L. Maes, L. Pieters, A. M. Baldé, J. Plant Sci. 2015, 3, 40–46, and 
references therein. 
130 M. Zhou, H. Zhu, K. Wang, W. Wei, Y. Zhang, Nat. Prod. Res. 2012, 26, 762–764. 
131 P. Babady-Bila, T. E. Gedris, W. Herz, Phytochemistry 1996, 41, 1441–1443. 
132 For a recent review on the Phyllanthus genus, see: X. Mao, L.-F. Wu, H.-L. Guo, W.-J. Chen, Y.-P. 
Cui, Q. Qi, S. Li, W.-Y. Liang, G.-H. Yang, Y.-Y. Shao, D. Zhu, G.-M. She, Y. You, L.-Z. Zhang, Evid. 
Based Complement. Alternat. Med. 2016, in press, doi:10.1155/2016/7584952. 
133 (a) N. B. Mulchandani, S. A. Hassarajani, Planta Med. 1984, 50, 104–105; (b) B. S. Joshi, D. H. 
Gawad, S. W. Pelletier, G. Kartha, K. Bhandary, J. Nat. Prod. 1986, 49, 614–620. 
134 P. Petchnaree, N. Bunypraphatsana, G. A. Cordell, H. J. Gowe, P. J. Cox, R. A. Howie, S. L. Patt, J. 
Chem. Soc., Perkin Trans. 1 1986, 1551–1556. 
135 J. B. Calixto, A. R. S. Santos, V. Cechinel Filho, R. A. Yunes, Med. Res. Rev. 1998, 18, 225–258. 
136 D. Raj, A. Kokotkiewicz, A. Drys, M. Luczkiewicz, Plant Cell Tiss. Organ Cult. 2015, 123, 39–45. 
137 A. Ahond, J. Guilhem, J. Hamon, J. Hurtado, C. Poupat, J. Pusset, M. Pusset, T. Sévenet, P. Potier, 
J. Nat. Prod. 1990, 53, 875–881. 
138 P. Hoffmann, H. Kathriarachchi, K. J. Wurdack, Kew Bull. 2006, 61, 37–53. 
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Figure 18: Two- and three-dimensional representations of securinine (171) and its stereoisomers. 
In 1956, securinine (171) was isolated from S. suffruticosa by Murav’eva and Ban’kovskii as 
the first member of this alkaloid family (Figure 18).139 Being the most abundant and best-
studied Securinega alkaloid, it has been the major representative ever since. The tetracyclic 
structure of securinine (171) was elucidated independently by two research groups in 1962140 
and the correct absolute configuration was established by chemical degradation studies141 and 
an X-ray crystal structure of securinine hydrobromide.142 Total synthesis of the racemic natural 
product and chiral resolution by recrystallization with (+)-10-camphorsulfonic acid confirmed 
the structural and stereochemical assignments.143 Another alkaloid isolated from S. suffruticosa 
showed great similarities to securinine (171)140b and was identified as the epimeric 
allosecurinine (172), in which the A and B rings are fused with an opposite configuration.144 
Surprisingly, the investigation of the alkaloid contents of F. virosa (synonymous with S. virosa) 
yielded yet another stereoisomer of securinine (171), which was found to be its enantiomer 
virosecurinine (173).145 A systematic study of the two plant species and their metabolites then 
led to the last possible stereoisomer viroallosecurinine (174), the enantiomer of allosecurinine 
(172).146 The study showed that while S. suffruticosa contained only securinine (171) and 
                                                 
139 V. I. Murav’eva, A. I. Ban’kovskii, Dokl. Akad. Nauk SSSR 1956, 110, 998–1000. 
140 (a) S. Saito, K. Kotera, N. Sugimoto, Z. Horii, Y. Tamura, Chem. Ind. 1962, 1652–1653; (b) I. Satoda, 
M. Murayama, J. Tsuji, E. Yoshii, Tetrahedron Lett. 1962, 3, 1199–1206. 
141 (a) S. Saito, K. Kotera, N. Shigematsu, A. Ide, Z. Horii, Y. Tamura, Chem. Ind. 1963, 689; (b) S. 
Saito, K. Kotera, N. Shigematsu, A. Ide, N. Sugimoto, Z. Horii, M. Hanaoka, Y. Yamawaki, Y. Tamura, 
Tetrahedron 1963, 19, 2085–2099. 
142 S. Imado, M. Shiro, Z. Horii, Chem. Pharm. Bull. 1965, 13, 643–651. 
143 Z. Horii, M. Hanaoka, Y. Yamawaki, Y. Tamura, S. Saito, N. Shigematsu, K. Kotera, H. Yoshikawa, 
Y. Sato, H. Nakai, N. Sugimoto, Tetrahedron 1967, 23, 1165–1174. 
144 Z. Horii, Y. Yamawaki, Y. Tamura, S. Saito, H. Yoshikawa, K. Kotera, Chem. Pharm. Bull. 1965, 
13, 1311–1318. 
145 T. Nakano, T. H. Yang, S. Terao, Tetrahedron 1963, 19, 609–619. 
146 S. Saito, T. Tanaka, T. Iwamoto, C. Matsumura, N. Sugimoto, Z. Horii, M. Makita, M. Ikeda, Y. 
Tamura, J. Pharm. Soc. Jpn. 1964, 84, 1126–1133. 
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allosecurinine (172), S. virosa contained exclusively their optical antipodes virosecurinine 
(173) and viroallosecurinine (174). However, leaves of the male plant of S. suffruticosa var. 
amamiensis contained both securinine (171) and virosecurinine (173) along with allosecurinine 
(172). Besides the very unusual distribution of stereoisomers, these observations also 
demonstrate the high diversity of alkaloid constituents in the different plants. 
 
Figure 19: The Securinega alkaloid skeletons and representative natural products of each class. 
The Securinega alkaloids can be divided into four groups based on their core structures (Figure 
19). The compounds shown in Figure 18 share a securinane-type core, which is characterized 
by an azabicyclo[3.2.1]octane BC ring system with fused piperidine (A) and butenolide (D) 
rings. A homologous series of norsecurinane-type structure contains a pyrrolidine instead of the 
piperidine A ring; norsecurinine (175)147 represents a member of this class. In contrast to 
securinine (171), only two natural stereoisomers of the lower homolog have been isolated, the 
second one being ent-norsecurinine.133b The numbering for the securinane and norsecurinane 
skeletons is identical except for the C6 position being omitted for norsecurinane-type alkaloids. 
Both groups comprise 14,15-dihydro derivatives with most of them bearing 15-hydroxy 
or -methoxy substituents. Also, numerous 4-hydroxy or -methoxy derivatives as well as 
combinations of both (i.e. 4,15-disubstituted 14,15-dihydro compounds) are known. The 
neosecurinane and neonorsecurinane skeletons are characterized by an azabicyclo[2.2.2]octane 
core with fused butenolide and either piperidine or pyrrolidine rings. The neosecurinane-type 
alkaloid securinol A (176) was isolated from S. suffruticosa in 1965 by Horii and coworkers.148 
The Japanese researchers found, that upon treatment with methanesulfonyl chloride and 
pyridine the compound was dehydrated to viroallosecurinine (174). Thus, securinol A (176) 
was assigned a 15-hydroxy-14,15-dihydrosecurinane-type structure. More than 25 years later, 
                                                 
147 G. O. Iketubosin, D. W. Mathieson, J. Pharm. Pharmacol. 1963, 15, 810–815. 
148 Z. Horii, M. Ikeda, Y. Tamura, S. Saito, K. Kotera, T. Iwamoto, Chem. Pharm. Bull. 1965, 13, 1307–
1311. 
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Arbain, Sargent and coworkers investigated the alkaloid contents of Margaritaria indica and 
revised the structure of securinol A (176).149 Based on a comparison of NMR data of alkaloid 
176 and other Securinega alkaloids, and ultimately on X-ray crystallographic analysis of 
securinol A hydrobromide, the neosecurinane-type structure shown in Figure 19 was 
established. 
 
Figure 20: Examples of Securinega alkaloids with unusual skeletons. 
Besides the four groups described so far, several alkaloids have been isolated possessing 
unprecedented structures, which do not fit the general motifs (Figure 20). Nirurine (178) was 
isolated from Phyllanthus niruri in 1986 by Cordell and coworkers, and its structure was 
elucidated by single crystal X-ray crystallography.134 The pentacyclic compound has an 
additional oxazolidine ring formed by a C5-O-C8 bridge. Secu’amamine A (179), which was 
isolated from S. suffruticosa var. amamiensis in 2003 by Ohsaki, Kobayashi and coworkers, 
contains an extended B ring and thus an azabicyclo[3.3.1]nonane core with an additional carbon 
atom between the C2 and C9 atoms.150 Its structure was assigned using spectroscopic methods, 
mainly NMR analysis, and was later confirmed by comparison with material obtained through 
total synthesis.151,152 Also, isolation of the C3-OH epimer secu’amamine H from F. suffruticosa 
(synonymous with S. suffruticosa) was reported by Wang, Ye and coworkers in 2014.153 An 
extended B ring was also observed for phyllantidine (180), which was isolated from Phyllanthus 
discoides in 1965 by Munavalli and Parello.154 Structural elucidation by Munavalli, Horii and 
coworkers was based on spectroscopic methods as well as the characterization of chemical 
degradation products of phyllanthidine.155 This alkaloid features an oxazabicyclo[3.3.1]nonane 
                                                 
149 D. Arbain, A. A. Birkbeck, L. T. Byrne, M. V. Sargent, B. W. Skelton, A. H. White, J. Chem. Soc., 
Perkin Trans. 1 1991, 1863–1869. 
150 A. Ohsaki, H. Ishiyama, K. Yoneda, J. Kobayashi, Tetrahedron Lett. 2003, 44, 3097–3099. 
151 P. Liu, S. Hong, S. M. Weinreb, J. Am. Chem. Soc. 2008, 130, 7562–7563. 
152 H. Han, A. B. Smith, III, Org. Lett. 2015, 17, 4232–4235. 
153 L. Zhou, B.-X. Zhao, R.-W. Jiang, X.-J. Huang, Z.-L. Wu, Y. Wang, W.-C. Ye, J. Asian Nat. Prod. 
Res. 2014, 16, 593–601. 
154 J. Parello, S. Munavalli, C. R. Acad. Sci. Paris 1965, 260, 337–340. 
155 Z. Horii, T. Imanishi, M. Yamauchi, M. Hanaoka, J. Parello, S. Munavalli, Tetrahedron Lett. 1972, 
19, 1877–1880. 
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core with an additional oxygen atom between the N and C7 atoms. Interestingly, this compound 
can be obtained from allosecurinine (172) by oxidation with hydrogen peroxide. The structure 
of phyllantidine (180) was also confirmed by comparison with a fully synthetic sample.156 
Arguably the most complex structures among the monomeric Securinega alkaloids discovered 
so far were reported for the pseudoenantiomeric virosaines A and B (181), which were isolated 
from F. virosa by Zhang, Ye and coworkers in 2012.157 The three-dimensional structures are 
best explained starting from a neonorsecurinane-type skeleton. The virosaines contain an 
additional oxygen atom between the N and C7 atoms as well as a bond between the C5 and C15 
atoms. Their structures were determined using a combination of NMR spectroscopic, circular 
dichroism (CD) and X-ray crystallographic analyses, and were both confirmed by comparison 
with material obtained by total synthesis.158,159 
 
Figure 21: Examples of Securinega alkaloid dimers with different connectivity. 
A large group within the Securinega alkaloids, of which many were only discovered recently, 
are oligomeric alkaloids. All known oligomers were isolated from F. virosa structurally 
spanning from dimeric to pentameric compounds.126,160 The different dimers discovered so far 
display a large structural variety with respect to the modes of connectivity of the individual 
subunits (Figure 21). While most oligomers contain norsecurinane-type monomers (e.g. 182 
                                                 
156 C. A. Carson, M. A. Kerr, Angew. Chem. Int. Ed. 2006, 45, 6560–6563. 
157 B.-X. Zhao, Y. Wang, D.-M. Zhang, X.-J. Huang, L.-L. Bai, Y. Yan, J.-M. Chen, T.-B. Lu, Y.-T. 
Wang, Q.-W. Zhang, W.-C. Ye, Org. Lett. 2012, 14, 3096–3099. 
158 H. Miyatake-Ondozabal, L. M. Bannwart, K. Gademann, Chem. Commun. 2013, 49, 1921–1923. 
159 H. Wei, C. Qiao, G. Liu, Z. Yang, C. Li, Angew. Chem. Int. Ed. 2013, 52, 620–624. 
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Tetrahedron 2013, 69, 3942–3946; (e) B.-X. Zhao, Y. Wang, C. Li, G.-C. Wang, X.-J. Huang, C.-L. 
Fan, Q.-M. Li, H.-J. Zhu, W.-M. Chen, W.-C. Ye, Tetrahedron Lett. 2013, 54, 4708–4711; (f) H. Zhang, 
Y.-S. Han, M. A. Wainberg, J.-M. Yue, Tetrahedron 2015, 71, 3671–3679; (g) H. Zhang, K.-K. Zhu, 
Y.-S. Han, C. Luo, M. A.  Wainberg, J.-M. Yue, Org. Lett. 2015, 17, 6274–6277; (h) H. Zhang, Y.-S. 
Han, M. A. Wainberg, J.-M. Yue, Tetrahedron Lett. 2016, 57, 1798–1800; (i) G.-Y. Wang, A.-T. Wang, 
B.-X. Zhao, X.-P. Lei, D.-M. Zhang, R.-W. Jiang, Y. Wang, W.-C. Ye, Tetrahedron Lett. 2016, 57, 
3810–3813. 
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and 183), securinane- and neosecurinane-type subunits have been identified as well (e.g. 184 
and 185). The larger oligomers are structurally less diverse and primarily feature norsecurinane-
type monomers connected via C-C bonds between the C12, C14 and C15 atoms (186–188, 
Figure 22). 
 
Figure 22: Examples of norsecurinine-based tetrameric Securinega alkaloids. 
Due to the great structural analogy between the different alkaloids and the plethora of 
stereoisomers present, the field of Securinega alkaloids can be confusing and several 
discrepancies and errors have found their way into the literature. For example, after the 
structural revision of securinol A (176) in 1991,149 it became obvious that several other known 
alkaloids like securinol B and C148,161 or 14,15-dihydroallosecurinine-15β-ol162 needed or still 
need to be reinvestigated. Also, the controversial interpretation of analytical data during the 
structural elucidation of different alkaloids raises questions about the integrity of the results. 
For example, CD spectroscopy has frequently been used to determine the absolute configuration 
of previously unknown compounds. The spectra of newly isolated alkaloids were compared to 
those of known ones to draw conclusions on the similarities and differences in absolute 
configuration. But whereas one study attributed the observation of an opposite Cotton effect to 
an inverted configuration at the AB ring fusion at C2 of neonorsecurinane-type alkaloids,163 
another study concludes inverted configurations at C7 and C10 in the bridged BC ring system 
of neosecurinane-type alkaloids from the same observation.164 
  
                                                 
161 Z. Horii, M. Yamauchi, M. Ikeda, T. Momose, Chem. Pharm. Bull. 1970, 18, 2009–2012. 
162 J. L. Mensah, J. Gleye, C. Moulis, I. Fouraste, J. Nat. Prod. 1988, 51, 1113–1115. 
163 P. J. Houghton, T. Z. Woldemariam, S. O’Shea, S. P. Thyagarayan, Phytochemistry 1996, 43, 715–
717. 
164 G.-C. Wang, Y. Wang, Q. Li, J.-P. Liang, X.-Q. Zhang, X.-S. Yao, W.-C. Ye, Helv. Chim. Acta 2008. 
91, 1124–1129. 
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4.1.2 Biological Activities 
The pharmacological value of plants from the Flueggea, Margaritaria, Phyllanthus and 
Securinega genera has been recognized a long time ago, which is proved by their widespread 
use in traditional medicine (cf. Section 4.1.1). The main alkaloid found in these plants is 
securinine (171) and thus most bioactivity studies have focused on the properties of securinine 
(171) and its stereoisomers. Over the past 60 years, many studies have investigated the effects 
of either crude plant extracts or pure Securinega alkaloids on numerous biological systems. 
Different compounds have shown activity on the CNS, cytotoxicity against several cancer cell 
lines as well as antimicrobial activity and this research area has been reviewed in 2011165 and 
2014.126 
Soon after securinine (171) had been isolated in 1956, the first pharmacological studies on this 
alkaloid were published. Securinine (171) was tested in different animal models including cats 
and mice, and CNS stimulant activity, primarily in the spinal cord, was reported.166 Oral and 
subcutaneous administration of securinine (171) in low doses increase reflex action, cardiac 
activity, and muscular tone without causing any secondary effects.128 Overdosage of securinine 
(171) leads to heavy convulsions of all skeletal muscles and eventually death due to respiratory 
arrest. The biological effects of securinine (171) are comparable to those of strychnine,167 but 
its toxicity is at least ten times lower resulting in a larger therapeutic window.168 In the Soviet 
Union, securinine nitrate was approved as a substitute for strychnine and marketed as a drug 
until the 1990s.126 In 1985, Beutler and coworkers reported γ-aminobutyric acid (GABA) 
receptor antagonism for securinine (171) and 14,15-dihydrosecurinine, and thus identified a 
molecular target of these alkaloids for the first time.169 However, while allosecurinine (172) 
and virosecurinine (173) did not show any GABA receptor binding affinity, both compounds 
exhibit convulsant activity suggesting that other biological targets are involved. Xu and Zhang 
reported in 2004 that daily oral administration of securinine (171) restored spatial cognitive 
function in rats, which had been treated with a high dose of β-amyloid protein (βAP) (25-35).170 
                                                 
165 W. Zhang, J.-Y. Li, P. Lan, P.-H. Sun, Y. Wang, W.-C. Ye, W.-M. Chen, J. Chin. Pharm. Sci. 2011, 
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167 S. L. Friess, R. C. Durant, E. R. Whitcomb, L. J. Reber, W. C. Thommesen, Tox. Appl. Pharmacol. 
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βAP deposition and accumulation play a major role in Alzheimer’s disease. The authors 
attributed this therapeutic effect to the alkaloid’s interaction with the GABA receptor. Recent 
studies by Magaji and coworkers on the antipsychotic effect of the aqueous fraction of root bark 
extract from F. virosa (which constitutes more than 60% of the total extract) proved an 
antagonistic activity on dopamine D1 receptors.
171 
 
Figure 23: Semisynthetic securinine conjugates by Klochkov et al. showing activity on rat neurons as 
well as antioxidant activity. R = H, OMe. 
Klochkov and coworkers investigated a series of semisynthetic securinine conjugates for their 
effect on kainic acid-induced currents in rat cerebellum Purkinje neurons (Figure 23).172 It was 
shown that securinine (171) as well as the semisynthetic derivatives 189 and 191 increased 
currents when administered in low concentration regimes (10–100 nM), but blocked them at 
high concentrations (1–10 µM), confirming the CNS activity of these alkaloids. In a more recent 
study, the same group investigated similar compounds for their effect on Fe3+-induced peroxide 
oxidation of lipids in rat-brain homogenates and reported antioxidant properties for derivatives 
189, 190 and 192.173 A group of Chinese researchers reported on the neuritogenic activity of 
different Securinega alkaloids and synthetic derivatives in 2016.174 While the monomeric 
alkaloids securinine (171), securitinine and 15α-methoxy-14,15-dihydroallosecurinine showed 
only minimal effects on neurite outgrowth of mouse neuroblastoma (Neuro-2a) cells, the 
dimeric norsecurinamine B (193)175 strongly promoted the formation and elongation of neurites 
                                                 
171 (a) M. G. Magaji, J. A. Anuka, I. Abdu-Aguye, A. H. Yaro, I. M. Hussaini, Afr. J. Tradit. 
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172 S. G. Klochkov, S. V. Afanas’eva, V. V. Grigor’ev, Chem. Nat. Compd. 2008, 44, 197–202. 
173 S. G. Klochkov, M. E. Neganova, S. V. Afanas’eva, E. F. Shevtsova, Pharm. Chem. J. 2014, 48, 15–
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174 G. Tang, X. Liu, N. Ma, X. Huang, Z.-L. Wu, W. Zhang, Y. Wang, B.-X. Zhao, Z.-Y. Wang, F. C. 
F. Ip, N. Y. Ip, W.-C. Ye, L. Shi, W.-M. Chen, ACS Chem. Neurosci. 2016, 7, 1442–1451. 
175 Despite the compound being shown with a different configuration in ref. 172, the accompanying 
drawings and text clearly suggest that norsecurinamine B was investigated. Isolation of norsecurinamine 
B: G.-Y. Wang, A.-T. Wang, B.-X. Zhao, X.-P. Lei, D.-M. Zhang, R.-W. Jiang, Y. Wang, W.-C. Ye, 
Tetrahedron Lett. 2016, 57, 3810–3813. 
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(Figure 24). Several analogs have been prepared featuring different bridging units between the 
two alkaloid moieties and significant neuritogenic activity has been observed for compounds 
194. The percentage of differentiated cells observed after incubation with analogs 194 (25 µM) 
paralleled the positive control compound retinoic acid (10 µM) with a slightly reduced total 
neurite length. In 2007, Lubick and coworkers reported activity of securinine (171) against 
infections with Coxiella burnetii (Q Fever) in mice.176 It was shown that the observed effect 
was not based on any bactericidal action of securinine (171), but due to innate immune cell 
stimulation resulting in enhanced macrophage clearance of phase II C. burnetii. A more than 
tenfold reduction of viable C. burnetii was observed in securinine-treated mice 96 hours after 
infection. A follow-up study together with Shipman and coworkers provided a detailed 
proteomic analysis of monocytes after exposure to securinine (171).177 It was suggested that 
securinine (171) removed an inhibitor of monocyte immune response and thus led to the 
observed stimulation.  
 
Figure 24: Securinega alkaloid dimers with neuritogenic activity. 
The cytotoxic effects of Securinega alkaloids have been investigated in numerous studies and 
Table 6 gives an overview of the cell lines that were affected with IC50 values in the micromolar 
range. Significant growth inhibition and induction of apoptosis has been observed for various 
                                                 
176 (a) K. Lubick, M. Radke, M. Jutila, J. Leukoc. Biol. 2007, 82, 1062–1069; (b) K. Lubick, M. Radke, 
M. Jutila, J. Leukoc. Biol. 2008, 83, 1068. 
177 M. Shipman, K. Lubick, D. Fouchard, R. Guram, P. Grieco, M. Jutila, E. A. Dratz, PLoS ONE 2012, 
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human cancer cell lines including leukemia,178 colon,179,180,181 epidermoid,181,182 lung,181 
ovarian,183 cervical184 and breast160b,185 cancer cells. While the observed activities were not 
outstanding, the selectivity against certain cell lines is an important advantage of these agents. 
An example for this selectivity was reported by Wald and coworkers in 2010.179 They 
investigated the effect of securinine (171) on human colon cancer HCT116 cells using two cell 
lines, one of which was protein p53-deficient (p53–) while the other one was not (p53+). They 
observed that apoptosis was induced in both cell lines, but with different efficiencies. A 
significantly lower IC50 value for the p53
– cell line (17.5 µM) was observed compared to the 
p53+ cell line (50 µM). Since protein p53 is inactivated in most human cancer cells, selective 
targeting of mutated cells might be possible. By knockdown experiments the authors showed 
that securinine (171) led to G2/M cell cycle arrest followed by p73-mediated apoptosis in p53– 
cells. While cell cycle arrest was also observed in p53+ cells, induction of p21 led to recovery 
of the cells, which re-entered the cell cycle after 24 hours. A broad SAR study concerning the 
cytotoxicity of the Securinega alkaloids has not been published to date. However, there are also 
many natural congeners without any cytotoxic activity including phyllantidine (180),182 
secu’amamines B–D182 and E–G,186 virosaines A and B (181),157 flueggenine B,160a flueggether 
A (185) and virosinine A,160g flueggether D,160h and the norsecurinine-derived tetra- and 
pentamers fluevirosinines B–J (e.g. 186–188).160f Furthermore, the study published by 
Tatematsu, Lee and coworkers in 1991 included virosecurinine (173) and viroallosecurinine 
(174) along with five semisynthetic analogs.181 Comparing the cytotoxic alkaloids from Table 
6 to the listed non-cytotoxic compounds leads to the same conclusion, that the Japanese 
researchers already drew in 1991. The α,β,γ,δ-unsaturated lactone moiety is an essential 
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structural feature for cytotoxic effects. Also, the relative configuration of the ring junction 
might be important, since securinine (171) and allosecurinine (172) as well as virosecurinine 
(173) and viroallosecurinine (174), respectively, do not exhibit similar cytotoxic effects. 
Table 6: Overview of Securinega alkaloids and their activity against cancer cell lines. 
Alkaloid Cell line (cancer type) Ref. 
Securinine (171) HCT116 (human colon cancer) 179 
 SW480 (human colon cancer) 180 
 KB (human epidermoid cancer) 182 
 L1210 (murine lymphoma) 182 
 HL60 (human leukemia) 178 
 THP-1 (human leukemia) 178a 
 OCI-AML3 (human leukemia) 178a 
 OVCAR-8 (human ovarian cancer) 183 
 A2780 (human ovarian cancer) 183 
 A2780cis (human ovarian cancer) 183 
 HeLa S3 (human cervical cancer) 184 
 MCF-7 (human breast cancer) 185 
Virosecurinine (173) P-388 (murine leukemia) 181 
 HCT-8 (human colon cancer) 181 
 KB (human epidermoid cancer) 181 
 A-549 (human lung cancer) 181 
Viroallosecurinine (174) P-388 (murine leukemia) 181 
4-Epiphyllanthine KB (human epidermoid cancer) 182 
 L1210 (murine lymphoma) 182 
Flueggine A (182) MCF-7 (human breast cancer) 160b 
 MDA-MD-231 (human breast cancer) 160b 
 MCF-7/ADR (human breast cancer) 160b 
Flueggine B MCF-7 (human breast cancer) 160b 
 MDA-MD-231 (human breast cancer) 160b 
 MCF-7/ADR (human breast cancer) 160b 
Flueggenine A (183) P-388 (murine leukemia) 160a 
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Scheme 37: Syntheses of semisynthetic securinine derivatives with cytotoxic properties reported by 
Fahy, Ratovelomanana-Vidal et al. Three of the most active compounds of each series are shown. 
dppp = 1,3-bis(diphenylphosphino)propane. 
In early 2016, Fahy, Ratovelomanana-Vidal and coworkers published the first systematic study 
on the antineoplastic activity of semisynthetic securinine derivatives.187 14-Iodosecurinine 
(195) was synthesized in moderate yield by iodination with NIS and a series of 14-arylsecu-
rinines was accessed through Suzuki coupling with different arylboronic acids (not shown). 
Cytotoxicity on human colon cancer HCT116 cells was investigated in vitro and while 80.9% 
growth inhibition was observed for iodosecurinine 195 after 72 h at a 1 µM concentration, no 
activity was observed for the arylated derivatives. The researchers then introduced an acetylene 
spacer and synthesized a second series (including compounds 196–198) via Sonogashira 
coupling (Scheme 37, left). A total of 24 derivatives was generated, of which 23 compounds 
exhibited greatly improved growth inhibition compared to securinine (171). For the most active 
semisynthetic derivatives bearing aromatic and non-aromatic side chains, the cytotoxicity assay 
was expanded to also include the three human cancer cell lines A375 (melanoma), A549 (lung) 
and HL60 (leukemia). IC50 values in the nanomolar range were observed for all cell lines (Table 
7). The same group reported a second study in early 2016 focusing on semisynthetic 15-aryl-
securinine derivatives generated by Heck coupling of securinine (171) with different aryl 
iodides (Scheme 37, right).188 While ortho-substituted aryl iodides did not react even under 
optimized conditions, 18 derivatives with meta- and para-substituents (including compounds 
199–201) as well as the unsubstituted phenyl derivative were synthesized. This series was 
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evaluated for cytotoxicity against the HCT116 cell line and efficient growth inhibition was 
observed for meta-substituted 15-aryl derivatives. In the expanded assay including four cell 
lines, the most active compounds displayed IC50 values in the nanomolar range, thus even 
outperforming the compounds tested in the first study. 
Table 7: IC50 values of the most active semisynthetic securinine derivatives against four human cancer 
cell lines reported by Fahy, Ratovelomanana-Vidal et al.  
Compound IC50 [µM]    
 HCT116 A375 A549 HL60 
196 0.34 0.06 0.29 0.66 
197 0.42 0.17 0.60 0.42 
198 1.66 0.36 2.64 5.00 
199 0.28 0.07 0.14 0.13 
200 0.26 0.08 0.12 0.14 
201 0.23 0.08 0.11 0.14 
Securinine (171) >10 6.1 >10 >10 
 
Securinine (171) and related Securinega alkaloids have also been reported to show 
antimicrobial activity. In 1990, Fouraste and coworkers reported mild antibacterial activity of 
securinine (171) against Escherichia coli, Enterococcus faecium, Mycobacterium smegmatis, 
Pseudomonas aeruginosa and Staphylococcus aureus with minimal inhibitory concentrations 
of 500 µg/mL for all species except E. faecium where 1 mg/mL was necessary.189 Antiprotozoal 
activity against Plasmodium falciparum (causative agent of malaria) was reported in the same 
year by Weenen, Nkunya and coworkers for extracts190a as well as pure securinine (171)190b 
isolated from M. discoidea. Quinn and coworkers have screened a natural product-based library 
using electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry 
(ESI-FTICR-MS) and have recently identified P. falciparum deoxyuridine 5′-triphosphate 
nucleotidohydrolase (PfdUTPase) as the molecular target of securinine-type natural products. 
Strong binding was observed for securinine (171), its three stereoisomers 172–174 and 
norsecurinine (175). IC50 values in the range of 17.1–82.4 µM were found for these compounds 
during the asexual- and gametocyte-stages of the parasite. Antiprotozoal activity of securinine 
(171) against Toxoplasma gondii (causative agent of toxoplasmosis) was reported by 
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Ananvoranich and coworkers in 2011.191 In this study, not only was an antiproliferative activity 
of securinine (171) with an IC50 of 9.8 µM observed, but also its ability to induce parasite 
differentiation from the actively replicating tachyzoite stage to the dormant encysted bradyzoite 
stage. Furthermore, Diallo, Baldé and coworkers reported on the activity of Securinega 
alkaloids in extracts from M. discoidea against Trypanosoma brucei brucei (causative agent of 
African trypanosomiasis, sleeping sickness) and Trypanosoma cruzi (causative agent of 
American trypanosomiasis, Chagas disease).129,192 Interestingly, these authors did not observe 
any antibacterial activity against S. aureus and E. coli with concentrations up to 64 µg/mL. 
Also, no activity against P. falciparum was observed in this concentration range.  
 
Figure 25: Examples of Securinega alkaloids with anti-HIV activity reported by Yue et al. 
The team of Yue and coworkers reported the isolation of several Securinega alkaloids. Since 
2015, they systematically tested these newly discovered natural products for their antiviral 
activity on HIV-1 NL 4-3 infected human T-lymphoblastoid MT-4 cells.160f–h Mild anti-HIV 
activity was observed for flueggethers A (185) and D (202), the structurally unusual virosinine 
A (203) and several of the norsecurinine-based tetra- and pentameric fluevirosinines (Figure 
25). The observed half maximal effective concentrations (EC50) typically ranged from 43.1 µM 
for flueggether D (202) to 139 µM for fluevirosinine I with the exception of fluevirosinine B 
(204) showing an EC50 of 14.1 µM. These compounds generally exhibited no or only marginal 
cytotoxicity with IC50 values >100 µM. From 2002 to 2008, Singh and coworkers investigated 
the antifungal activities of ent-norsecurinine,193a norsecurinine (175),193b allosecurinine 
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(172)193c and securinine (171).193d These alkaloids were evaluated for their activities against 
spore germination of different plant pathogenic and saprophytic fungi including species from 
the Alternaria, Curvularia, Colletotrichum and Helminthosporium genera among others. Also, 
Erysiphe pisi, a causative agent of the pea powdery mildew, was tested. While all compounds 
were active, the best results were obtained with securinine (171) and allosecurinine (172). 
Complete inhibition of spore germination of some species was observed at concentrations as 
low as 200 ppm and strong growth inhibition of all investigated species was observed at 
1000 ppm. 
 
4.1.3 Biosynthesis 
The biosynthesis of Securinega alkaloids was investigated by three different groups in the 
1970s. Extensive feeding experiments of S. suffruticosa plants with radio-labeled compounds 
followed by extraction and chemical degradation of (mainly) securinine (171) established the 
biosynthetic origin of the Securinega alkaloids and led to the formulation of a plausible 
biogenetic pathway. Since the 1990s, several groups contributed to this area with refined 
proposals, many of which focused on the biogenesis of structurally unusual members. 
 
Scheme 38: Biogenetic origin of securinine. Only atoms shown in black were incorporated in the 
natural product. 
The biosynthesis of the tetracyclic alkaloid core was first investigated in 1974. Parry 
investigated the origin of the CD ring fragment and feeding experiments using racemic [2-14C]-
tyrosine (206) yielded radioactive securinine (171, Scheme 38).194 Administration of radio-
labeled phenylalanine did not yield radioactive securinine (171) and suggested that S. 
suffruticosa is not able to convert phenylalanine into tyrosine (206). Furthermore, Parry 
predicted that, in analogy to other piperidine alkaloids, the piperidine A ring of securinine (171) 
is naturally derived from lysine (205). A study by Yamasaki and coworkers proved that this 
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was indeed the case.195 Feeding experiments with racemic [2-14C]-lysine, L-[U-14C]-lysine 
(205) and [1,5-14C]-cadaverine (207) gave radioactive securinine (171), whereas the 
administration of other radio-labeled compounds like DOPA (1) and tyramine did not lead to 
incorporation of the labels. The authors also noted that similar results were obtained for 
allosecurinine (172) suggesting that both alkaloids are formed via similar pathways. In 1975, 
Parry reported the administration of (3R)-[3-3H]- and (3S)-[3-3H]-tyrosine (206) to S. 
suffruticosa plants.196 Securinine (171), that was biosynthetically derived from the (3S)-tritiated 
compound 206, showed only 6% incorporation of tritium while the (3R)-tritiated compound 
206 was incorporated in 72%. Since both chirally tritiated tyrosine (206) versions were only ca. 
85% stereochemically pure, these results demonstrated the stereospecific abstraction of 
hydrogen from the si face during biosynthesis. A study by Spenser and coworkers followed in 
1976 showing that the incorporation of lysine (205) was also proceeding in a non-symmetrical 
fashion.197 When racemic [2-14C]-lysine (205) or [2-14C]-Δ1-piperideine (208) were fed to the 
plants, the radio-label was specifically incorporated in the C2 position of securinine (171). 
Further experiments using [RS-6-3H;6-14C]-DL-lysine (205) indicated incorporation of the ε-
nitrogen of lysine (205) into securinine (171) as loss of the ε-nitrogen would have been 
accompanied by at least partial loss of tritium, which was not observed. 
 
Scheme 39: General biogenetic pathway for Securinega alkaloids proposed in the 1970s. 
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Based on these results, a general biosynthetic pathway was formulated.196,197 A similar 
biogenesis was expected for norsecurinine (175) involving ornithine instead of lysine (205). 
However, this pathway remains speculative and the detailed synthetic steps are still unknown. 
Since the neosecurinane-type alkaloids had not been discovered at the time, they were not 
considered in the investigations outlined above. Observations by Magnus and coworkers in the 
early 1990s provided some new insights on how securinane- and neosecurinane-type alkaloids 
might be linked biosynthetically.198 During the total synthesis of nirurine (178), an unusual 
rearrangement of a synthetic intermediate was observed under Mitsunobu reaction conditions. 
Starting from an azabicyclo[2.2.2]octane substrate, an azabicyclo[3.2.1]octane product was 
obtained in high yield. The authors investigated this transformation and optimized it for use in 
the total synthesis of racemic norsecurinine ((±)-175, Scheme 40A). When intermediate (±)-
215 was treated with methanesulfonyl chloride in the presence of triethylamine, clean 
rearrangement was observed giving racemic norsecurinine ((±)-175) in 91% yield. This 
observation refuels speculation about the biogenesis of such compounds. From previously 
proposed biosynthetic intermediate 213, two pathways become possible (Scheme 40B). The 
first scenario is a branched pathway leading to either neo(nor)securinane-type alkaloids via 1,6-
addition of the amine and reduction of the carbonyl or (nor)securinane-type alkaloids by 
reduction and amination. The second possibility is a linear pathway, where intermediate 213 
only forms neo(nor)securinane-type alkaloids, which are then rearranged to norsecurinane-type 
compounds through an aziridinium intermediate 216. Although a possible biogenetic relevance 
of the transformation was noted by Magnus and coworkers, the resulting significance for the 
biogenesis of Securinega alkaloids was not pointed out. In the literature, only one report by Ye, 
Jiang and coworkers took note of this rearrangement and reproduced the earlier findings.199 
Busqué, de March and coworkers suggested an alternative biosynthesis of intermediate 214 of 
the original proposal in 2008.200 The isomeric natural products (–)-menisdaurilide ((–)-217) and 
(–)-aquilegiolide ((–)-218, Scheme 41A), originally isolated from Aquilegia atrata in 1984,201 
                                                 
198 (a) P. Magnus, J. Ródriguez-López, K. Mulholland, I. Matthews, J. Am. Chem. Soc. 1992, 114, 383–
385; (b) P. Magnus, J. Ródriguez-López, K. Mulholland, I Matthews, Tetrahedron 1993, 49, 8059–
8072. 
199 N. Ma, Y. Yao, B.-X. Zhao, Y. Wang, W.-C. Ye, S. Jiang, Chem. Commun. 2014, 50, 9284–9287. 
200 G. G. Bardají, M. Cantó, R. Alibés, P. Bayón, F. Busqué, P. de March, M. Figueredo, J. Font, J. Org. 
Chem. 2008, 73, 7657–7662. 
201 A. Guerriero, F. Pietra, Phytochemistry 1984, 23, 2394–2396. 
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have also been isolated from plants of the genus Phyllanthus.202 In 2006, the isolation of 
(+)-menisdaurilide ((+)-217) and (+)-aquilegiolide ((+)-218) along with securinine (171) and 
other alkaloids from S. suffruticosa was reported for the first time.203 This study prompted the 
Spanish team to suggest these bicyclic lactones as biosynthetic intermediates of the Securinega 
alkaloids (Scheme 41B). The alternative route proposes formation of a CD ring subunit (217 or 
218) from tyrosine (206). Vinylogous Mannich addition of either butenolide 217 or 218 with 
Δ1-piperideine (208) or an equivalent C5N unit would lead to formation of the previously 
proposed intermediate 214. This strategy was realized in the total syntheses of allosecurinine 
(172) and viroallosecurinine (174, see Section 4.1.4). 
 
Scheme 40: A) Direct rearrangement of neonorsecurinane-type intermediate ((±)-215) to 
norsecurinane-type (±)-norsecurinine ((±)-175) reported by Magnus et al.; B) Possible biogenetic 
pathways for Securinega alkaloids. Similar pathways are expected for homologous alkaloids. 
 
                                                 
202 (a) T. L. Bachmann, F. Ghia, K. B. G. Torssel, Phytochemistry 1993, 33, 189–191; (b) R. M. Kuster, 
W. B. Mors, H. Wagner, Biochem. Syst. Ecol. 1997, 25, 675; (c) J. Youkwan, P. Srisomphot, S. 
Sutthivaiyakit, J. Nat. Prod. 2005, 68, 1006–1009. 
203 Y. Wang, Q. Li, W.-C. Ye, F. Ip, N. Ip, S.-X. Zhao, Zhongguo Tianran Yaowu 2006, 4, 260–263; 
Chem. Abstr. 2006, 146, 518050. 
Synthetic Studies on the Securinega Alkaloids 
88 
 
Scheme 41: A) Structures of natural lactones menisdaurilide (217) and aquilegiolide (218). B) 
Biosynthesis of Securinega alkaloids proposed by Busqué, de March et al. 
Further biogenetic investigations and speculations concerned the structurally unusual 
Securinega alkaloids. Cordell and coworkers isolated nirurine (178) in 1986 and proposed a 
biosynthesis for the compound (Scheme 42A).134 The authors suggested an intermediate 219 
derived from ornithine and dopamine. Cyclization to prenirurine (177) followed by oxidative 
oxazolidine formation possibly via an additional iminium ion intermediate (not shown) would 
lead to the formation of nirurine (178). Prenirurine (177) was isolated from Phyllanthus amarus 
in 1996 and named epibubbialine.163 Magnus and coworkers investigated the last cyclization 
step during their total synthesis of nirurine (178, Scheme 42B).198a When epibubbialine (177) 
was treated with mCPBA, nirurine (178) was formed but only in ca. 10% yield. The main 
product of this transformation was the tetracyclic compound 220 and it was concluded that the 
oxazolidine ring is probably formed earlier in the biosynthesis. 
 
Scheme 42: A) Biogenesis of nirurine (178) proposed by Cordell et al. B) Experimental observations 
by Magnus et al. 
Synthetic Studies on the Securinega Alkaloids 
89 
 
Scheme 43: A) Biosynthesis of secu’amamine A (179) proposed by Magnus et al. B) Model study 
providing evidence for an aziridinium ion intermediate. PNB = para-nitrobenzoyl. 
In 2006, Magnus and coworkers proposed a biosynthesis for secu’amamine A (179, Scheme 
43A).204 Starting from allosecurinine (172), the authors hypothesized that oxidation to 3β-
hydroxyallosecurinine (221) would give rise to a possible rearrangement. Formation of 
aziridinium intermediate 222 followed by the attack of water in the tertiary C2 position. 
Evidence for the existence of the putative aziridinium intermediate 222 was provided through 
a model system (Scheme 43B). When the deuterated ester 223 was treated with sodium acetate 
in refluxing acetic acid, two products were observed by 1H NMR analysis. The desired 
rearranged product 224 along with the transesterified compound 225 was identified proving the 
possibility of this transformation in the less-strained bicyclic system. 
 
Scheme 44: Biosyntheses of virosaine A (228) and flueggine A (182) proposed by Wang, Ye et al. 
                                                 
204 P. Magnus, A. I. Padilla, Org. Lett. 2006, 8, 3569–3571. 
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Along with the isolation of flueggine A (182)160b as well as virosaines A (228) and B (181),157 
Wang, Ye and coworkers provided a biosynthetic proposal for these compounds (Scheme 44). 
The authors speculated that the common intermediate 226 could be oxidized to nitrone 227, 
which could either react with norsecurinine (175) in an intermolecular 1,3-dipolar cycloaddition 
or perform an intramolecular 1,3-dipolar cycloaddition to give virosaine A (228) or B (181). 
Viability of both transformations was indicated by DFT calculations205 and all three natural 
products were synthesized using this strategy.158,159,199 
 
Scheme 45: The photodimerization of virosecurinine to flueggedine reported by Zhu, Chen, Ye et al. 
After the isolation of flueggedine (184), Zhu, Chen, Ye and coworkers deduced the compound 
was formed from virosecurinine (172) by a [2+2] cycloaddition (Scheme 45). When a solution 
of virosecurinine (172) in dichloromethane was irradiated with UV light, the formation of 
flueggedine (184) was observed. Even though dimer 184 was obtained in only 5% yield, it was 
the only photodimer formed in the reaction and 90% of starting material 172 were recovered. 
 
Scheme 46: Biosynthesis of flueggenine A (183) proposed by Yue et al. 
Biosyntheses of other Securinega alkaloid oligomers were proposed by Yue and coworkers. 
For example, biosynthetic dimerization of norsecurinine (175) could proceed via an acid-
catalyzed cycloaddition/ring-opening sequence involving an ammonium ion intermediate 229 
to give flueggenine A (183, Scheme 46).160c Using different monomer units or performing a 
similar transformation on the D ring double bond would explain the different connectivity 
observed among the oligomers.160f  
                                                 
205 P. P. Painter, R. P. Pemberton, B. M. Wong, K. C. Ho, D. J. Tantillo, J. Org. Chem. 2014, 79, 432–
435. 
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4.1.4 Total Synthesis of Securinega Alkaloids 
Numerous synthetic studies on the Securinega alkaloids have been published and more than 20 
papers have reported the total synthesis of one or several members of the compound family 
(Table 8).206 Most approaches targeted the azabicyclo[3.2.1]octane-based alkaloids securinine 
(171), norsecurinine (175) and their stereoisomers. But also different members featuring an 
azabicyclo[2.2.2]octane core such as nirurine (178),198 virosine A207 and bubbialidine158 as well 
as compounds with an unusual structure like virosaines A (228)158 and B (181)159 or flueggine 
A (182)159,199 have been synthesized. While a number of innovative strategies have been 
developed for the construction of the tetracyclic Securinega alkaloid core, different motifs have 
reoccurred over time and certain transformations have proven exceptionally useful. 
 
Scheme 47: The first total synthesis of racemic securinine (171) reported by Horii et al. in 1967. 
DBPO = dibenzoyl peroxide. 
The first total synthesis focused on securinine (171) and has been reported by Horii and coworkers in 
1967,143 right after their structural determination of the compound. The synthesis started with ketal 230, 
which was reacted with 2-pyridinyllithium (231), the two fragments representing rings C and A of the 
final natural product, respectively (Scheme 47). The pyridine 232 was reduced by hydrogenation 
affording diastereomers and the ketal group was cleaved using hydrochloric acid. The amine was 
protected with acetic anhydride and diastereomers were separated at this stage. By comparison with a 
degradation product of securinine (171) the major isomer was identified to possess the correct relative 
configuration and bromination afforded intermediate 233 in 14% yield. The unsaturation in the C ring 
was achieved by elimination of hydrogen bromide and the D ring was installed by addition of lithium 
ethoxyacetylide followed by acidic hydrolysis. The acyl protecting group on the amine had to be 
                                                 
206 Review: S. M. Weinreb, Nat. Prod. Rep. 2009, 26, 758–775. 
207 G. Bélanger, M. Dupuis, R. Larouche-Gauthier, J. Org. Chem. 2012, 77, 3215–3221. 
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exchanged to a more labile formyl group at this point affording the tricyclic intermediate 234. Final 
formation of the B ring was achieved applying an allylic bromination/deprotection/nucleophilic 
substitution sequence producing racemic securinine ((±)-171), although in low yield. Resolution of the 
enantiomers afforded pure securinine (171) and virosecurinine (173). 
Table 8: Previously published total syntheses of Securinega alkaloids in chronological order. 
Entry Author(s) Year Securinega Alkaloid(s) Ref. 
1 Horii et al. 1967 securinine (rac.) 143 
2 Heathcock et al. 1987 norsecurinine (rac.) 208 
3 Jacobi et al. 1991 (–)-, (+)-norsecurinine 209 
4 Magnus et al. 1992 norsecurinine (rac.), nirurine (rac.) 198 
5 Weinreb et al. 2000 (–)-norsecurinine, (+)-14,15-
dihydronorsecurinine, phyllanthine 
223 
6 Honda et al. 2000 securinine (rac., formal) 220 
7 Liras et al. 2001 securinine (rac.) 210 
8 Honda et al. 2004 viroallosecurinine 219 
9 Alibes, de March et al. 2004 securinine, (–)-allonorsecurinine 216 
10 Honda et al. 2004 securinine 218 
11 Figueredo et al. 2005 (–)-norsecurinine 213 
12 Kerr et al. 2006 (+)-phyllanthidine 156 
13 Weinreb et al. 2008 secu’amamine A 151 
14 Busqué, de March et 
al. 
2008 allosecurinine, viroallosecurinine 200 
15 Kerr et al. 2008 allosecurinine 212 
16 Thadani et al. 2009 securinine 217 
17 Bayón, Figueredo et al. 2009 securinine, (–)-norsecurinine 214 
18 Wood et al. 2010 (+)-norsecurinine, (+)-
allonorsecurinine 
211 
19 Srihari et al. 2012 (–)-allonorsecurinine 221 
20 Bélanger et al. 2012 virosine A 207 
21 Wood et al. 2012 securinine (rac.), allosecurinine (rac.) 215 
22 Yang, Li et al. 2013 virosaine B, flueggine A 159 
23 Gademann et al. 2013 bubbialidine, virosaine A 158 
24 Ye, Jiang et al. 2014 (–)-norsecurinine, (–)-niruroidine, 
flueggine A 
199 
25 Zheng et al. 2015 14,15-dihydrosecurinine, securinine 
(formal) 
224 
26 Smith et al. 2015 secu’amamine A 152 
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Scheme 48: The first enantiospecific total synthesis of norsecurinine (175) reported by Jacobi et al. in 
1991. 
After this seminal work, it took 20 years before the second total synthesis of a Securinega 
alkaloid was published by Heathcock and coworkers in 1987.208 Starting from proline 
representing the A ring fragment, the B, C and D rings were constructed in this sequence in 12 
linear steps affording racemic norsecurinine ((±)-175) in 2% overall yield. The first 
enantioselective synthesis of norsecurinine (175) was reported by Jacobi and coworkers in 
1991,209 who also utilized proline as a starting material (Scheme 48). Starting from either L- or 
D-proline afforded the enantiomerically pure (+)- or (–)-norsecurinine (175), respectively. In 
this approach, proline served as the A ring fragment and was converted to oxazole 235, which 
underwent spontaneous Michael addition with enone 236 to generate labile intermediate 237. 
Upon attempted chromatography of intermediate 237, retro-Michael addition was observed. 
Tricycle 238 was obtained in 46% yield by heating of the crude substance leading to a Diels-
Alder reaction between the oxazole and acetylene moieties under release of acetonitrile. The 
minor diastereomer could be separated and recycled by retro-Michael addition. Reduction of 
the keto function followed by dehydration formed the C ring double bond. The D ring was set 
up by desilylation and subsequent demethylation. Mesylation of the primary hydroxyl group 
gave intermediate 239. Final formation of the B ring was achieved by treatment with KHMDS 
leading to an intramolecular substitution reaction giving the natural product 175 in 69% yield. 
                                                 
208 C. H. Heathcock, T. W. von Geldern, Heterocycles 1987, 25, 75–78. 
209 P. A. Jacobi, C. A. Blum, R. W. DeSimone, U. E. S. Udodong, J. Am. Chem. Soc. 1991, 113, 5384–
5392. 
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Scheme 49: Key cycloaddition step in the total synthesis of nirurine (178) reported by Magnus et al. 
in 1992. 
One year later, Magnus and coworkers reported the total synthesis of nirurine (178), the first 
synthetic study on a Securinega alkaloid with an azabicyclo[2.2.2]octane core (Scheme 49).198 
This synthesis also relies on a key Diels-Alder reaction to form the tetracyclic core skeleton. 
Ester 242 was derived from 3-hydroxypyridine (240) and transformed into diene 243 in one 
step. Desilylation using potassium fluoride in aqueous acetic acid presumably led to formation 
of allene 244. An intramolecular [4+2] cycloaddition produced intermediate 245 in 45% yield, 
which was further transformed into nirurine (178). 
 
Scheme 50: The total synthesis of racemic securinine ((±)-171) reported by Liras et al. in 2001. 
Within the first four decades after their discovery, only four studies on the total synthesis of 
Securinega alkaloids have been published. Since 2000, however, interest in the synthesis of 
these challenging natural products has increased tremendously and a variety of synthetic 
strategies have been developed. The total synthesis of racemic securinine ((±)-171) reported by 
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Liras and coworkers in 2001 (Scheme 50)210 was pioneering in a sense, that it combined several 
methodologies, which frequently reoccurred in the syntheses published afterwards. Starting 
from silyloxyfuran 246, serving as the D ring precursor, addition to allyl bromide gave 
allylfuran 247 in good yield. Vinylogous Mannich reaction with an iminium species generated 
in situ from protected piperidine derivative 248 introduced the A ring. Addition of allyl phenyl 
sulfoxide (250) produced the intermediate 251, which was cyclized in a ring-closing metathesis 
(RCM) reaction using Grubbs’ first generation catalyst providing tricyclic intermediate 252. 
The double bond in the D ring was introduced by addition to phenylselenyl bromide and 
subsequent oxidation/elimination (253). Final formation of the B ring was achieved via acidic 
Boc deprotection followed by a dibromination/nucleophilic substitution/elimination sequence 
furnishing racemic securinine ((±)-171). This strategy is reminiscent of the allylic 
bromination/nucleophilic substitution sequence in the synthesis by Horii and coworkers (cf. 
Scheme 47) but distinct as it also leads to a net double bond isomerization. The same strategy 
has been used by Wood and coworkers in their 2010 total synthesis of (+)-allonorsecurinine.211 
 
Scheme 51: Diastereoselective total synthesis of securinine (171) reported by Honda et al. in 2004. 
The synthesis by Liras and coworkers exemplified the utility of RCM in the construction of the 
tetracyclic Securinega alkaloid frameworks and several other groups have used this 
transformation in their syntheses. While several approaches have adopted RCM for the 
                                                 
210 S. Liras, J. E. Davoren, J. Bordner, Org. Lett. 2001, 3, 703–706. 
211 M. R. Medeiros, J. L. Wood, Tetrahedron 2010, 66, 4701–4709. 
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formation of the C ring as seen above,156,198,212,213,214,215 there are also examples of D ring 
formations accomplished by this technique.216,217 An impressive one-step C/D ring formation 
approach via tandem RCM in the first stereoselective total synthesis of securinine has been 
reported by Honda and coworkers in 2004 (Scheme 51).218 Starting from known R-pipecolic 
acid-derived thioester 254 unsaturated side-chains were introduced sequentially by addition of 
(Z)-3-hexenylmagnesium bromide (255) to the thioester followed by addition of TMS acetylene 
to the ketone and desilylation to give enyne 257 in excellent yield. Alkylation of the hydroxyl 
function using allyl trichloroacetimidate (258) affording dienyne 259 set up the stage for the 
key tandem RCM reaction using the ruthenium catalyst 260 to construct the C/D ring system in 
one step and high yield. Attempts to use an acrylate ester instead of allyl ether 259 in this 
transformation were unsuccessful and thus allylic oxidation with chromium trioxide and 3,5-
dimethylpyrazole (262) was applied to form the butenolide 263. Final B ring formation was 
accomplished using the bromination/deprotection/substitution sequence originally developed 
by Horii and coworkers. A very similar strategy has been applied in the total synthesis of 
viroallosecurinine (174) reported in a follow-up publication by Honda and coworkers in 
2004.219 
 
Scheme 52: Tandem RCM in the synthesis of norsecurinine (175) reported by Yang, Li et al. in 2013. 
  
                                                 
212 A. B. Leduc, M. A. Kerr, Angew. Chem. Int. Ed. 2008, 47, 7945–7948. 
213 R. Alibés, P. Bayón, P. de March, M. Figueredo, J. Font, E. García-García, D. González-Gálvez, 
Org. Lett. 2005, 7, 5107–5109. 
214 D. González-Gálvez, E. García-García, R. Alibés, P. Bayón, P. de March, M. Figueredo, J. Font, J. 
Org. Chem. 2009, 74, 6199–6211. 
215 J.-H. Chen, S. R. Levine, J. F. Buergler, T. C. McMahon, M. R. Medeiros, J. L. Wood, Org. Lett. 
2012, 14, 4531–4533. 
216 R. Alibés, M. Ballbé, F. Busqué, P. de March, L. Elias, M. Figueredo, J. Font, Org. Lett. 2004, 6, 
1813–1816. 
217 B. Dhudshia, B. F. T. Cooper, C. L. B. Macdonald, A. N. Thadani, Chem. Commun. 2009, 463–465. 
218 T. Honda, H. Namiki, K. Kaneda, H. Mizutani, Org. Lett. 2004, 6, 87–89. 
219 T. Honda, H. Namiki, M. Watanabe, H. Mizutani, Tetrahedron Lett. 2004, 45, 5211–5213. 
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This tandem RCM strategy was later picked up by Yang, Li and coworkers in their total 
syntheses of virosaine B (181) and flueggine A (182) published in 2013,159 which proceeded 
via norsecurinine (175) and (+)-allonorsecurinine as intermediates. In this report, commercially 
available Weinreb amide 264 was converted into intermediate 265 in an alkylation sequence 
very similar to the one described above (Scheme 52). The use of relay RCM facilitated tandem 
enyne metathesis on the α,β-unsaturated ester 265 allowing for the direct formation of the 
butenolide moiety obviating an additional oxidation step. Again, B ring formation of tricyclic 
intermediate 267 was accomplished using the sequence by Horii and coworkers affording 
norsecurinine (175) in this case. Interestingly, this sequence became increasingly popular and 
many groups reported on its use in the recent years.199,216,220,221 
 
Scheme 53: Total synthesis of norsecurinine (175) reported by Figueredo et al. in 2005. 
Application of the vinylogous Mannich reaction to connect A and D ring fragments, which was 
pioneered by Liras and coworkers (cf. Scheme 50), was also implemented by other research 
groups. In the total synthesis of norsecurinine (175) reported by Figueredo and coworkers in 
2005 (Scheme 53),213 this transformation was used to prepare RCM precursor 271. Hydroxy-
lactam 269 was synthesized from succinimide (268) in three steps. Exposure to boron trifluoride 
etherate lead to formation of the corresponding N-acyliminium ion, which was captured with 
silyloxyfuran 270 to form product 271. Cyclization by RCM followed by reduction of the 
lactam and desilylation gave known intermediate 272. Following the mesylation/nucleophilic 
substitution sequence developed by Jacobi and coworkers (cf. Scheme 48) yielded 
                                                 
220 T. Honda, H. Namiki, M. Kudoh, N. Watanabe, H. Nagase, H. Mizutani, Tetrahedron Lett. 2000, 41, 
5927–5930. 
221 A. S. Reddy, P. Srihari, Tetrahedron Lett. 2012, 53, 5926–5928. 
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norsecurinine (175). This approach has also been applied in the total synthesis of securinine 
(171) reported by the same group in 2009.214 
 
Scheme 54: Total synthesis of allosecurinine (172) starting from the natural product 
(+)-menisdaurilide ((+)-217) reported by Busqué, de March et al. in 2008. 
The same group reported another strategy involving a key vinylogous Mannich reaction in 
2008.200 Their synthesis commenced from the natural product (+)-menisdaurilide ((+)-217), the 
synthesis of which they had reported before,222 and a possible biogenetic relevance of the key 
transformation was suggested (Scheme 54). After protection of (+)-menisdaurilide ((+)-217), a 
one-pot procedure including formation of a silyloxyfuran from butenolide 273 followed by 
vinylogous Mannich reaction with an N-acyliminium ion afforded intermediate 275. The N-
acyliminium ion was generated in situ from lactamol 274 by Lewis acid activation using 
dibutylboron triflate. Only two chromatographically separable diastereomers were formed in 
this transformation in a ratio of 4:1 with the major isomer 275 possessing the desired absolute 
configuration. The synthesis was completed by desilylation followed by mesylation to create a 
leaving group. Acidic Boc cleavage and subsequent intramolecular substitution furnished 
allosecurinine (172). The same synthetic route was applied using (–)-menisdaurilide ((–)-217) 
providing viroallosecurinine (174). 
                                                 
222 F. Busqué, M. Cantó, P. de March, M. Figueredo, J. Font, S. Rodríguez, Tetrahedron: Asymmetry 
2003, 14, 2021–2032. 
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Scheme 55: Recent approach to the tricyclic core of Securinega alkaloids using NHC catalysis by 
Snyder et al. and an extension of the methodology employing a hetero-Pauson-Khand reaction by 
Porée et al. 
Beside the frequently reoccurring synthetic motifs described so far other unique methods have 
enriched the diversity of Securinega alkaloid total synthesis. For example, the studies on 
butenolide D ring formation by Horner-Wadsworth-Emmons reaction or a related one-pot 
procedure applying the Bestmann ylide during the total syntheses of norsecurinine (175), 
(+)-14,15-dihydronorsecurinine and phyllanthine by Weinreb and coworkers,223 which have 
been picked up during the recent total synthesis of 14,15-dihydrosecurinine by Zheng and 
coworkers.224 Also the aza-Michael addition/aldol addition/lactonization sequence developed 
by Weinreb and coworkers for the construction of secu’amamine A should be mentioned at this 
point.151 Another unique approach toward the bridged B/C/D ring system of securinine (171) 
was recently reported by Snyder and coworkers (Scheme 55).225 By an intramolecular 
N-heterocyclic carbene (NHC)-catalyzed [3+2] cycloaddition using catalyst precursor 278 in 
the presence of titanium isopropoxide, the ynal and keto functions of compound 277 were 
cyclized in a single step to yield the protected Securinega alkaloid core 279 in 31%. Inspired 
by this work, Porée and coworkers have developed a [2+2+1] cycloaddition approach featuring 
a hetero-Pauson-Khand reaction.226 Thus, the precursor 280 carries a terminal alkyne and the 
missing C1 unit is introduced by metal-bound carbon monoxide. Although the product 279 was 
obtained in only 50% yield, this transformation seems highly valuable for the development of 
further synthetic strategies toward the Securinega alkaloid family. 
 
                                                 
223 (a) G. Han, M. G. LaPorte, J. J. Folmer, K. M. Werner, S. M. Weinreb, Angew. Chem. Int. Ed. 2000, 
39, 237–240; (b) G. Han, M. G. LaPorte, J. J. Folmer, K. M. Werner, S. M. Weinreb, J. Org. Chem. 
2000, 65, 6293–6306. 
224 X. Zheng, J. Liu, C.-X. Ye, A. Wang, A.-E. Wang, P.-Q. Huang, J. Org. Chem. 2015, 80, 1034–1041. 
225 A. M. ElSohly, D. A. Wespe, T. J. Poore, S. A. Snyder, Angew. Chem. Int. Ed. 2013, 52, 5789–5794. 
226 E. Chirkin, S. Michel, F.-H. Porée, J. Org. Chem. 2015, 80, 6525–6528. 
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4.1.5 The Total Syntheses of Bubbialidine and Virosaine A 
In 2013, our research group has published the first enantioselective total syntheses of the 
neosecurinane-type alkaloid bubbialidine (292) and the unusual birdcage-shaped virosaine A 
(228),158 which were both accessed by the synthetic route outlined in the following. A key 
intermediate of the synthesis is the butenolide 288, which represents the C and D rings in the 
final natural product and is the TBDPS-protected form of the natural product (+)-aquilegiolide 
((+)-218). The route to compound 288 was based on related synthetic studies reported in the 
literature.200,227 Initially the synthesis was designed to yield virosaine A (228), which had been 
isolated from F. virosa in 2012 by Wang, Zhang, Ye and coworkers.157 Bubbialidine (292) was 
obtained by deprotection of an intermediate en route. 
 
Scheme 56: Synthesis of the bicyclic key intermediate 288. 
The synthesis commenced with a mono-epoxidation of commercially available 1,4-cyclohexa-
diene (281) with meta-chloroperbenzoic acid (mCPBA) followed by epoxide opening using 
cyanomethyllithium (Scheme 56). The resulting secondary alcohol was acetylated with acetic 
anhydride giving the racemic acetate 282 in 22% yield. Enzymatic kinetic resolution was 
applied as the source of chirality in the synthesis and alcohol 283 was obtained in 95% 
enantiomeric excess. Basic hydrolysis of the nitrile function and subsequent acid-catalyzed 
lactone formation gave compound 286 in 80% yield.227a The D ring double bond was introduced 
by an α-selenation/oxidative elimination sequence affording the butenolide 287 in a moderate 
yield of 48%. Diastereoselective introduction of the hydroxyl group and concomitant 
isomerization of the C-C double bond into conjugation with the butenolide moiety was achieved 
through epoxidation using mCPBA followed by regioselective epoxide opening using 
potassium carbonate. Protection with TBDPSCl afforded the intermediate 288 in 50% yield. 
                                                 
227 (a) N. Kato, M. Inada, H. Sato, S. Ito, M. Shoji, M. Ueda, Tetrahedron Lett. 2007, 48, 7702–7705; 
(b) G. Audran, K. Mori, Eur. J. Org. Chem. 1998, 57–62. 
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Scheme 57: Construction of the bridged tetracyclic framework and synthesis of bubbialidine (292). 
The A ring pyrrolidine fragment was introduced by a vinylogous Mannich reaction applying 
the one-pot procedure developed by Busqué, de March and coworkers.200 The reaction afforded 
an excellent yield of 90% and only two out of four possible diastereomers were formed and 
could be separated chromatographically (290, Scheme 57). Rather surprisingly a diastereomeric 
ratio of only 1:1 was observed diminishing the high yield. In contrast, the original publication 
reported a diastereomeric ratio of 4:1 in favor of the desired isomer using a homologous 6-
membered lactamol. The secondary amine of diastereomer 290 was deprotected under acidic 
conditions affording the corresponding hydrochloride salt. Under extremely mild conditions 
using dipotassium hydrogen phosphate as a base, intramolecular vinylogous aza-Michael 
addition occurred affording the bridged tetracycle 291 in an excellent yield of 86% over the two 
steps. Desilylation of this intermediate using Olah’s reagent led to the natural product 
bubbialidine (292) in 92% yield. 
 
Scheme 58: Final steps in the total synthesis of virosaine A (228). 
Moving on toward the second natural product intermediate 291 was oxidized to the 
corresponding N-oxide using mCPBA (Scheme 58). Cope elimination was observed upon 
exposure to silica opening up the B ring to give hydroxylamine 293. Oxidation to the nitrone 
295 with N-tert-butylbenzenesulfinimidoyl chloride (294) in the presence of 1,8-diazabicyclo-
[5.4.0]undec-7-en (DBU) proceeded regioselectively and a spontaneous intramolecular 1,3-
dipolar cycloaddition furnished the unusual alkaloid framework. Final desilylation using 
tetrabutylammonium fluoride (TBAF) produced the natural product virosaine A (228) in 81% 
yield. 
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4.1.6 Secu’amamine E and its Enantiomer Virosine A 
In continuation of the synthetic program on Securinega alkaloids within our research group, we 
turned our focus on neosecurinane-type alkaloid secu’amamine E (296, Figure 26), which was 
isolated alongside secu’amamines F and G from Securinega suffruticosa var. amamiensis by 
Ohsaki and coworkers in 2009.186 Their structures were elucidated by spectroscopic means 
(mainly NMR spectroscopy) and the absolute configuration of their BC ring systems was 
determined to be opposite to securinol A (176) by a comparison of the respective circular 
dichroism (CD) spectra showing an opposite Cotton effect. Thus, secu’amamine E (296) is the 
higher homolog of bubbialidine (292) and represents an attractive target for total synthesis, as 
it should be obtainable using a similar synthetic strategy. No detailed investigations concerning 
the bioactivity of secu’amamine E (296) have been reported. The isolation paper states that no 
cytotoxicity on P388 leukemia cells was observed, in a short comment at the end of the 
publication. Also, no synthetic studies by other research groups towards this alkaloid have been 
reported to date. 
 
Figure 26: Structures of different neosecurinane-type alkaloids. 
Another neosecurinane-type alkaloid isolated from Flueggea virosa by Ye and coworkers in 
2008 is virosine A (297), the optical antipode of secu’amamine E (296).164 Its structure and 
absolute configuration were determined using the same techniques mentioned above, namely 
NMR and CD spectroscopy. Again, no investigations concerning the bioactivity of this alkaloid 
have been reported. The structure of virosine A (297) was confirmed via total synthesis of the 
natural product by Bélanger and coworkers in 2012.207 Due to the enantiomeric relationship 
between virosine A (297) and secu’amamine E (296), which has not been pointed out in any of 
the mentioned literature reports, the key features of the synthesis by Bélanger and coworkers 
shall be presented at this point. 
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Scheme 59: Enantioselective total synthesis of virosine A (297) reported by Bélanger et al. in 2012. 
The synthesis started from meso-epoxide 298, which was elaborated into intermediate 299 in 
46% overall yield via chromium-catalyzed desymmetrization using azidotrimethylsilane, 
hydroxyl-directed epoxidation followed by silyl protection and subsequent epoxide opening 
with diethylphosphonoacetic acid (Scheme 59). The hydroxyl function was oxidized using 
Dess-Martin periodinane (DMP) and treatment with potassium tert-butoxide triggered an 
intramolecular Horner-Wadsworth-Emmons reaction to obtain butenolide 300 representing the 
C/D ring system of the final natural product. The azide group was then reduced and the resulting 
amine was alkylated and formylated sequentially using 3-butynyl tosylate (301) and N-formyl-
benzotriazole (303), respectively. Silylation of the butenolide moiety afforded silyloxyfuran 
304 in 49% yield from azide 300. The key transformation of the synthesis was a Vilsmeier-
Haack/Mannich cyclization cascade leading to the bridged tetracyclic core structure, a method 
that had been reported by the same group in 2008.228 Activation of the formyl group using triflic 
anhydride and 2,6-di-tert-butyl-4-methylpyridine (DTBMP) led to Vilsmeier-Haack reaction 
with the silyloxyfuran moiety. The resulting iminium species then reacted with the terminal 
alkyne function in a Mannich reaction upon addition of tetrabutylphosphonium bromide giving 
tetracycle 305 in 58% yield. Cleavage of the bromide, reduction of the A ring by hydrogenation 
and final desilylation of the hydroxyl group provided virosine A (297) in 46% yield. In 
summary, the natural product 297 was obtained by a sequence of 13 linear steps in 3.4% overall 
yield from meso-epoxide 298.  
                                                 
228 R. Larouche-Gauthier, G. Bélanger, Org. Lett. 2008, 10, 4501–4504. 
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4.2 The First Enantioselective Total Synthesis of Secu’amamine E229 
4.2.1 Synthetic Outline 
After the total syntheses of bubbialidine (292) and virosaine A (228) had been accomplished in 
our group, focus turned toward secu’amamine E (296). Structurally the two alkaloids only differ 
in the A ring. While bubbialidine (292) is characterized as a neonorsecurinane-type alkaloid 
containing a pyrrolidine unit, secu’amamine E (296) belongs to the neosecurinane group 
containing a piperidine unit instead and thus it represents the higher homolog of bubbialidine 
(292). We therefore envisioned that secu’amamine E (296) could be constructed using a strategy 
based on the synthetic route developed for bubbialidine (292) and virosaine A (228, cf. Section 
4.1.5). 
 
Scheme 60: Retrosynthetic analysis of secu’amamine E (296). 
The vinylogous Mannich/aza-Michael reaction sequence was very efficient in the construction 
of the bridged tetracycle and should be adopted for the present project leading back to the 
known intermediate 288. In our earlier work, this intermediate was synthesized in 11 linear 
steps. Due to some low yielding transformations as well as an enzymatic kinetic resolution, 
intermediate 288 was obtained in only 1.6% overall yield from 1,4-cyclohexadiene (281). A 
more convenient approach to access this compound is desirable, as it could serve as a general 
intermediate on the way to several Securinega alkaloids considering that both configurations of 
the silyl ether might be obtainable through the same route. The configuration of the butenolide 
moiety is of no concern at this point, as the following vinylogous Mannich reaction proceeds 
via the corresponding planar silyloxyfuran. We planned to synthesize butenolide 288 by 
α-hydroxylation of enone 306 and cyclization either through intramolecular aldol condensation 
or Horner-Wadsworth-Emmons olefination of a suitable ester precursor would furnish the 
butenolide moiety. An efficient synthesis of enone 306 from mono-ketal 307 was described by 
Hayashi and coworkers during the total synthesis of (+)-panepophenanthrin.230 
                                                 
229 Simone M. Grendelmeier has contributed to this work during her Master’s thesis, Basel, 2015. 
230 M. Matsuzawa, H. Kakeya, J. Yamaguchi, M. Shoji, R. Onose, H. Osada, Y. Hayashi, Chem. Asian 
J. 2006, 1, 845–851. 
Synthetic Studies on the Securinega Alkaloids 
105 
4.2.2 Synthesis of the C Ring Fragment 
 
Scheme 61: Introduction of chirality via organocatalysis and stereoselective reduction. 
Our synthetic efforts commenced with the synthesis of enone 306 via the route developed by 
Hayashi and coworkers (Scheme 61).230 Nitrosobenzene (309) was obtained in 39% yield by 
oxidation of aniline (308) with sodium tungstate and hydrogen peroxide following a known 
procedure.231 Mono-ketal 307 was then subjected to an organocatalyzed α-aminoxylation 
reaction using nitrosobenzene as the electrophile and D-proline as the catalyst affording the 
(S)-configured ketal 310 in 76% yield after flash chromatography on an 84-mmol scale. The 
keto function was then reduced in a stereoselective fashion using K-selectride (potassium tri-
sec-butylborohydride) to afford exclusively the syn-product. After workup, the crude material 
was hydrogenated overnight using palladium on charcoal under a hydrogen atmosphere. The 
syn-diol 311 was obtained in 77% yield from ketone 310. An alternative method for reductive 
N-O bond cleavage reported in the literature using catalytic amounts of copper(II) sulfate232 
(and thus avoiding the use of hydrogen gas) was not successful leading to decomposition of the 
substrate. 
 
Scheme 62: Synthesis of silyl-protected enone 311. 
Acidic treatment of diol 311 with Amberlyst 15 in a refluxing mixture of THF, acetone and 
water led to cleavage of the ketal moiety followed by elimination of water to give the enone 
306 in 68% yield (Scheme 62). While thorough washing of the acidic resin with THF had to be 
performed in all cases to obtain workable amounts of product, the mode of heating had a large 
                                                 
231 S. M. Opalka, A. R. Longstreet, D. T. McQuade, Beilstein J. Org. Chem. 2011, 7, 1671–1679. 
232 N. Momiyama, H. Yamamoto, J. Am. Chem. Soc. 2003, 125, 6038–6039. 
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impact on the composition of the reaction mixture after different reaction times. When this 
transformation was performed conventionally by heating on an oil bath at 80 °C, slow 
conversion of starting material was observed (>24 h) and only the desired product 306 could be 
identified in the reaction mixture by means of 1H NMR spectroscopy. The rest of the material 
seemed to have decomposed, possibly by polymerization of the enone function or elimination 
of the second hydroxyl group. When performed in a sealed tube in a microwave reactor at 100 
°C, only the desired enone 306 and the starting material 311 were observed by 1H NMR analysis 
of the mixture after 1 h reaction time. Further heating of the mixture did not lead to further 
conversion of substrate 311. In both cases the enone 306 was usually isolated in ca. 50% yield 
with the latter procedure providing an additional amount of 36% of the starting material 311. 
While enone 306 could be obtained by the route of Hayashi and coworkers, on large scale only 
30% overall yield from ketal 307 could be achieved, as microwave reactions were limited to 
small scale. It should be mentioned at this point, that even though all four transformations (307 
to 306) were performed several times independently by two experimenters using different 
substrate and reagent batches, the high yields reported in the literature could not be reproduced 
in our hands (76%/77%/68% vs. 93%/85%/85%).230 
The hydroxyl group of enone 306 was protected as a silyl ether using TBDPS chloride in the 
presence of imidazole and DMAP. Initially this transformation was performed following a 
procedure reported by Busqué, de March and coworkers for the silylation of menisdaurilide 
(217, cf. Scheme 54),200 which used an excess of imidazole (3.1 eq.). Employing the same 
amount of reagent in the present transformation led to a low isolated yield of the desired product 
312. In one case, an undesired compound was isolated in large amount. HRMS analysis 
confirmed that the compound was formed by addition of imidazole onto the desired enone 312. 
Most probably 1,4-addition of imidazole gave the trans-Michael adduct as indicated by 1H 
NMR analysis. When a smaller amount of only 1.02 eq. of imidazole was applied together with 
1.02 eq. of TBDPSCl and 0.1 eq. DMAP, the desired silyl ether 312 was obtained in 94% yield 
on a 13-mmol scale. 
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4.2.3 Construction of the D Ring Butenolide 
 
Scheme 63: Rubottom oxidation was not successful in the synthesis of the α-hydroxy enone 314. 
R = Me, Et. 
For the formation of the D ring we planned to perform α-hydroxylation on the enone 312 
followed by esterification with a C2 building block suitable for an intramolecular olefination to 
forge the butenolide moiety. Initial attempts to synthesize the α-hydroxy ketone 314 focused on 
the Rubottom oxidation (Scheme 63). Treatment with either TMSCl or TESCl in 
dichloromethane at 0 °C and NaHMDS as a base produced silyl ethers 313 from enone 312. 
After extraction and evaporation, the successful formation of both silyl ethers 313 was 
confirmed by 1H NMR analysis of the crude substances. Intermediate 313 was then redissolved 
in dichloromethane and mCPBA was added at 0 °C. Unfortunately, the desired product 314 was 
not formed and only decomposition of the starting material was observed. The outcome of this 
transformation is likely due to the presence of a second double bond in the substrate leading to 
undesired side reactions. 
 
Scheme 64: Preparation of Davis oxaziridine 318. 
To avoid possible side reactions of the second double bond, we switched to the use N-sulfonyl-
oxaziridines (Davis oxaziridines) as an electrophilic oxygen source. Following the original 
procedures developed by Davis and coworkers,233 benzenesulfonamide (315) and benzaldehyde 
dimethyl acetal (316) were condensed to obtain the sulfonimine 317 and oxidation with mCPBA 
gave the Davis oxaziridine 318 in excellent yield (Scheme 64). 
                                                 
233 (a) F. A. Davis, J. Lamendola, Jr., U. Nadir, E. W. Kluger, T. C. Sedergran, T. W. Panunto, R. 
Billmers, R. Jenkins, Jr., I. J. Turchi, W. H. Watson, J. S. Chen, M. Kimura, J. Am. Chem. Soc. 1980, 
102, 2000–2005; (b) F. A. Davis, O. D. Stringer, J. Org. Chem. 1982, 47, 1774–1775. 
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Scheme 65: α-Hydroxylation efforts using Davis oxaziridines. 
When enone 312 was reacted with NaHMDS in THF at –78 °C followed by the addition of 
Davis oxaziridine 318, clean formation of the desired α-hydroxy ketone 314 as a single 
diastereomer was observed (Scheme 65). In the reaction mixture, only the desired product 314 
along with sulfonimine 317, the oxaziridine-derived byproduct, was detected by 1H NMR 
analysis after quenching with an aqueous ammonium chloride solution. The same reaction 
outcome was observed when a mixture of enone 312 and oxaziridine 318 in THF at –78 °C was 
directly treated with NaHMDS simplifying the experimental procedure. However, purification 
of product 314 proved to be difficult. Not only was the compound decomposing slowly during 
chromatography over silica, also an identical Rf value of the similarly decomposing sulfonimine 
317 was observed. Chromatography over alumina resulted in complete decomposition of the 
product 314. Addition of 1 M aqueous hydrogen chloride solution to the reaction mixture after 
quenching led to hydrolysis of the sulfonimine 317 but only <50% yield of the desired product 
314 was obtained after chromatography over a short silica column. Also, experiments using 
powdered active charcoal to remove the byproduct 317 were not successful. The best results 
were obtained when after extraction of the reaction mixture with diethyl ether, the combined 
organic layers were washed several times with a 10% aqueous solution of sodium hydrogen 
sulfite. This procedure removed most of the imine and aldehyde (from hydrolysis of 
sulfonimine 317) contents and, after drying and evaporation, gave crude α-hydroxy ketone 314 
as a yellow oil, which was not purified further. Attempts to avoid byproduct 317 by the use of 
oxaziridine 319 failed as formation of compound 314 was not observed. 
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Scheme 66: Two-step esterification/olefination approaches towards butenolide 288. R = Me, Et. 
Esterification of α-hydroxy ketone 314 was performed using either acetic anhydride to generate 
acetate 320 or a 2-(dialkylphosphoryl)acetic acid (321) to generate the dimethyl- as wells as the 
diethylphosphonate 322 (Scheme 66). While TLC and 1H NMR analyses indicated clean 
formation of each of the three esters, cyclization efforts to obtain butenolide 288 failed in all 
cases and only decomposition of the substrates was observed. 
 
Scheme 67: Optimized synthesis of intermediate 288 by α-hydroxylation with Davis oxaziridine 318 
and butenolide formation with the Bestmann ylide (323). 
A very attractive approach Weinreb and coworkers had used for the late stage D ring formation 
in their synthesis of (+)-14,15-dihydronorsecurinine223 is the use of the Bestmann ylide (323).234 
In a one-pot procedure, nucleophilic addition of alcohol 314 to the ketene carbonyl and 
subsequent intramolecular Wittig olefination gave the desired silyl-protected (+)-aquilegiolide 
288 (Scheme 67). The highest yields were obtained when a mixture of crude α-hydroxy ketone 
314 (as described above) and ylide 323 in benzene were heated at 85 °C in a microwave reactor 
giving 43% yield of the key intermediate 288 over two steps in a diastereomeric ratio 3.3:1 
estimated by 1H NMR analysis. The outcome of this transformation was highly dependent on 
the quality of the starting materials used. The moisture sensitive ylide 323 was best prepared 
                                                 
234 H. J. Bestmann, D. Sandmeier, Chem. Ber. 1980, 113, 274–277. 
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by elimination of ethanol from the corresponding ester, ethyl (triphenylphosphanylidene)-
acetate,235 and used within a few days. But also, the purity of the α-hydroxy ketone 314 was 
crucial and yields for this sequence varied substantially. The addition of triethylamine had no 
influence on the transformation. In contrast to our earlier work, where the intermediate 288 was 
obtained as a colorless solid,158 material produced via the present route was always obtained as 
a yellowish oil, which could not be purified further by repeated flash chromatography. Although 
1H NMR analysis indicated high purity of the butenolide 288, further investigations on the 
identity and origin of the impurities might lead to improved results in the D ring formation. 
 
Scheme 68: Comparison of the two syntheses of intermediate 288 developed by our group. 
Compared to our old synthesis we could shorten the route from 11 linear synthetic steps to only 
7 steps and we could significantly improve the overall yield from 1.6% to 16.1% (Scheme 68). 
Considering the moderate yield of 43% for the last two steps of the sequence, further 
improvements of these transformations would boost the overall results of the present synthesis. 
 
4.2.4 Final Assembly of Secu’amamine E 
In order to set up the carbon skeleton of secu’amamine E (296) from the butenolide key inter-
mediate 288, the piperidine A ring had to be introduced and the bridging B ring needed to be 
closed. Due to the structural similarity between secu’amamine E (296) and bubbialidine (292) 
we planned to adopt the remaining steps from our total synthesis of the latter alkaloid. Thus, 
the A ring fragment was introduced using the vinylogous Mannich reaction described by 
Busqué, de March and coworkers.200 
                                                 
235 I. S. Marcos, A. Benéitez, R. F. Moro, P. Basabe, D. Dìez, J. G. Urones, Tetrahedron 2010, 66, 8605–
8614. 
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Scheme 69: Introduction of the piperidine A ring by a vinylogous Mannich reaction. 
Butenolide 288 was converted into the silyloxyfuran 324 using triisopropylsilyl triflate in the 
presence of triethylamine and TLC indicated a clean spot-to-spot transformation (Scheme 69). 
Since stereo information of the butenolide moiety is erased during this step, the starting material 
could be utilized as a diastereomeric mixture. The Boc-protected δ-lactamol 274 served as the 
A ring precursor and was prepared from the corresponding lactam by reduction with lithium 
triethylborohydride.236 Addition of dibutylboron triflate to a mixture of silyloxyfuran 324 and 
lactamol 274 in diethyl ether at –78 °C triggered formation of an N-acyliminium ion. 
Subsequent attack of the silyloxyfuran 324 gave the Mannich addition product as a mixture of 
two diastereomers in a ratio of 4.3:1 and a combined yield of 85%. The diastereomers were 
separated by repeated flash chromatography affording the pure major isomer 275 in 69% yield. 
In contrast to our earlier work, where the five-membered γ-lactamol 289 had been used instead 
of δ-lactamol 274 and the two diastereomers were obtained in a 1:1 ratio (cf. Scheme 57), the 
present transformation proceeded with good diastereoselectivity reproducing the values 
reported in the original publication. Furthermore, the pure diastereomer 275 displayed two sets 
of signals in the 1H NMR spectrum corresponding to rotamers as described by Busqué, de 
March and coworkers.200 
 
Scheme 70: B ring formation and synthesis of secu’amamine E (296). 
The Boc protecting group was removed from the piperidine ring by heating of intermediate 275 
in a 2 M ethereal hydrogen chloride solution giving the hydrochloride salt 325 in an excellent 
                                                 
236 R. K. Dieter, R. R. Sharma, J. Org. Chem. 1996, 61, 4180–4184. 
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yield of 97% after dilution with dichloromethane, filtration, and evaporation of the reaction 
mixture (Scheme 70). This transformation was also performed in a 1 M solution of acid 
requiring approximately double reaction time. When the reaction was carried out by 
conventional heating on an oil bath, small amounts of the starting material 275 were detected 
even after 40 h reaction time. Hydrochloride 325 was then subjected to an intramolecular 
vinylogous aza-Michael addition to close the bridging B ring and form the azabicyclo[2.2.2]-
octane core of the natural product. When the reaction was performed under our original 
conditions using dipotassium hydrogen phosphate in DMF at 75 °C, only partial conversion to 
the desired tetracycle 326 was observed. The transformation required long reaction times of 
more than 24 h and strongly varying yields of the product were isolated after flash 
chromatography (ca. 20–73%). Upon switching to more basic potassium carbonate instead of 
the phosphate base, a reproducible yield of 81% of tetracycle 326 was obtained after only 3 h 
reaction time. Final desilylation was achieved by treatment with an excess of Olah’s reagent in 
THF at room temperature affording the natural product secu’amamine E (296) in an excellent 
yield of 98% after flash chromatography. Analytical data collected from the synthetic material 
matched those reported by Ohsaki and coworkers for the authentic natural product (Table 9). 
While optical rotation values were almost identical for natural and synthetic samples, also the 
NMR data were in good agreement. In the 1H NMR spectrum, chemical shifts of synthetic 
secu’amamine E (296) did not deviate more than 0.02 ppm from the values of the natural sample 
except for three overlapping signals, which were not resolved in the spectrum of the synthetic 
material and were therefore averaged as one signal. Chemical shifts in the 13C NMR spectrum 
showed a small general deviation of –0.04 to –0.06 ppm for all signals, possibly due to slight 
differences in pH of the deuterated solvents. Furthermore, FTIR and HRMS data were collected 
supporting the identity of the synthetic natural product. Thus, we have achieved the first 
enantioselective total synthesis of secu’amamine E (296) in 12 synthetic steps from 
commercially available ketal 307 in an overall yield of 8.5%. 
We investigated the toxicity of secu’amamine E (296) in an assay against Thamnocephalus 
platyurus (beaver-tail fairy shrimp).237 After 24 h of incubation, no toxic effects were 
observed in concentrations up to 100 µM confirming the findings by Ohsaki and coworkers.186 
                                                 
237 The assay was conducted in cooperation with Manuel Scherer at the University of Zurich. 
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Table 9: Comparison of analytical data for natural and synthetic secu’amamine E (296). Data for 
natural secu’amamine E were adopted from Ohsaki et al.186 All NMR data were collected using 
CD3OD as the solvent. 
 
Atom 
No. 
δH(natural) [ppm], 
multiplicity, J [Hz] 
δH(synthetic) [ppm], 
multiplicity, J [Hz] 
δC(natural) 
[ppm] 
δC(synthetic) 
[ppm] 
2 2.79, dd, 12.0, 1.8 2.78, ma 66.50 66.46 
3 1.50, m 1.50, m 26.80 26.75 
 0.86, qd, 12.0, 4.0 0.87, qd, 11.8, 4.0   
4 1.35, m 1.34, m 25.11 25.07 
 1.81, m 1.82, m   
5 1.56, m 1.58, m 27.71 27.66 
6 2.75, td, 11.0, 3.2 2.78, ma 53.55 53.51 
 2.94, m 2.96, m   
7 2.88, ddd, 5.7, 1.4, 1.3 2.88, m 60.39 60.33 
8 4.30, dddd, 9.5, 5.0, 3.0, 1.4 4.31, m 65.37 65.30 
9 2.66, dd, 12.2, 9.5 2.67, dd, 12.2, 9.6 41.57 41.50 
 1.38, dd, 12.2, 5.0 1.38, dd, 12.2, 4.9   
10   86.29 86.23 
12   176.31 176.25 
13 5.74, t, 1.9 5.74, t, 1.9 112.04 111.99 
14   177.25 177.20 
15 2.82, m 2.78, ma 30.32 30.28 
 2.97, ddd, 18.4, 1.9, 1.3 2.96, m   
a Signals were not resolved and averaged as a single multiplet. 
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4.3 Rearrangements of Neo(nor)securinane- to (Nor)securinane-type 
Alkaloids 
The transformation of an azabicyclo[2.2.2]octane core into an azabicyclo[3.2.1]octane core 
observed by Magnus and coworkers during the total synthesis of nirurine (178) might be of 
great significance for the biosynthesis of the Securinega alkaloids (see Scheme 40).198 Although 
Horii and coworkers also reported similar transformations for securinol A (176),148 B and C,161 
the correct structural foundation had not been established at the time. As a consequence, these 
observations have not been considered during the development of the general biosynthetic 
pathway formulated in the 1970s (see Scheme 39). Also, the observations by Magnus and 
coworkers did not receive much attention in the literature. The only similar transformation 
reported to date is the rearrangement of niruroidine ((–)-215) to norsecurinine (175, Scheme 
71).199 However, a closer look at the reported substrates reveals that niruroidine ((–)-215) 
represents the (–)-enantiomer of the racemic synthetic intermediate 215 reported by Magnus 
and coworkers. 
 
Scheme 71: Rearrangement reported by Ye, Jiang et al. 
With synthetic access to secu’amamine E (296) we decided to investigate the generality of the 
dehydrative rearrangement of neonorsecurinane- to norsecurinane-type alkaloids. Synthetic 
bubbialidine (292) was obtained through the previously published route and also bubbialine 
(327) was prepared from the other diastereomer of intermediate 290 (Scheme 57).158 Thus, three 
different alkaloids were tested (Figure 27). 
 
Figure 27: The three Securinega alkaloids investigated in the present study. 
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Structurally, all three candidates were distinct from the substrates of the earlier reports. The 
present alkaloids have an inverted configuration at the AB ring junction at C2 relative to 
niruroidine ((–)-215). Secu’amamine E (296) and bubbialidine (292) are homologous featuring 
a piperidine and a pyrrolidine A ring, respectively. Furthermore, both feature an antiperiplanar 
configuration of the tertiary amine and hydroxyl functions, whereas bubbialine (327) features 
a synperiplanar configuration. 
 
Scheme 72: Dehydrative rearrangement of secu’amamine E (296) to allosecurinine (172). 
When a mixture of secu’amamine E (296), DMAP and triethylamine in dichloromethane was 
treated with methanesulfonyl chloride at room temperature, very fast conversion of the substrate 
was observed (Scheme 72). The mixture turned yellow and a colorless solid precipitated. 
Although reactions were typically run for 10–15 min, complete consumption of the alkaloid 
296 was observed by TLC, even when the sample was taken from the reaction mixture within 
1 min after addition of the reagent. The mixture was then concentrated under high vacuum and 
subjected to flash chromatography giving allosecurinine (172) in an excellent yield of 93%. 
Very similar results were obtained with the homologous bubbialidine (292, Scheme 73). A fast 
spot-to-spot transformation proceeded upon the same experimental treatment described above 
and (–)-allonorsecurinine (329) was isolated, albeit in a somewhat lower yield of only 63%. 
 
Scheme 73: Dehydrative rearrangement of bubbialidine (292) to (–)-allonorsecurinine (329). 
When bubbialine (327) was treated under same conditions, again, fast spot-to-spot transfor-
mation was observed (Scheme 74). However, after separation of the crude mixture, bubbialine 
mesylate 330 was obtained in almost quantitative yield. Also, prolonged stirring of the reaction 
mixture did not trigger the rearrangement. Only under forcing conditions transformation of this 
intermediate was observed. A mixture of mesylate 330 and triethylamine in dichloromethane 
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was prepared in a pressure tube and heated in a microwave reactor at 100 °C for 6 h. During 
this time the mixture developed a dark brown color and TLC indicated the formation of side 
products. Purification by flash chromatography afforded (+)-allonorsecurinine (331) in a low 
yield of 21% and only in moderate purity as judged by 1H NMR analysis. 
 
Scheme 74: Dehydrative rearrangement of bubbialine (327) to (+)-allonorsecurinine (331). 
The three (nor)securinane-type products 172, 329 and 331 obtained from the above 
transformations were identified by comparison of their NMR and optical rotation data with 
those reported in the literature.211,212,221 The results of these experiments are in agreement with 
the proposed mechanism of the rearrangement process. The configuration at C2 apparently has 
no influence on the transformation and short reaction times in combination with good yields 
were observed. For the decreased yield of (–)-allonorsecurinine (329) compared to 
allosecurinine (172) two reasons were considered. On one hand, a loss of material during flash 
chromatography cannot be excluded, as these alkaloid compounds are polar and tend to stick to 
silica gel. Possibly, the amount of triethylamine added to the eluent used for separation was not 
sufficient. On the other hand, norsecurinine (175) is known to be a reactive compound and the 
large variety of known norsecurinine-based oligomers is a result and testimony thereof. While 
decomposition of the synthetic allosecurinine (172) upon storage at 4 °C was observed within 
several days to a few weeks, the decomposition of both allonorsecurinine enantiomers 329 and 
331 appeared to be faster. Also, the clean transformation observed by TLC analysis of the 
reaction mixture did not indicate undesired side reactions. The stability of the mesylate 
intermediate 330 obtained from bubbialine (327) can be explained by the synperiplanar 
configuration of the amine and ester groups. While the antiperiplanar configuration of the other 
two alkaloids allows for an intramolecular SN2 reaction leading to the aziridinium intermediate, 
this is not possible with mesylate 330. The lone pair of the nucleophilic amine group cannot 
reach into the σ* orbital of the C-O bond and thus the mesylate needs to be extruded via an SN1 
mechanism. The high temperatures required for the SN1 reaction probably led to undesired side 
reactions as well as decomposition of (+)-allonorsecurinine (331). Hence, a low yield of impure 
product 331 was obtained. 
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Scheme 75: Linear biogenetic hypothesis for allosecurinine (172). 
These results support the hypothesis that the dehydrative rearrangement of neo(nor)securinane-
type alkaloids with an azabicyclo[2.2.2]octane core to (nor)securinane-type alkaloids featuring 
an azabicyclo[3.2.1]octane core is involved in the biogenesis of Securinega alkaloids. Thus, we 
support a linear biosynthetic pathway for these compounds (Scheme 75). In the case of 
allosecurinine (172), a CD ring fragment represented by (+)-menisdaurilide ((+)-217) or (+)-
aquilegiolide ((+)-218) would be generated from tyrosine (206). Lysine-derived Δ1-piperideine 
(208) would be introduced and intramolecular 1,6-addition would furnish the neosecurinane-
type secu’amamine E (296). Dehydrative rearrangement would then forge the securinane-type 
allosecurinine (172). However, this hypothesis raises new questions about the family of 
Securinega alkaloids, some of which might be addressed through further phytochemical 
investigations of the plants producing these compounds. Since the rearrangement only proceeds 
with alkaloids featuring an antiperiplanar configuration of the amine and hydroxyl groups, the 
fate of the syn-configured congeners remains unclear. These alkaloids were not reported to 
accumulate in plants and isomerization at the C15 position to invert the orientation of the 
hydroxyl function might occur in nature. A linear biogenesis implies a connection between 
certain alkaloid members and allows for a prediction, which compounds should occur in the 
same plant. For example, every plant, that contains secu’amamine E (296), should also contain 
allosecurinine (172) due to their stereochemical relationship. Accordingly, every plant, that 
contains bubbialidine (292), should also contain (–)-allonorsecurinine (329). In fact, both 
enantiomers of allonorsecurinine (329 and 331) have not been isolated from a natural source 
and remain putative natural products to date. Therefore, isolation of either compound would 
corroborate the linear biogenetic hypothesis. Furthermore, a general detailed mapping of the 
occurrence of the different alkaloids and their relative amounts would help in understanding 
their interrelationships. 
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4.4 Conclusion 
We have achieved the first enantioselective total synthesis of secu’amamine E (296) in 12 linear 
synthetic steps from commercially available 1,4-cyclohexanedione monoethylene acetal (307) 
in an overall yield of 8.5%. Introduction of chirality via proline-catalyzed α-aminoxylation 
allows for modulation of the synthesis and gives access to virosine A (297), the enantiomer of 
secu’amamine E (296). An improved synthesis of known bicyclic lactone 288 has been 
developed affording the compound in 16.1% yield in only seven synthetic steps. Key steps in 
the assembly of secu’amamine E (296) include D ring formation using the Bestmann ylide, a 
vinylogous Mannich reaction to introduce the A ring fragment and an intramolecular 
vinylogous aza-Michael addition to generate the bicyclic core structure. 
The dehydrative rearrangement reactions of neosecurinane-type secu’amamine E (296) and 
neonorsecurinane-type bubbialidine (292) and bubbialine (327) to securinane-type allosecu-
rinine (172) and norsecurinane-type (–)- and (+)-allonorsecurinine (329 and 331), respectively, 
have been investigated. The fast and high-yielding transformation of the azabicyclo[2.2.2]-
octane core to the azabicyclo[3.2.1]octane core observed with alkaloids 296 an 327 featuring 
an antiperiplanar configuration of the involved amine and hydroxyl groups confirms a possible 
biogenetic relevance of this process. These results support a linear biogenetic hypothesis 
classifying the neo(nor)securinane-type alkaloids as biogenetic precursors of the (nor)secu-
rinane-type alkaloids. Further evidence to support this hypothesis might be gained through 
detailed phytochemical investigations involving more species from the Phyllanthaceae plant 
family. 
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5 Conclusion 
The present thesis entitled “Design of Bio-Inspired Materials and Total Synthesis of Securinega 
Alkaloids” demonstrates the versatility of modern organic chemistry and its immeasurable 
importance for fundamental research. The four projects presented throughout this work have 
yielded novel synthetic approaches contributing to the generation of complex chemical systems, 
the investigation of essential cellular processes and the study of plant natural products. 
The first chapter described the development a of nitrocatechol-based surface anchoring unit for 
the immobilization and controlled release of small molecular cargos. An operationally simple 
dip-and-rinse procedure allowed for the formation of self-assembled monolayers on bare 
titanium dioxide surfaces and UV irradiation induced cleavage of the deposited substances from 
the solid support. Protocols for the straightforward production and modification of the coating 
agent were established. The potential to employ cargos exploiting different functional groups, 
especially amino and hydroxyl groups, was shown. The technique holds potential for drug 
delivery and uncaging of bioactive substances under temporal as well as spatial control. 
In the second chapter, the synthesis of new catechol derivatives and their application in systems 
chemistry was presented. A modular branched synthesis was elaborated providing valuable 
intermediates for the introduction of further structural diversity. The compounds feature 
electron-withdrawing substituents on the aryl moiety, which have not been investigated in 
related materials. The novel catechol binders were utilized in the formation and dynamic 
exchange of boronate esters and led to the discovery of the third orthogonal dynamic covalent 
bond. Complementing the use of hydrazones and disulfides this additional component could 
potentiate the complexity achieved with dynamic functional systems. The use of 
naphthalenediol derivatives for boronate ester formation was suggested and first efforts towards 
their preparation were reported. 
The third chapter documented the design of biochemical probes based on the immuno-
suppressive natural product rapamycin. The bacterial macrolide was combined with biotin in 
three natural product hybrids for the isolation and structural characterization of the cellular 
target of rapamycin. While the two first-generation compounds exhibited antiproliferative 
activity against S. cerevisiae and allowed for binding to streptavidin, these functions appeared 
to be exclusive and an extended rapamycin-biotin hybrid was synthesized. Efforts on the 
assembly of a rapamycin-gold nanoparticle conjugate established the first steps towards a 
crucial amino rapamycin intermediate. Further development into fully functional biochemical 
probes might enable the isolation of the large multiprotein target of rapamycin complex 1 from 
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cell protein extracts and facilitate its characterization by single-crystal X-ray diffraction. 
Attachment of a gold nanoparticle would install a tag, which can be visualized by cryo-electron 
microscopy for additional structural investigations. 
The fourth chapter provided a comprehensive introduction into the fascinating realm of the 
Securinega alkaloids. The first enantioselective total synthesis of secu’amamine E was achieved 
in 12 linear synthetic steps and 8.5% overall yield. The synthetic strategy was based on a 
previous synthesis of related alkaloids developed in our group and a new route to a common 
intermediate was devised. Key transformations on the way to secu’amamine E included 
butenolide formation using the Bestmann ylide, introduction of the piperidine moiety by a 
vinylogous Mannich reaction and an intramolecular vinylogous aza-Michael addition to forge 
the bridged structure of the natural product. Experiments on the rearrangement reactions of 
three different alkaloids, which were synthesized in our laboratories, afforded three additional 
known compounds through direct interconversion of the tetracyclic core structures. These 
results suggested a linear biogenetic hypothesis for the different subtypes of the Securinega 
alkaloids. 
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6 Experimental 
6.1 General Information 
 
All chemicals have been purchased from Sigma-Aldrich, Acros, Alfa Aesar, TCI or Fluorochem 
and were used without further purification (except for Et3N which was freshly distilled before 
use). All reactions have been carried out in heat gun-dried glassware (unless aqueous reagents 
were used) and reactions involving air sensitive compounds have been performed under an 
argon atmosphere. Solvents applied for chemical transformations were either puriss quality or 
HPLC grade solvents, which have been dried by filtration through activated aluminium oxide 
under nitrogen (water content <10 ppm, Karl-Fischer titration). For workup and purification 
solvents have been distilled from technical grade. All synthetic transformations have been 
monitored by either thin layer chromatography (TLC), UPLC-MS or 1H NMR spectroscopy. 
Microwave heating (µw) was performed in sealed glass vials using a Biotage Initiator+ 
microwave synthesizer. 
TLC was performed on Merck silica gel 60 F254 plates (0.25 mm thickness) precoated with 
fluorescent indicator. The developed plates were examined under UV light and stained with 
ceric ammonium molybdate or potassium permanganate followed by heating. 
Concentration under reduced pressure was performed by rotary evaporation at 40 °C (unless 
stated otherwise). 
Flash chromatography was performed using silica gel 60 (230-400 mesh) from Sigma-Aldrich 
with a forced flow eluent at 0.3–0.5 bar pressure.  
1H and 13C NMR spectra were recorded using Bruker 300 MHz (1H) or Bruker 400 MHz (1H) 
& 101 MHz (13C) or Bruker 500 MHz (1H) & 126 MHz (13C) spectrometers at room 
temperature. Chemical shifts (δ-values) are reported in ppm, spectra were calibrated related to 
solvents’ residual proton chemical shifts (CDCl3, δ = 7.26; CD3OD, δ = 3.31; C6D6, δ = 7.16; 
DMSO-d6, δ = 2.50) and solvents’ residual carbon chemical shifts (CDCl3, δ = 77.16; CD3OD, 
δ = 49.00; C6D6, δ = 128.06; DMSO-d6, δ = 39.52), multiplicity is reported as follows: s = 
singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, p = pentet, h = hextet, m = 
multiplet or unresolved and coupling constant J in Hz. 
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IR spectra were recorded on a Varian 800 FT-IR ATR Spectrophotometer or a PerkinElmer 
Spectrum Two IR Spectrometer both equipped with a diamond ATR unit. The absorptions are 
reported in cm–1. 
Optical rotations were determined on a Jasco P-2000 digital polarimeter at the 589.3 nm sodium 
D line using a 1 ml cell with a length of 10 cm and concentrations (c) are stated in g/100 mL. 
High resolution mass spectra (HRMS-ESI) were recorded by Dr. Heinz Nadig at the University 
of Basel on a Bruker maXis 4G QTOF ESI mass spectrometer or by the mass spectrometry 
service at the University of Zürich on a Finnigan MAT95 mass spectrometer. 
Melting points (M.p.) were determined using a Büchi B-545 apparatus in open capillaries and 
are uncorrected. 
Preparative, reversed-phase HPLC was performed with a Varian 218 pump, a Dionex VWD-
3400 detector and a Dionex AFC-3000 fraction collector on a Phenomenex Gemini-NX 10µ 
C18 110A (250 x 21.2 mm) column eluting with a constant gradient of MeCN in water from 5–
100% over 30 min at a flow rate of 20 mL min–1. 
Semi-preparative, reversed-phase HPLC was performed on a Dionex HPLC system equipped 
with a P680 pump, an ASI-100 automated sample injector, a TCC-100 thermostatic column 
compartment, and a PDA-100 photodiode array detector on a Phenomenex Gemini 10μ C18 
(150 x 10 mm) column eluting with stated gradients of MeCN in H2O at a flow rate of 5 mL 
min–1. 
Analytical, reversed-phase UPLC was performed with an Agilent 1290 Infinity LC system on 
a Zorbax SB-C18 (1.8 µm, 50 x 2.1 mm) column eluting with a linear gradient of MeCN in 
H2O containing 0.1% formic acid at a flow rate of 0.8 mL min
–1. 
For the acute toxicity assay "Thamnotoxkit F" was purchased from MicroBioTests Inc., 
Kleimoer 15, 9030 Mariakerke/Ghent, Belgium, and the assay was conducted as described in 
the operating procedure. 
IBX (54),47 rapamycin hemisuccinate (150),116 5-azidopentan-1-amine (168),120 Davis 
oxaziridine 318,233 the Bestmann ylide (323)234 and δ-lactamol 274236 were obtained following 
known literature procedures. 
Samples of bubbialidine (292) and bubbialine (327) were synthesized by Dr. Hideki Miyatake-
Ondozabal and Linda Bannwart following the published route.158 
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6.2 UV-Labile Nitrocatechol Derivatives 
 
Ethyl catechol (47):  
To a solution of 4-ethyl phenol (53, 1.00 g, 8.10 mmol, 1.0 eq.) in MeOH 
(80 mL) at 0 °C was added IBX (54, 2.50 g, 8.91 mmol, 1.1 eq.) and the 
mixture was stirred for 1.5 h at room temperature. Sodium dithionite was added and stirring 
continued for 10 min. The solvent was removed under reduced pressure. Sat. aq. NaHCO3 was 
added and the mixture extracted with EtOAc. The combined organic layers were washed with 
water, dried over Na2SO4 and evaporated to afford crude ethyl catechol (47, 953 mg) as a red 
oil, which was used without further purification. 
 
5-Ethyl-2,2-dimethylbenzo[d][1,3]dioxole (48): 
A solution of crude ethyl catechol (947 mg), 2,2-dimethoxypropane 
(1.68 mL, 13.7 mmol) and pTsOH (13.0 mg, 68.5 µmol) in benzene 
(25 mL) was refluxed overnight. After cooling to room temperature, the mixture was poured 
into sat. aq. NaHCO3 followed by extraction with Et2O. The combined organic layers were 
washed with water, dried over Na2SO4 and evaporated to afford crude acetonide 48 (1.10 g) as 
a yellow oil, which was used without further purification. 
To obtain analytically pure 48, the crude product could be subjected to flash chromatography 
(pentane, 1% Et3N). Rf = 0.6 (pentane); FTIR (neat): ν̃ = 2965, 2934, 2873, 1496, 1445, 1377, 
1228, 1156, 982, 837, 808 cm–1; 1H NMR (400 MHz, CDCl3) δ 6.65–6.58 (m, 3H), 2.56 (q, J = 
7.6 Hz, 2H), 1.66 (s, 6H), 1.20 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 147.49, 
145.43, 137.68, 119.87, 117.56, 108.36, 108.01, 28.80, 25.99, 16.14. 
 
5-Ethyl-2,2-dimethyl-6-nitrobenzo[d][1,3]dioxole (49): 
Neat, crude acetonide 48 (1.10 g) was cooled to 0 °C, a cold solution of 
HNO3 (2.7 mL) in water (2.7 mL) was added and the mixture was stirred 
for 1 h at room temperature. The mixture was slowly poured into sat. aq. NaHCO3 followed by 
extraction with Et2O. The combined organic layers were washed with water dried over Na2SO4 
and evaporated to afford 49 (1.08 g, 60% over three steps) as a yellow solid. 
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M.p. = 56–59 °C; Rf = 0.3 (pentane); FTIR (neat): ν̃ = 2988, 2938, 2877, 1615, 1519, 1492, 
1416, 1379, 1331, 1250, 1215, 981, 876 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.39 (s, 1H), 6.64 
(s, 1H), 2.88 (q, J = 7.4 Hz, 2H), 1.71 (s, 6H), 1.26 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 151.76, 145.98, 142.30, 136.26, 120.81, 109.72, 105.59, 27.23, 26.03, 15.18; HRMS 
(ESI) Exact mass calcd. for C11H13O4NNa
+ [M+Na]+: 246.0737, found: 246.0738. 
 
2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propan-1-ol (50): 
A solution of 49 (700 mg, 3.13 mmol, 1.0 eq.) and paraformaldehyde 
(188 mg, 6.26 mmol, 2.0 eq.) in DMSO (3.0 mL) was added methanolic 
benzyltrimethylammonium hydroxide solution (Triton B, 40 wt%, 
0.66 mL, 1.57 mmol, 0.5 eq.) and the mixture was stirred at 90 °C for 4.5 h in a sealed tube. 
After cooling to room temperature, the mixture was diluted with water and neutralized using 
1 M aq. HCl followed by extraction with Et2O. The combined organic layers were washed with 
water, dried over Na2SO4 and evaporated. The residue was subjected to flash chromatography 
(pentane/Et2O, 1:1, 1% Et3N) and product fractions were first concentrated, washed with water 
(to remove Et3N, which was not possible by evaporation), dried over Na2SO4 and then 
evaporated to afford 50 (675 mg, 85%) as a yellow oil, which eventually solidified at 4 °C. 
Rf = 0.3 (pentane/EtOAc, 3:2); FTIR (neat): ν̃ = 3335, 2988, 2927, 2878, 1519, 1493, 1379, 
1335, 1256, 1214, 1033, 978, 872, 822, 759 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.24 (s, 1H), 
6.77 (s, 1H), 3.81–3.70 (m, 2H), 3.67–3.59 (m, 1H), 1.71 (s, 6H), 1.27 (d, J = 6.8 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ 151.68, 146.12, 143.94, 134.86, 121.03, 106.67, 105.31, 68.20, 
36.55, 26.10, 17.84; HRMS (ESI) Exact mass calcd. for C12H15NNaO5
+ [M+Na]+: 276.0842, 
found: 276.0842. 
 
5-(1-(Benzyloxy)propan-2-yl)-2,2-dimethyl-6-nitrobenzo[d][1,3]dioxole (55): 
A solution of 50 (69.0 mg, 272 µmol, 1.0 eq.) in THF (0.5 mL) 
was cooled to 0 °C and sodium hydride (60% dispersion in 
mineral oil, 16.3 mg, 409 µmol, 1.5 eq.) was added. After stirring 
for 30 min, benzyl bromide (69.9 mg, 409 µmol, 1.5 eq.) was added dropwise and the mixture 
was stirred at room temperature for 24 h in the dark. The reaction mixture was cooled to 0 °C 
and quenched by the slow addition of water. The mixture was extracted with CH2Cl2 and the 
combined organic layers were washed with water, dried over Na2SO4 and evaporated. The 
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residue was subjected to flash chromatography (pentane/Et2O, 7:1, 1% Et3N) to yield 55 
(68 mg, 73%) as a yellow oil. 
Rf = 0.5 (pentane/Et2O, 7:1); FTIR (neat): ν̃ = 2890, 2853, 1522, 1496, 1338, 1262,  
1219 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.35–7.26 (m, 5H), 7.24 (s, 1H), 6.77 (s, 1H), 4.50 
(s, 2H), 3.78 (h, J = 6.7 Hz, 1H), 3.60 (dd, J = 9.5, 6.3 Hz, 1H), 3.52 (dd, J = 9.5, 6.4 Hz, 1H), 
1.71 (s, 3H), 1.71 (s, 3H), 1.30 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 151.39, 
145.92, 143.58, 138.45, 135.27, 128.46, 127.66, 120.77, 107.14, 105.25, 74.80, 72.96, 34.26, 
26.06, 18.38; HRMS (ESI) Exact mass calcd. for C19H21NNaO5
+ [M+Na]+: 366.1312, found: 
366.1310. 
 
4-(1-(Benzyloxy)propan-2-yl)-5-nitrobenzene-1,2-diol (56): 
Neat 55 (54 mg, 157 µmol) was mixed with TFA (1.0 mL) and water 
(0.4 mL) and the mixture was stirred at room temperature for 72 h in 
the dark. Volatiles were removed under reduced pressure and the 
residue was separated by preparative reversed-phase HPLC to obtain 56 (36 mg, 76%) as a 
yellow semisolid. 
FTIR (neat): ν̃ = 3600–3100, 2873, 1522, 1329, 1283, 1217, 1189, 1061, 882, 805, 749, 
698 cm–1; 1H NMR (400 MHz, CD3OD) δ 7.36 (s, 1H), 7.31–7.20 (m, 5H), 6.84 (s, 1H), 4.45 
(s, 2H), 3.75 (h, J = 6.8 Hz, 1H), 3.58 (dd, J = 9.3, 6.4 Hz, 1H), 3.49 (dd, J = 9.3, 6.7 Hz, 1H), 
1.26 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 151.77, 144.72, 142.79, 139.61, 
133.50, 129.27, 128.68, 128.53, 115.01, 112.81, 76.11, 73.83, 34.81, 18.43; HRMS (ESI) Exact 
mass calcd. for C16H17NNaO5
+ [M+Na]+: 326.0999, found: 326.1001. 
 
2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propanal (57): 
To a solution of 50 (100 mg, 395 µmol, 1.0 eq.) in CH2Cl2 (2.0 mL) Dess-
Martin periodinane (1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-
3(1H)-one, 251 mg, 592 µmol, 1.5 eq.) was added and the mixture was 
stirred at room temperature for 1.5 h. The mixture was poured into sat. aq. NaHCO3 followed 
by extraction with CH2Cl2. The combined organic layers were dried over Na2SO4 and 
evaporated, and the residue was subjected to flash chromatography (pentane/Et2O, 4:1, 1% 
Et3N) to yield 57 (92 mg, 93%) as a yellow oil. 
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Rf = 0.5 (pentane/Et2O, 4:1); FTIR (neat): ν̃ = 2991, 1725, 1493, 1379, 1332, 1259, 1211, 978, 
823 cm–1; 1H NMR (400 MHz, CDCl3) δ 9.74 (s, 1H), 7.46 (s, 1H), 6.58 (s, 1H), 4.32 (q, J = 
7.1 Hz, 1H), 1.72 (s, 6H), 1.48 (d, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 199.65, 
152.23, 147.09, 142.95, 129.83, 121.70, 108.78, 106.10, 48.61, 26.09, 14.58; HRMS (ESI) 
Exact mass calcd. for C12H13NNaO5
+ [M+Na]+: 274.0686, found 274.0684. 
 
N-Benzyl-2-(2,2-dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propan-1-amine (58): 
To a solution of 57 (80.0 mg, 318 µmol, 1.0 eq.) in 2,2,2-
trifluoroethanol (1.5 mL) benzylamine (39 µL, 350 µmol, 
1.1 eq.) was added and the mixture was stirred at 40 °C for 
10 min during which the mixture turned deep red. NaBH4 (14.8 mg, 382 µmol, 1.2 eq.) was 
added and stirring continued for 75 min in the dark. The mixture was slowly poured into sat. 
aq. NaHCO3 followed by extraction with CH2Cl2. The combined organic layers were washed 
with sat. aq. NaHCO3, dried over Na2SO4 and evaporated to yield 58 (95 mg, 87%) as a yellow 
oil, which was used without further purification. 
Rf = 0.3 (pentane/EtOAc, 1:1); FTIR (neat): ν̃ = 2988, 1520, 1494, 1338, 1260, 1219,  
979 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.35–7.21 (m, 5H), 7.22 (s, 1H), 6.69 (s, 1H), 3.76 (s, 
2H), 3.67–3.58 (m, 1H), 2.81 (dd, J = 11.9, 7.6 Hz, 1H), 2.75 (dd, J = 11.9, 6.6 Hz, 1H), 1.72 
(s, 3H), 1.70 (s, 3H), 1.26 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 151.54, 145.84, 
143.75, 140.49, 136.40, 128.46, 128.12, 126.99, 120.80, 106.35, 105.19, 55.69, 53.69, 34.23, 
26.08, 20.01; HRMS (ESI) Exact mass calcd. for C19H23N2O4
+ [M+H]+: 343.1652, found: 
343.1655. 
 
4-(1-(Benzylamino)propan-2-yl)-5-nitrobenzene-1,2-diol (59): 
Deprotection of 58 (67.0 mg, 196 µmol) was performed analogously 
to 56 yielding 59 (50.0 mg, 84%) as a red oil. 
FTIR (neat): ν̃ = 3094, 2984, 2828, 1669, 1530, 1332, 1289, 1183, 
1135, 801, 722, 698 cm–1; 1H NMR (400 MHz, CD3OD) δ 7.47–7.43 (m, 5H), 7.42 (s, 1H), 
6.85 (s, 1H), 4.21–4.16 (m, 2H), 3.90–3.81 (m, 1H), 3.35–3.30 (m, 1H), 3.22 (dd, J = 12.6, 
6.8 Hz, 1H), 1.34 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 152.72, 145.85, 142.49, 
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132.10, 131.07, 131.02, 130.77, 130.28, 114.70, 113.21, 54.39, 52.86, 32.55, 20.07; HRMS 
(ESI) Exact mass calcd. for C16H19N2O4
+ [M+H]+: 303.1339, found: 303.1340. 
 
5-(1-Bromopropan-2-yl)-2,2-dimethyl-6-nitrobenzo[d][1,3]dioxole (62): 
To a solution of 50 (100 mg, 0.395 mmol, 1.0 eq.) in CH2Cl2 (2.0 mL) 
at 0 °C, CBr4 (164 mg, 0.494 mmol, 1.25 eq.) and PPh3 (129 mg, 
0.494 mmol, 1.25 eq.) were added. After 20 min the cooling bath was 
removed and stirring continued at room temperature for 90 min. The mixture was evaporated 
under reduced pressure, the residue taken up in Et2O and filtered. The filtrate was evaporated 
and the residue subjected to flash chromatography (pentane/Et2O, 5:1, 1% Et3N) to give 62 
(127 mg, quant.) as a yellow oil. 
Rf = 0.7 (pentane/Et2O, 5:1); FTIR (neat): ν̃ = 3069, 2991, 1496, 1379, 1336, 1264, 1214, 979, 
882, 821, 685 cm–1;  1H NMR (400 MHz, CDCl3) δ 7.28 (s, 1H), 6.73 (s, 1H), 3.84 (h, J = 
6.7 Hz, 1H), 3.62 (dd, J = 10.0, 6.0 Hz, 1H), 3.54 (dd, J = 10.0, 6.8 Hz, 1H), 1.72 (d, J = 5.7 Hz, 
6H), 1.41 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 151.60, 146.47, 143.38, 134.30, 
121.25, 106.70, 105.51, 39.07, 36.23, 26.09, 20.08. 
 
Benzyl (2-(2,2-dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propyl)carbonate (65): 
A solution of 50 (100 mg, 395 µmol, 1.2 eq.) and Et3N 
(56 µL, 395 µmol, 1.2 eq.) in THF (0.6 mL) was added 
dropwise to a solution of triphosgene (137 mg, 461 µmol, 
1.4 eq.) at 0 °C. The mixture was stirred for 30 min at 0 °C, after which volatiles were removed 
in vacuo without heating. The residue was taken up in CH2Cl2 (1.0 mL), added slowly to a 
solution of benzyl alcohol (34 µL, 329 µmol, 1.0 eq.) in pyridine (1.0 mL) at 0 °C. The resulting 
mixture was stirred for 20 min at 0 °C followed by another 60 min at room temperature. The 
mixture was poured into water and extracted with CH2Cl2. The combined organic layers were 
dried over Na2SO4 and evaporated to yield crude 65 (152 mg), which was used without further 
purification. 
1H NMR (400 MHz, CDCl3) δ 7.42–7.28 (m, 5H), 7.26 (s, 1H), 6.75 (s, 1H), 5.14 (s, 2H), 4.34–
4.22 (m, 2H), 3.84 (h, J = 6.8 Hz, 1H), 1.71 (s, 6H), 1.31 (d, J = 6.9 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 155.16, 151.63, 146.35, 143.53, 135.29, 133.53, 128.74, 128.68, 128.49, 
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121.12, 106.87, 105.52, 71.86, 69.85, 33.55, 26.08, 18.06; HRMS (ESI) Exact mass calcd. for 
C20H25N2O7
+ [M+NH4]
+: 405.1656, found: 405.1661. 
 
Benzyl (2-(4,5-dihydroxy-2-nitrophenyl)propyl) carbonate (66): 
Deprotection of crude 65 (134 mg) was performed analogously 
to 56 yielding 66 (66.5 mg, 66% over two steps) as a yellow oil. 
FTIR (neat): ν̃ = 3395, 2974, 1719, 1523, 1401, 1380, 1331, 
1269, 950, 884, 755, 696 cm–1; 1H NMR (400 MHz, CD3OD) δ 7.38 (s, 1H), 7.35–7.26 (m, 
5H), 6.86 (s, 1H), 5.08 (s, 2H), 4.30–4.22 (m, 2H), 3.85–3.77 (m, 1H), 1.27 (d, J = 7.0 Hz, 3H); 
13C NMR (101 MHz, CD3OD) δ 156.47, 151.89, 145.08, 142.64, 136.96, 131.93, 129.51, 
129.35, 129.07, 114.96, 113.04, 72.93, 70.50, 34.20, 17.98; HRMS (ESI) Exact mass calcd. for 
C17H17NNaO7
+ [M+Na]+: 370.0897, found: 370.0894. 
 
2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propyl benzylcarbamate (67): 
Coupling of 50 (100 mg, 395 µmol, 1.2 eq.) with 
benzylamine (36 µL, 329 µmol, 1.0 eq.) was performed 
analogously to 65 yielding crude carbamate 67 (137 mg) as 
a yellow oil. 
FTIR (neat): ν̃ = 3414, 3397, 2989, 1707, 1518, 1494, 1253, 1214, 979, 823 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 7.34–7.24 (m, 5H), 7.21 (s, 1H), 6.74 (s, 1H), 4.94 (s, 1H), 4.34–4.09 (m, 
4H), 3.85–3.77 (m, 1H), 1.71 (s, 3H), 1.71 (s, 3H), 1.29 (d, J = 6.9 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 156.35, 151.49, 146.17, 143.81, 138.49, 133.91, 128.80, 127.64, 127.62, 
121.01, 106.60, 105.31, 69.13, 45.20, 33.51, 26.08, 17.74; HRMS (ESI) Exact mass calcd. for 
C20H22N2NaO6
+ [M+Na]+: 409.1370, found: 409.1373. 
 
2-(4,5-Dihydroxy-2-nitrophenyl)propyl benzylcarbamate (68): 
Deprotection of crude 67 (131 mg) was performed analogously 
to 56 yielding 68 (79.7 mg, 73% over two steps) as a yellow oil. 
FTIR (neat): ν̃ = 3398, 2973, 1682, 1593, 1520, 1453, 1433, 
1331, 1284, 1198, 1151, 883, 804, 698 cm–1; 1H NMR (400 MHz, CD3OD) δ 7.38 (s, 1H), 
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7.28–7.07 (m, 5H), 6.87 (s, 1H), 4.22 (s, 2H), 4.20–4.07 (m, 2H), 3.82–3.73 (m, 1H), 1.27 (d, 
J = 6.9 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 158.94, 151.85, 144.93, 142.78, 140.42, 
132.54, 129.40, 128.03, 127.97, 114.82, 112.95, 69.77, 45.29, 34.52, 18.28; HRMS (ESI) Exact 
mass calcd. for C17H18N2NaO6
+ [M+Na]+: 369.1057, found: 369.1053. 
 
2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propyl 2-phenylacetate (69): 
To a solution of 50 (92 mg, 363 µmol, 1.0 eq.) and 
phenylacetic acid (64.9 mg, 472 µmol, 1.3 eq.) in CH2Cl2 
(1.8 mL) at 0 °C were added EDC·HCl (90.5 mg, 472 µmol, 
1.3 eq.) and DMAP (22.2 mg, 182 µmol, 0.5 eq.) and the mixture was stirred overnight at room 
temperature in the dark. The mixture was concentrated under reduced pressure and the residue 
directly subjected to flash chromatography (pentane/Et2O, 5:1, 1% Et3N) to yield 69 (107 mg, 
79%) as a yellow oil. 
Rf = 0.3 (pentane/Et2O, 5:1); FTIR (neat): ν̃ = 2990, 1737, 1522, 1497, 1339, 1263, 1218, 980, 
874, 835 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.25 (m, 5H), 7.23 (s, 1H), 6.63 (s, 1H), 4.21 
(dd, J = 10.9, 6.2 Hz, 1H), 4.17 (dd, J = 10.9, 6.9 Hz, 1H), 3.87–3.74 (m, 1H), 3.57 (s, 2H), 
1.72 (s, 3H), 1.71 (s, 3H), 1.24 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 171.40, 
151.47, 146.20, 143.67, 133.98, 133.78, 129.38, 128.67, 127.19, 121.01, 106.73, 105.34, 68.79, 
41.53, 33.26, 26.07, 17.87; HRMS (ESI) Exact mass calcd. for C20H25N2O6
+ [M+NH4]
+: 
389.1707, found: 389.1712. 
 
2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propyl 2,2-diphenylacetate (71): 
Coupling of 50 (100 mg, 0.395 µmol, 1.0 eq.) with 
diphenylacetic acid (101 mg, 474 µmol, 1.2 eq.) was 
performed analogously to 69 yielding 71 (178 mg, quant.) as 
a yellow oil. 
Rf = 0.4 (pentane/Et2O, 5:1); FTIR (neat): ν̃ = 3063, 3030, 2999, 1736, 1520, 1494, 1380, 1336, 
1260, 1215, 1145, 979, 874, 743, 699 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.31–7.22 (m, 10H), 
7.21 (s, 1H), 6.59 (s, 1H), 4.97 (s, 1H), 4.30 (dd, J = 10.9, 7.2 Hz, 1H), 4.24 (dd, J = 10.9, 
5.9 Hz, 1H), 3.85–3.77 (m, 1H), 1.71 (s, 3H), 1.70 (s, 3H), 1.21 (d, J = 7.0 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 172.27, 151.46, 146.17, 143.59, 138.56, 133.74, 128.71, 128.67, 127.36, 
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127.35, 120.98, 106.78, 105.37, 68.96, 57.30, 33.33, 26.08, 26.06, 17.89; HRMS (ESI) Exact 
mass calcd. for C26H25NNaO6
+ [M+Na]+: 470.1574, found: 470.1577. 
 
2-(4,5-Dihydroxy-2-nitrophenyl)propyl 2,2-diphenylacetate (72): 
Deprotection of 71 (40.0 mg, 89.4 µmol) was performed 
analogously to 56 yielding 72 (21 mg, 58%) as a yellow oil. 
FTIR (neat): ν̃ = 3448, 3168, 3029, 2978, 1709, 1601, 1522, 1452, 
1374, 1346, 1292, 1203, 1010, 879, 800, 738, 695 cm–1; 1H NMR 
(400 MHz, CD3OD) δ 7.34 (s, 1H), 7.30–7.11 (m, 10H), 6.79 (s, 1H), 4.96 (s, 1H), 4.31 (dd, 
J = 10.8, 8.0 Hz, 1H), 4.22 (dd, J = 10.8, 6.0 Hz, 1H), 3.85–3.76 (m, 1H), 1.20 (d, J = 6.9 Hz, 
3H); 13C NMR (101 MHz, CD3OD) δ 173.87, 151.93, 145.03, 142.80, 140.02, 139.98, 132.20, 
129.63, 129.58, 129.46, 129.44, 128.13, 128.11, 114.76, 113.06, 70.01, 58.37, 34.01, 18.07; 
HRMS (ESI) Exact mass calcd. for C23H21NNaO6
+ [M+Na]+: 430.1261, found: 430.1267. 
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6.3 New Electron-Poor Catechol Derivatives 
 
5-Bromo-6-ethyl-2,2-dimethylbenzo[d][1,3]dioxole (86): 
To a solution of acetonide 48 (50 mg, 0.281 mmol, 1.0 eq.) in 
acetone/water (4:3, 3.5 mL) KBr (38 mg, 0.323 mmol, 1.15 eq.) and 
Oxone (172 mg, 281 mmol, 1.0 eq.) were added and the mixture was stirred at room temperature 
for 5 h. Volatiles were removed under reduced pressure and the mixture extracted with CH2Cl2. 
The combined organic layers were washed with sat. aq. Na2S2O3, dried over Na2SO4 and 
evaporated. The residue was subjected to flash chromatography (pentane, 1% Et3N) to give aryl 
bromide 86 (57 mg, 79%) as a yellowish oil. 
Rf = 0.5 (pentane); 1H NMR (250 MHz, CDCl3) δ 6.89 (s, 1H), 6.63 (s, 1H), 2.64 (q, J = 7.5 Hz, 
2H), 1.66 (s, 6H), 1.17 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 147.35, 146.40, 
135.83, 118.87, 113.42, 112.53, 109.18, 29.41, 25.95, 14.68. 
 
Methyl 2-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetate (96): 
A solution of 3,4-dihydroxyphenylacetic acid (94, 500 mg, 
2.97 mmol) in MeOH (50 mL) containing a few drops of conc. H2SO4 
was refluxed overnight. The mixture was concentrated under reduced pressure and the residue 
taken up in EtOAc. The mixture was washed with sat. aq. NaHCO3, dried over Na2SO4 and 
evaporated to give essentially pure methyl 3,4-dihydroxyphenylacetate (95, 540 mg) as a yellow 
oil. 
Rf = 0.5 (pentane/EtOAc, 1:1); 1H NMR (400 MHz, CDCl3) δ 6.82–6.74 (m, 2H), 6.72–6.64 
(m, 1H), 5.52 (s, 1H), 5.36 (s, 1H), 3.70 (s, 3H), 3.52 (s, 2H). 
A solution of methyl 3,4-dihydroxyphenylacetate (95, 540 mg, 2.97 mmol, 1.0 eq.), 2,2-
dimethoxypropane (0.73 mL, 5.93 mmol, 2.0 eq.) and a catalytic amount of pTsOH in benzene 
(11 mL) was refluxed overnight. The mixture was poured in water and extracted with CH2Cl2. 
The combined organic layers were dried over Na2SO4 and evaporated to yield crude 96 
(678 mg) which could be used in the next step without further purification. To obtain an 
analytically pure sample the batch was subjected to flash chromatography (pentane, 1% Et3N) 
and 96 (631 mg, 96% over two steps) was obtained as a yellow oil. 
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Rf = 0.6 (pentane); 1H NMR (400 MHz, CDCl3) δ 6.69–6.67 (m, 1H), 6.67–6.65 (m, 2H), 3.69 
(s, 3H), 3.52 (s, 2H), 1.66 (s, 6H). 
Analytical data are in agreement with the literature: (a) B. Geiseler, L. Fruk, J. Mater. Chem. 
2012, 22, 735–741; (b) B. Almeida Cotrim, J. Joglar, M. J. L. Rojas, J. M. Decara del Olmo, 
M. Macias-González, M. R. Cuevas, M. Fitó, D. Muñoz-Aguayo, M. I. Covas Planells, M. 
Farré, F. R. de Fonseca, R. de la Torre, J. Agric. Food Chem. 2012, 60, 1067–1074. 
 
Methyl 2-(6-chloro-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetate (97): 
To a solution of 96 (700 mg, 3.15 mmol, 1.0 eq.) in CH2Cl2 (15 mL) 
were added NCS (607 mg, 4.41 mmol, 1.4 eq.) and AlCl3 (63 mg, 
473 µmol, 0.15 eq.) at room temperature and the mixture stirred for 4 h. EtOAc was added and 
the mixture washed with brine, dried over Na2SO4 and evaporated. The residue was eluted 
through a short silica column (pentane/Et2O, 1:1, 1% Et3N, no fractionation) to yield 97 
(804 mg, 99%) as a yellow oil. 
Rf = 0.7 (pentane/Et2O, 1:1); M.p.: 55–57 °C; FTIR (neat): ν̃ = 2985, 2957, 1744, 1490, 1380, 
1338, 1259, 1198, 1164, 1151, 975, 856, 781 cm–1; 1H NMR (400 MHz, CDCl3) δ 6.75 (s, 1H), 
6.65 (s, 1H), 3.71 (s, 3H), 3.66 (s, 2H), 1.66 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 171.48, 
147.53, 146.71, 125.70, 124.45, 119.42, 110.69, 109.75, 52.28, 38.80, 25.99; HRMS (ESI) 
Exact mass calcd. for C12H13ClNaO4
+ [M+Na]+: 279.0395, found: 279.0394. 
 
Methyl 2-(6-bromo-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetate (98): 
To a solution of 96 (300 mg, 1.35 mmol, 1.0 eq.) in acetone (14 mL) 
and water (8.0 mL) were added Oxone (873 mg, 1.42 mmol, 1.05 eq.) 
and KBr (193 mg, 1.62 mmol, 1.2 eq.) and the mixture was stirred at room temperature for 1 h. 
The mixture was filtered and acetone was removed under reduced pressure. Sat. aq. Na2S2O3 
was added and the mixture extracted with CH2Cl2. The combined organic layers were dried 
over Na2SO4 and evaporated to give 98 (409 mg, quant.) as a yellow oil. 
Rf = 0.4 (pentane/Et2O, 10:1); M.p.: 49–50 °C; FTIR (neat): ν̃ = 2991, 2952, 1738, 1489, 1380, 
1215, 1149, 980, 855, 783 cm–1; 1H NMR (400 MHz, CDCl3) δ 6.92 (s, 1H), 6.67 (s, 1H), 3.72 
(s, 3H), 3.68 (s, 2H), 1.66 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 171.41, 147.69, 147.38, 
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126.32, 119.46, 114.81, 112.63, 110.90, 52.29, 41.36, 26.00; HRMS (ESI) Exact mass calcd. 
for C12H13BrNaO4
+ [M+Na]+: 322.9889, found: 322.9888. 
 
Methyl 2-(6-iodo-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetate (99): 
To a solution of 96 (302 mg, 1.36 mmol, 1.0 eq.) in MeOH (8.0 mL) 
were added Ag2SO4 (636 mg, 2.04 mmol, 1.5 eq.) and iodine (517 mg, 
2.04 mmol, 1.5 eq.) and the brown mixture was stirred at room temperature for 1 h during which 
the brown color faded. The mixture was filtered, diluted with water and extracted with Et2O. 
The combined organic layers were dried over Na2SO4 and evaporated. The residue was eluted 
through a short silica column (pentane/Et2O, 5:1, 1% Et3N, no fractionation) to yield 99 
(468 mg, 99%) as an orange oil that solidified overnight at 4 °C. 
Rf = 0.5–0.6 (pentane/Et2O, 5:1); M.p.: 68–69 °C; FTIR (neat): ν̃ = 2988, 2956, 1728, 1489, 
1458, 1380, 1335, 1224, 1189, 1151, 981, 836 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.15 (s, 
1H), 6.71 (s, 1H), 3.72 (s, 3H), 3.70 (s, 2H), 1.66 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 
171.41, 148.45, 147.69, 130.13, 119.38, 118.55, 110.43, 88.18, 52.30, 45.98, 26.03; HRMS 
(ESI) Exact mass calcd. for C12H13INaO4
+ [M+Na]+: 370.9751, found: 370.9750. 
 
Methyl 2-(2,2-dimethyl-6-(trifluoromethyl)benzo[d][1,3]dioxol-5-yl)acetate (100): 
A mixture of 99 (468 mg, 1.34 mmol, 1.0 eq.), KF (156 mg, 
2.69 mmol, 2.0 eq.; predried at 100 °C under high vacuum) and CuI 
(538 mg, 2.82 mmol, 2.1 eq.) was suspended in NMP (3.7 mL). TMS-CF3 (0.40 mL, 2.69 mmol, 
2.0 eq.) was added and the mixture was heated to 80 °C for 22 h in a sealed tube. The mixture 
was poured in water and some solid NaCl was added followed by extraction with CH2Cl2. The 
combined organic layers were washed with water, dried over Na2SO4 and evaporated. The 
residue was subjected to flash chromatography (pentane/Et2O, 5:1, 1% Et3N) to yield 100 
(341 mg, 88%) as a yellow oil. 
Rf = 0.7 (pentane/Et2O, 5:1); FTIR (neat): ν̃ = 2995, 2956, 1743, 1504, 1386, 1295, 1218, 1144, 
1109, 979, 870 cm–1; 1H NMR (400 MHz, CDCl3) δ 6.99 (s, 1H), 6.72 (s, 1H), 3.71 (s, 5H), 
1.69 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 171.38, 149.93, 146.60, 126.60 (q, J = 2.1 Hz), 
124.22 (q J = 273.2 Hz), 121.79 (q, J = 30.7 Hz), 119.79, 112.08, 106.21 (q, J = 6.0 Hz), 52.17, 
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37.73 (q, J = 1.8 Hz), 25.91; HRMS (ESI) Exact mass calcd. for C13H13F3NaO4
+ [M+Na]+: 
313.0658, found: 313.0658. 
 
Methyl 2-(2,2-dimethyl-6-(methylsulfonyl)benzo[d][1,3]dioxol-5-yl)acetate (101): 
A mixture of 99 (153 mg, 439 µmol, 1.0 eq.), sodium 
methanesulfinate (67.3 mg, 659 µmol, 1.5 eq.), L-proline (20.4 mg, 
176 µmol, 0.4 eq.) and Cu(OAc)2 (31.9 mg, 176 µmol, 0.4 eq.) was suspended in DMSO and 
the mixture was heated to 100 °C for 24 h in a sealed tube. The reaction mixture was cooled to 
room temperature and quenched with sat. aq. NH4Cl, diluted with water and extracted with 
EtOAc. The combined organic layers were washed with water and brine, and dried over 
Na2SO4. The residue was subjected to flash chromatography (pentane/Et2O, 1:1, 1% Et3N) to 
yield 101 (102 mg, 77%) as a yellowish solid. 
Rf = 0.4 (pentane/Et2O, 1:1); M.p.: 117–119 °C; FTIR (neat): ν̃ = 3019, 2988, 2966, 2923, 
1727, 1496, 1300, 1244, 1196, 1136, 983, 830, 764 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.38 
(s, 1H), 6.68 (s, 1H), 4.11 (s, 2H), 3.73 (s, 3H), 3.10 (s, 3H), 1.70 (s, 6H); 13C NMR (101 MHz, 
CDCl3) δ 171.94, 151.84, 147.40, 131.72, 129.05, 120.79, 112.30, 109.72, 52.42, 45.08, 38.22, 
26.12; HRMS (ESI) Exact mass calcd. for C13H16NaO6S
+ [M+Na]+: 323.0560, found: 
323.0561. 
 
2-(6-Chloro-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetic acid (102): 
To a solution of 97 (773 mg, 3.01 mmol) in THF (15 mL) was added 
1 M aq. NaOH (12 mL) and the resulting turbid mixture was stirred at 
room temperature for 1 h during which the mixture turned clear. Volatiles were removed under 
reduced pressure and the residue was acidified to pH 5 using 1 M aq. HCl. The mixture was 
extracted with EtOAc and the combined organic layers were washed with water, dried over 
Na2SO4 and evaporated to yield 102 (726 mg, 99%) as an off-white solid. 
M.p.: 150–152 °C (dec.); FTIR (neat): ν̃ = 2992, 2937, 1704, 1496, 1378, 1262, 1223, 1155, 
975, 861, 830 cm–1; 1H NMR (400 MHz, CDCl3) δ 6.76 (s, 1H), 6.65 (s, 1H), 3.70 (s, 2H), 1.66 
(s, 6H); 13C NMR (101 MHz, CDCl3) δ 176.71, 147.73, 146.75, 125.86, 123.72, 119.55, 
110.73, 109.79, 38.59, 25.98; HRMS (ESI) Exact mass calcd. for C11H11ClNaO4
+ [M+Na]+: 
265.0238, found: 265.0241. 
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2-(6-Bromo-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetic acid (103): 
Saponification of 98 (593 mg, 1.97 mmol) was performed analogously 
to 102 yielding 103 (543 mg, 96%) as an off-white solid. 
M.p.: 158–160 °C (dec.); FTIR (neat): ν̃ = 2995, 2935, 1704, 1492, 1378, 1222, 1153, 972, 
858, 829 cm–1; 1H NMR (400 MHz, CDCl3) δ 6.93 (s, 1H), 6.68 (s, 1H), 3.73 (s, 2H), 1.66 (s, 
7H); 13C NMR (101 MHz, CDCl3) δ 176.40, 147.88, 147.43, 125.60, 119.59, 114.94, 112.68, 
110.95, 41.11, 26.01; HRMS (ESI) Exact mass calcd. for C11H11BrNaO4
+ [M+Na]+: 308.9733, 
found: 308.9737. 
 
2-(6-Iodo-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetic acid (104): 
Saponification of 99 (613 mg, 1.76 mmol) was performed analogously 
to 102 yielding 104 (488 mg, 83%) as a yellow solid. 
M.p.: 170–172 °C (dec.); FTIR (neat): ν̃ = 2994, 2933, 1704, 1490, 1378, 1218, 1153, 965, 
854, 829, 782 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.16 (s, 1H), 6.72 (s, 1H), 3.75 (s, 2H), 1.66 
(s, 6H); 13C NMR (101 MHz, CDCl3) δ 176.05, 148.50, 147.88, 129.44, 119.51, 118.60, 
110.48, 88.29, 45.68, 26.05; HRMS (ESI) Exact mass calcd. for C11H11INaO4
+ [M+Na]+: 
356.9594, found: 356.9600. 
 
2-(2,2-Dimethyl-6-(trifluoromethyl)benzo[d][1,3]dioxol-5-yl)acetic acid (105): 
Saponification of 100 (327 mg, 1.13 mmol) was performed analogously 
to 102 yielding 105 (315 mg, quant.) as a yellowish solid. 
M.p.: 133–135 °C; FTIR (neat): ν̃ = 3001, 2927, 1711, 1504, 1389, 1297, 1249, 1217, 1145, 
1109, 979, 872, 835 cm–1; 1H NMR (250 MHz, CDCl3) δ 6.99 (s, 1H), 6.71 (s, 1H), 3.78–3.73 
(m, 2H), 1.69 (s, 6H); HRMS (ESI) Exact mass calcd. for C12H11F3NaO4
+ [M+Na]+: 299.0502, 
found: 299.0506. 
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2-(2,2-Dimethyl-6-(methylsulfonyl)benzo[d][1,3]dioxol-5-yl)acetic acid (106): 
Saponification of 101 (50.0 mg, 166 µmol) was performed analogously 
to 102 yielding 106 (34.4 mg, 72%) as a colorless solid. 
M.p.: 185–187 °C; FTIR (neat): ν̃ = 2993, 2929, 2361, 1714, 1495, 1379, 1301, 1250, 1218, 
1138, 766 cm–1; 1H NMR (400 MHz, CD3OD) δ 7.33 (s, 1H), 6.83 (s, 1H), 4.07 (s, 2H), 3.10 
(s, 3H), 1.71 (s, 6H); 13C NMR (101 MHz, CD3OD) δ 174.79, 153.05, 148.41, 132.84, 131.36, 
121.90, 113.67, 110.08, 45.00, 39.05, 25.92; HRMS (ESI) Exact mass calcd. for C12H14NaO6S
+ 
[M+Na]+: 309.0403, found: 309.0408. 
 
Methyl 2-(2-bromo-4,5-dihydroxyphenyl)acetate (108): 
Compound 98 (161 mg, 535 µmol) was cooled to 0 °C and precooled 20% 
aq. TFA (1 mL) was added. After 5 min the ice bath was removed and 
stirring continued at room temperature for 2.5 h. Volatiles were removed under reduced 
pressure and the residue was separated by preparative reversed-phase HPLC to yield 108 
(102 mg, 73%) as an off-white solid. 
M.p.: 106–108 °C; FTIR (neat): ν̃ = 3370, 2955, 2364, 1712, 1510, 1436, 1339, 1282, 1221, 
1162, 1011, 870, 821 cm–1; 1H NMR (400 MHz, CD3OD) δ 6.94 (s, 1H), 6.75 (s, 1H), 3.68 (s, 
3H), 3.63 (s, 2H); 13C NMR (101 MHz, CD3OD) δ 173.51, 146.76, 146.15, 126.22, 119.93, 
119.12, 114.06, 52.48, 41.37; HRMS (ESI) Exact mass calcd. for C9H9BrNaO4
+ [M+Na]+: 
282.9576, found: 282.9576. 
 
Methyl 2-(4,5-dihydroxy-2-iodophenyl)acetate (109): 
Deprotection of 99 (120 mg, 345 µmol) was performed analogously to 
108, yielding 109 (66 mg, 62%) as an off-white solid. 
M.p.: 112–114 °C; FTIR (neat): ν̃ = 3385, 2952, 2360, 2338, 1711, 1504, 1437, 1335, 1279, 
1224, 1162 cm–1; 1H NMR (400 MHz, CD3OD) δ 7.18 (s, 1H), 6.76 (s, 1H), 3.68 (s, 3H), 3.64 
(s, 2H); 13C NMR (101 MHz, CD3OD) δ 173.52, 147.06, 146.71, 130.12, 126.32, 118.58, 
87.46, 52.48, 45.89; HRMS (ESI) Exact mass calcd. for C9H9INaO4
+ [M+Na]+: 330.9438, 
found: 330.9438. 
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Methyl 2-(4,5-dihydroxy-2-(trifluoromethyl)phenyl)acetate (110): 
Deprotection of 100 (200 mg, 689 µmol) was performed analogously to 
108, yielding 110 (134 mg, 78%) as an off-white solid. 
M.p.: 131–133 °C; FTIR (neat): ν̃ = 3507, 3293, 1712, 1459, 1344, 1310, 1281, 1234, 1159, 
1114, 1018, 841 cm–1; 1H NMR (400 MHz, CD3OD) δ 7.03 (s, 1H), 6.80 (s, 1H), 3.67 (s, 3H), 
3.66 (s, 2H); 13C NMR (101 MHz, CD3OD) δ 173.57, 149.47, 145.43, 126.09 (q, J = 271.5 Hz), 
125.42 (q, J = 1.8 Hz), 120.86 (q, J = 30.2 Hz), 120.60, 114.08 (q, J = 5.5 Hz), 52.51, 38.13 (q, 
J = 2.2 Hz); HRMS (ESI) Exact mass calcd. for C10H9F3NaO4
+ [M+Na]+: 273.0345, found: 
273.0346. 
 
Methyl 2-(4,5-dihydroxy-2-(methylsulfonyl)phenyl)acetate (111): 
Deprotection of 101 (96.0 mg, 320 µmol) was performed analogously to 
108, yielding 111 (37.3 mg, 45%) as a hygroscopic, orange solid. 
FTIR (neat): ν̃ = 3362, 3027, 2957, 1721, 1595, 1520, 1440, 1293, 1208, 1128, 764 cm–1; 
1H NMR (400 MHz, CD3OD) δ 7.38 (s, 1H), 6.78 (s, 1H), 3.99 (s, 2H), 3.69 (s, 3H), 3.06 (s, 
3H); 13C NMR (101 MHz, CD3OD) δ 173.82, 151.65, 146.02, 130.28, 127.51, 120.72, 117.58, 
52.51, 45.16, 38.59; HRMS (ESI) Exact mass calcd. for C10H12NaO6S
+ [M+Na]+: 283.0247, 
found: 283.0249. 
 
Naphthalene-1,8-diol (134): 
KOH pellets (50 g) were molten at 230–250 °C. To the melt 1,8-naphthosultone 
(133, 10.0 g, 48.5 mmol) was added in small portions reacting violently to give a 
black slurry. Addition took around 45 min and heating to 250 °C was continued for 
an additional 20 min. The mixture was allowed to cool to 100–150 °C (and not allowed to 
solidify!) and carefully diluted with water. After cooling to 0 °C, conc. HCl was added until 
pH 1 and the mixture was extracted with CH2Cl2. The combined organic layers were dried over 
Na2SO4 and filtered repeatedly through cotton wool to remove all fine black suspended solids. 
Volatiles were removed under reduced pressure and the residue was crystallized from CHCl3 
several times to obtain 134 (4.86 g, 63%) as grey to grey-brown needles. 
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Rf = 0.4 (pentane/Et2O, 1:1); M.p.: 140–142 °C; 1H NMR (400 MHz, CDCl3) δ 7.78 (s, 2H), 
7.36 (dd, J = 8.4, 1.0 Hz, 2H), 7.29 (dd, J = 8.2, 7.5 Hz, 2H), 6.79 (dd, J = 7.5, 1.1 Hz, 2H); 
13C NMR (101 MHz, CDCl3) δ 152.81, 137.17, 126.85, 120.67, 114.67, 109.54. 
Analytical data are in agreement with the literature: K. A. Parker, T. Iqbal, J. Org. Chem. 1980, 
45, 1149–1151. 
 
2,2-Dimethylnaphtho[1,8-de][1,3]dioxine (137): 
A solution of diol 134 (820 mg, 5.12 mmol, 1.0 eq.), 2,2-dimethoxypropane 
(1.26 mL, 10.2 mmol, 2.0 eq.) and pTsOH monohydrate (9.7 mg, 51.2 µmol, 
1 mol-%) in benzene (15 mL) was heated to reflux overnight. After cooling to room 
temperature, the mixture was poured into sat. aq. NaHCO3 followed by extraction with Et2O. 
The combined organic layers were dried over Na2SO4 and evaporated under reduced pressure. 
The residue was subjected to flash chromatography (petroleum ether) to give 137 (482 mg, 
47%) as a colorless oil which eventually solidified at 4 °C. 
Rf = 0.3 (petroleum ether); M.p.: 59–61 °C; 1H NMR (400 MHz, CDCl3) δ 7.44 (dd, J = 8.4, 
1.2 Hz, 2H), 7.39 (dd, J = 8.4, 7.2 Hz, 2H), 6.85 (dd, J = 7.2, 1.2 Hz, 2H), 1.67 (s, 6H); 
13C NMR (126 MHz, CDCl3) δ 148.11, 134.35, 127.46, 120.12, 113.69, 108.90, 101.82, 25.41. 
 
2,2-Dimethyl-6,7-dinitronaphtho[1,8-de][1,3]dioxine (138): 
A solution of acetonide 137 (20 mg, 99.9 µmol, 1.0 eq.) in CH2Cl2 (0.3 mL) was 
cooled to 0 °C and conc. HNO3 (0.999 mmol, 69 µL, 10 eq.) was added. After 
stirring for 10 min the mixture was poured into half-sat. aq. NaHCO3 followed by 
extraction with CH2Cl2. The combined organic layers were dried over Na2SO4 and 
evaporated under reduced pressure. The residue was subjected to flash chromatography 
(pentane/EtOAc, 10:1) to obtain dinitro compound 138 (11.5 mg, 40%) as an orange-brown 
solid. 
Rf = 0.1 (pentane/EtOAc, 10:1); FTIR (neat): ν̃ = 3003, 2922, 2852, 1604, 1580, 1518, 1502, 
1332, 1263, 1092, 852, 735 cm–1; 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 8.5 Hz, 2H), 7.04 
(d, J = 8.5 Hz, 2H), 1.75 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 152.44, 139.49, 129.86, 
118.73, 113.44, 110.07, 104.23, 25.14; HRMS (ESI) Exact mass calcd. for C13H11N2O6
+ 
[M+H]+: 291.06116, found: 291.06110. 
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1-(2,2-Dimethylnaphtho[1,8-de][1,3]dioxin-6-yl)ethan-1-one (139): 
To a solution of acetonide 137 (50 mg, 0.250 mmol, 1.0 eq.) and 
AcCl (19 µL, 0.263 mmol, 1.05 eq.) in CH2Cl2 (1.0 mL) at rt 
AlCl3 (37 mg, 0.275 mmol, 1.1 eq.) was added and the mixture 
immediately turned deep red. After 1 h the mixture was diluted 
with Et2O, filtered and washed with sat. aq. NaHCO3. The 
aqueous layer was back-extracted once with Et2O and the combined organic layers were dried 
over Na2SO4 and evaporated under reduced pressure. The residue was subjected to flash 
chromatography (pentane/Et2O, 15:1, 1% Et3N) to give an isomeric mixture of ketone 139 
(58 mg, 96%; para/ortho: 5:1 by 1H NMR) as a yellow oil. Isomers could partially be separated 
by flash chromatography (pentane/Et2O, 30:1, 1% Et3N). 
Rf = 0.2 (pentane/Et2O, 9:1); FTIR (neat): ν̃ = 2997, 2924, 1662, 1600, 1582, 1506, 1403, 1262, 
1245, 1194, 1076, 954, 828, 763, 577 cm–1; 1H NMR (400 MHz, CDCl3, para-isomer) δ 8.63 
(dd, J = 8.8, 0.8 Hz, 1H), 8.05 (d, J = 8.1 Hz, 1H), 7.55 (dd, J = 8.8, 7.6 Hz, 1H), 6.93 (dd, J = 
7.6, 0.9 Hz, 1H), 6.84 (d, J = 8.1 Hz, 1H), 2.71 (s, 3H), 1.67 (s, 6H); 1H NMR (400 MHz, 
CCDl3, ortho-isomer) δ 7.92 (d, J = 8.8 Hz, 1H), 7.50 (dd, J = 8.2, 7.5 Hz, 1H), 7.42 (dd, J = 
8.2, 0.8 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 6.91 (dd, J = 7.6, 1.0 Hz, 1H), 2.71 (s, 3H), 1.74 (s, 
6H); 13C NMR (126 MHz, CDCl3, para-isomer) δ 199.81, 152.45, 147.91, 133.02, 132.13, 
130.23, 127.41, 119.88, 113.76, 110.27, 107.70, 102.24, 29.26, 25.27; HRMS (ESI) Exact mass 
calcd. for C15H15O3
+ [M+H]+: 243.10157, found: 243.10153. 
 
1-(2,2-Dimethyl-7-nitronaphtho[1,8-de][1,3]dioxin-6-yl)ethan-1-one (140): 
A solution of ketone 139 (isomeric mixture described above, 139 mg, 
0.574 mmol, 1.0 eq.) in CH2Cl2 (2.5 mL) was cooled to 0 °C and conc. HNO3 
(78 µL, 1.72 mmol, 3.0 eq.) was added. After 5 min the cooling bath was removed 
and stirring continued at rt for 30 min. The mixture was diluted with Et2O and 
poured into sat. aq. NaHCO3. Layers were separated and the aq. layer was 
extracted with Et2O. The combined organic layers were dried over Na2SO4 and evaporated 
under reduced pressure. The residue was subjected to flash chromatography (pentane/Et2O, 5:1, 
1% Et3N) to give 140 (single isomer, 90 mg, 0.313 mmol, 55%) as a yellow oil. 
Rf = 0.2 (pentane/Et2O, 5:1); FTIR (neat): ν̃ = 2920, 2850 1683, 1604, 1522, 1337, 1263, 1248, 
1197, 1096, 842, 751 cm–1; 1H NMR (400 MHz, CDCl3) δ 8.14 (d, J = 8.4 Hz, 1H), 7.88 (d, 
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J = 8.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 2.68 (s, 3H), 1.70 (s, 6H); 
13C NMR (101 MHz, CDCl3) δ 200.03, 152.58, 150.62, 141.30, 131.19, 130.37, 128.21, 
123.12, 114.00, 109.73, 109.12, 103.39, 28.48, 25.19; HRMS (ESI) Exact mass calcd. for 
C15H14NO5
+ [M+H]+: 288.08665, found: 288.08664. 
 
Surface Modifications: 
Test tubes (5 mL) were cleaned with piranha solution (conc. H2SO4/30% H2O2, 3:1), rinsed 
with millipore water and oven-dried (120 °C). Portions of TiO2 particles (10 mg, rutile, 1.0–
2.0 μm) were suspended in toluene (3 mL), ultrasonicated for 20 min at 35 °C, centrifuged 
(4500 rpm, 10 min) and the solvent was decanted. This washing was repeated with iPrOH and 
the particles were oven-dried (120 °C) overnight.  
To the TiO2 particles (10 mg) catechol (2.0 mg) dissolved in a few drops of DMSO and MOPS 
buffer (3 mL) were added followed by ultrasonication for 2 min and subsequent incubation at 
50 °C for 4 h under exclusion of light. During incubation TiO2 particles were re-suspended 
with a syringe several times. The mixture was centrifuged (4500 rpm, 10 min), the particles 
were washed with millipore water (2 x 3 mL) and MeOH (3 x 3 mL) with centrifugation after 
each washing and dried under a stream of nitrogen.  
Photolysis Experiments 
Applying a Falcon® Multiwell™ 24-well plate, wells were loaded with millipore water (1 mL) 
and a 1 mM solution of catechol in MeCN (50 μL) was added. On a sheet of aluminum foil the 
plate was positioned under a common laboratory UV lamp and irradiation at 366 nm was 
performed with a distance of approximately 3.5 cm between the lamp and the sample solutions. 
After certain time intervals, the entire solution of one well at a time was filtered and subjected 
to UPLC-MS analysis. Substance ratios were determined by integration of their respective 
peaks in the UV trace recorded at 254 nm. 
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6.4 Rapamycin-Based Probes 
 
tert-Butyl (6-aminohexyl)carbamate (153): 
A solution of Boc2O (152, 1.52 g, 6.84 mmol, 1.0 eq.) in CHCl3 (14 mL) was 
slowly added to a solution of 1,6-hexanediamine (151, 5.04 g, 34.2 mmol, 5.0 eq.) 
in CHCl3 (180 mL) at 0 °C during 100 min via syringe pump. After stirring over night at room 
temperature the mixture was filtered and evaporated. The residue was dissolved in EtOAc, 
washed with half-sat. aq. NaCl, dried over Na2SO4 and the solvent was evaporated. The residue 
was subjected to flash chromatography (CH2Cl2/MeOH 10:1, 1% Et3N). The yellow semisolid 
obtained was suspended in a small amount of EtOAc. Solids were collected by filtration, 
recovered from the filter with MeOH, and after evaporation 153 (1.32 g, 89%) was obtained as 
a colorless solid. 
Rf = 0.2 (CH2Cl2/MeOH, 10:1); 1H NMR (400 MHz, CDCl3) δ 4.54 (s, 1H), 3.10 (q, J = 6.7 Hz, 
2H), 2.69 (t, J = 7.0 Hz, 2H), 1.80 (br s, 2H), 1.43 (s, 9H), 1.27–1.37 (m, 4H). 
Analytical data are in agreement with the literature: C. Dardonville, C. Fernandez-Fernandez, 
S.-L. Gibbons, G. J. Ryan, N. Jagerovic, A. M. Gabilondo, J. J. Meana, L. F. Callado, Bioorg. 
Med. Chem. 2006, 14, 6570–6580. 
 
tert-Butyl (6-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentan-
amido)hexyl) carbamate (154): 
To a solution of D-biotin (250 mg, 1.02 mmol, 1.0 eq.) and 153 (221 
mg, 1.02 mmol, 1.0 eq.) in pyridine (8.4 mL) was added EDC·HCl 
(235 mg, 1.23 mmol, 1.2 eq.) and the mixture was stirred overnight at 
room temperature. The mixture was concentrated under reduced 
pressure and solids were collected by filtration. After washing with aq. NaOH (1 M) and Et2O, 
and drying 154 (392 mg, 86%) was obtained as a colorless solid. 
1H NMR (400 MHz, CD3OD) δ 4.49 (ddd, J = 7.9, 5.0, 1.0 Hz, 1H), 4.30 (dd, J = 7.9, 4.4 Hz, 
1H), 3.24–3.10 (m, 3H), 3.02 (t, J = 7.0 Hz, 2H), 2.93 (dd, J = 12.8, 5.0 Hz, 1H), 2.71 (d, J = 
12.7 Hz, 1H), 2.19 (t, J = 7.3 Hz, 2H), 1.81–1.23 (m, 14H), 1.43 (s, 9H); 13C NMR (101 MHz, 
CD3OD) δ 175.94, 166.10, 158.56, 79.78, 63.38, 61.62, 57.02, 41.24, 41.04, 40.27, 36.82, 
30.90, 30.36, 29.79, 29.51, 28.80, 27.65, 27.51, 26.94. 
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Analytical data are in agreement with the literature: M. Collot, B. Sendid, A. Fievez, C. Savaux, 
A. Standaert-Vitse, M. Tabouret, A. S. Drucbert, P. M. Danzé, D. Poulain, J.-M. Mallet, J. Med. 
Chem. 2008, 51, 6201–6210. 
 
N-Biotinyl-1,6-hexanediamine (155): 
To neat 154 (100 mg, 0.226 mmol) TFA (0.6 mL) was added at room 
temperature and the yellow mixture was stirred for 20 min. Volatiles 
were removed under reduced pressure and the residue was taken up in 
MeOH. The mixture was neutralized using Dowex Marathon WBA 
ion-exchange resin and the solvent was evaporated to yield 155 (63 mg, 81%) as a yellow oil. 
1H NMR (400 MHz, D2O) δ 4.60 (ddd, J = 8.0, 5.0, 0.9 Hz, 1H), 4.42 (dd, J = 8.0, 4.5 Hz, 1H), 
3.36–3.30 (m, 1H), 3.26–3.10 (m, 2H), 3.04–2.93 (m, 3H), 2.78 (d, J = 13.0 Hz, 1H), 2.24 (t, 
J = 7.2 Hz, 2H), 1.83–1.22 (m, 14H). 
Analytical data are in agreement with the literature: M. Collot, B. Sendid, A. Fievez, C. Savaux, 
A. Standaert-Vitse, M. Tabouret, A. S. Drucbert, P. M. Danzé, D. Poulain, J.-M. Mallet, J. Med. 
Chem. 2008, 51, 6201–6210. 
 
Probe 1 (156): 
To a solution of rapamycin hemisuccinate (150, 
25.4 mg, 25.0 µmol, 1.0 eq.) in DMF (0.2 mL) amine 
155 (10.3 mg, 30.0 µmol, 1.2 eq.), HBTU (12.3 mg, 
32.0 µmol, 1.3 eq.) and DIPEA (10 µL, 60.0 µmol, 
2.4 eq.) were added and the mixture was stirred 
overnight at room temperature. The mixture was 
eluted through a small C18 SPE column using MeCN 
and evaporated. Separation by preparative reversed-
phase HPLC gave 156 (14.3 mg, 43%) as a colorless solid. 
HRMS (ESI) calcd. for C71H111N5NaO17S
+ [M+Na]+: 1360.7588, found: 1360.7580. 
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mono-Boc cystamine (158): 
A solution of Boc2O (1.90 g, 8.53 mmol, 1.0 eq.) and Et3N (3.59 mL, 25.6 mmol, 
3.0 eq.) in MeOH (15 mL) was added to a solution of cystamine dihydrochloride 
(157, 2.00 g 12.8 mmol, 1.0 eq.) in MeOH (100 mL) at room temperature during 20 min and 
the resulting mixture was stirred for another 2.5 h. Volatiles were removed under reduced 
pressure and the residue was taken up in aq. NaH2PO4 (1 M, 50 mL). The mixture was extracted 
with Et2O to remove any doubly protected compound and the aqueous layer was basified to pH 
9 using 1 M aq. NaOH. The mixture was extracted with EtOAc and the combined organic layers 
were dried over Na2SO4 and evaporated to yield 158 (1.09 g, 51%) as a yellow semisolid. 
1H NMR (250 MHz, CDCl3) δ 4.93 (s, 1H), 3.45 (q, J = 6.3 Hz, 2H), 3.01 (t, J = 6.1 Hz, 2H), 
2.77 (td, J = 6.2, 3.7 Hz, 4H), 1.44 (s, 9H). 
Analytical data are in agreement with the literature: J. Niu, Z. Liu, L. Fu, F. Shi, H. Ma, Y. 
Ozaki, X. Zhang, Langmuir 2008, 24, 11988–11994. 
 
N-Biotinyl-N’-Boc-cystamine (159): 
A solution of D-biotin (48.4 mg, 198 µmol, 1.0 eq.) and amine 158 
(50.0 mg, 198 µmol, 1.0 eq.) in pyridine (1.7 mL) was added HBTU 
(90.2 mg, 238 µmol, 1.2 eq.) and the mixture was stirred overnight at 
room temperature. Volatiles were removed under reduced pressure 
and the residue was separated by preparative reversed-phase HPLC to yield 159 (47.0 mg, 50%) 
as a colorless solid. 
Rf = 0.3 (CH2Cl2/MeOH, 15:1); 1H NMR (400 MHz, DMSO-d6) δ 7.95 (t, J = 5.7 Hz, 1H), 
6.97 (t, J = 5.7 Hz, 1H), 6.40 (s, 1H), 6.34 (s, 1H), 4.34–4.26 (m, 1H), 4.19–4.07 (m, 1H), 3.36–
3.26 (m, 2H), 3.20 (q, J = 6.5 Hz, 2H), 3.14–3.03 (m, 1H), 2.82 (dd, J = 12.4, 5.1 Hz, 1H), 
2.80–2.70 (m, 3H), 2.57 (d, J = 12.4 Hz, 1H), 2.06 (t, J = 7.4 Hz, 2H), 1.69–1.18 (m, 6H), 1.38 
(s, 9H). 
Analytical data are in agreement with the literature: C. Gnaccarini, W. Ben-Tahar, W. D. 
Lubell, J. N. Pelletier, J. W. Keillor, Bioorg. Med. Chem. 2009, 17, 6354–6359. 
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Cystaminyl biotinate hydrochloride (160): 
A solution of 159 (40.0 mg 83.4 µmol) in MeOH (0.8 mL) at 0 °C 
was added a solution of HCl in dioxane (4 M, 0.4 mL) and the mixture 
was stirred at room temperature for 3 h. The mixture was 
concentrated under reduced pressure and the residue separated by 
preparative reversed-phase HPLC to yield 160 (35.0 mg, quant.) as a colorless solid. 
1H NMR (400 MHz, DMSO-d6) δ 7.98 (t, J = 5.7 Hz, 1H), 7.91 (s, 3H), 6.34 (s, 1H), 6.30 (s, 
1H), 4.24 (dd, J = 7.8, 5.1 Hz, 1H), 4.10–4.02 (m, 1H), 3.32–3.23 (m, 2H), 3.08–2.96 (m, 3H), 
2.91–2.81 (m, 2H), 2.80–2.69 (m, 3H), 2.51 (d, J = 12.4 Hz, 1H), 2.01 (t, J = 7.4 Hz, 2H), 1.62–
1.15 (m, 6H). 
Analytical data are in agreement with the literature: C. Gnaccarini, W. Ben-Tahar, W. D. 
Lubell, J. N. Pelletier, J. W. Keillor, Bioorg. Med. Chem. 2009, 17, 6354–6359. 
 
Probe 2 (161): 
To a solution of rapamycin hemisuccinate (150, 
54.5 mg, 53.7 µmol, 1.0 eq.) in DMF (0.2 mL) 
amine 160 (23.4 mg, 56.4 µmol, 1.05 eq.), HBTU 
(24.5 mg, 64.5 µmol, 1.2 eq.) and DIPEA (33 µL, 
188 µmol, 3.5 eq.) were added and the mixture was 
stirred overnight at room temperature. The mixture 
was eluted through a small C18 SPE column using 
MeCN and evaporated. Separation by preparative 
reversed-phase HPLC gave 161 (28.0 mg, 38%) as a colorless solid. 
HRMS (ESI) calcd. for C69H107N5NaO17S3
+ [M+Na]+: 1396.6716, found: 1396.6711. 
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Boc-linker 3 (163): 
A solution of 160 (30.0 mg, 72.3 µmol, 1.0 eq.) in DMF (0.4 mL) 
was added N-boc-N'-succinyl-4,7,10-trioxa-1,13-tridecanediamine 
(162, 32.0 mg, 72.3 µmol, 1.0 eq.), HBTU (30.2 mg, 79.5 µmol, 
1.1 eq.) and DIPEA (38 µL, 217 µmol, 3.0 eq.) and the mixture was 
stirred overnight at room temperature. The mixture was eluted 
through a small C18 SPE column using MeCN and evaporated. 
Separation by preparative reversed-phase HPLC gave 163 (41.5 mg, 74%) as a colorless solid. 
1H NMR (400 MHz, DMSO-d6) δ 8.03 (t, J = 5.6 Hz, 1H), 7.99 (t, J = 5.6 Hz, 1H), 7.79 (t, J = 
5.6 Hz, 1H), 6.76 (t, J = 5.7 Hz, 1H), 6.42 (s, 1H), 6.36 (s, 1H), 4.34–4.26 (m, 1H), 4.16–4.08 
(m, 0H), 3.54–3.43 (m, 8H), 3.37 (td, J = 6.4, 3.1 Hz, 4H), 3.34–3.26 (m, 3H), 3.14–3.01 (m, 
3H), 2.95 (q, J = 6.8 Hz, 2H), 2.82 (dd, J = 12.4, 5.1 Hz, 1H), 2.75 (td, J = 6.7, 4.1 Hz, 4H), 
2.57 (d, J = 12.4 Hz, 1H), 2.33–2.23 (m, 4H), 2.06 (t, J = 7.4 Hz, 2H), 1.71–1.14 (m, 12H), 1.37 
(s, 9H); 13C NMR (101 MHz, DMSO-d6) δ 172.20, 171.52, 171.12, 162.70, 155.55, 77.39, 
69.76 (2C), 69.54 (2C), 68.08, 68.06 (2C), 61.03, 59.19, 55.41, 37.98, 37.88, 37.31, 37.22, 
35.79, 35.14, 30.78, 30.74, 29.72, 29.37, 28.26 (3C), 28.18, 28.03, 25.23; HRMS (ESI) calcd. 
for C33H60N6NaO9S3
+ [M+Na]+: 803.3476, found: 803.3486. 
 
Linker 3 (164): 
A solution of 163 (22.0 mg 28.2 µmol) in MeOH (1.0 mL) was added 
a solution of HCl in dioxane (4 M, 1.0 mL) and the mixture was stirred 
at room temperature for 2 h. The mixture was concentrated under 
reduced pressure and the residue eluted through a small C18 SPE 
column using 60% aq. MeCN and evaporated to yield crude 
hydrochloride 164 (13.0 mg, 64%) as a colorless solid, which was 
used without further purification. 
HRMS (ESI) calcd. for C28H53N6O7S3
+ [M+H]+: 681.3132, found: 681.3137. 
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Probe 3 (165): 
To a solution of rapamycin hemi-
succinate (150, 18.4 mg, 18.1 µmol, 
1.0 eq.) in DMF (0.2 mL) was added 
amine 164 (13.0 mg, 18.1 µmol, 
1.0 eq.), HBTU (8.24 mg, 21.7 µmol, 
1.2 eq.) and DIPEA (11 µL, 63.4 µmol, 
3.5 eq.) and the mixture was stirred 
overnight at room temperature. The 
mixture was eluted through a small C18 SPE column using MeCN and evaporated. Separation 
by preparative reversed-phase HPLC gave 165 (13.0 mg, 43%) as a colorless solid. 
HRMS (ESI) calcd. for C83H133N7NaO22S3
+ [M+Na]+: 1698.8558, found: 1698.8570. 
 
Boc-protected amino rapamycin 166: 
To a solution of rapamycin hemisuccinate (150, 30.4 mg, 
30.0 µmol, 1.0 eq.) in DMF (0.2 mL) amine 153 
(9.73 mg, 45.0 µmol, 1.5 eq.), HBTU (17.1 mg, 
45.0 µmol, 1.5 eq.) and DIPEA (9.69 mg, 75.0 µmol, 
2.5 eq.) were added and the resulting mixture was stirred 
overnight at room temperature. The mixture was 
subjected to flash chromatography (CH2Cl2/MeOH, 
30:1) to afford 166 (34.5 mg, 95%) as an off-white foam. 
Rf = 0.4 (CH2Cl2/MeOH, 20:1); HRMS (ESI) calcd. for C66H105N3NaO17
+ [M+Na]+: 
1234.7336, found: 1234.7330. 
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Azido rapamycin 169: 
A solution of rapamycin hemisuccinate (155, 17.0 mg, 
16.8 µmol, 1.0 eq.) in DMF (0.4 mL) was added 
5-azidopentan-1-amine (168, 3.01 mg, 23.5 µmol, 
1.4 eq.), HBTU (9.56 mg, 25.2 µmol, 1.5 eq.) and 
DIPEA (5.43 mg, 42.0 µmol, 2.5 eq.) and the mixture 
was stirred overnight at room temperature. The mixture 
was poured into sat. aq. NaHCO3 and extracted with 
CH2Cl2. The combined organic layers were washed with 
water, dried over Na2SO4 and evaporated. The residue was subjected to flash chromatography 
(CH2Cl2/MeOH, 20:1) to afford azide 169 (16.5 mg, 87%) as a colorless foam. 
Rf = 0.4 (CH2Cl2/MeOH, 20:1); HRMS (ESI) calcd. for C60H93N5NaO15
+ [M+Na]+: 1146.6560, 
found: 1146.6553. 
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6.5 Securinega Alkaloids 
 
Nitrosobenzene (309): 
A solution of sodium tungstate (2.02 g, 6.12 mmol, 0.01 eq.) in aqueous hydrogen 
peroxide (30%, 40 mL) was cooled to 15–19 °C in an ice bath. Aniline (308, 40.8 g, 
40.0 mL, 438 mmol, 1.0 eq) was added over 2 h at a constant flow rate of 0.33 mL/min 
using a syringe pump. During the reaction, three more portions of hydrogen peroxide (10.0 mL 
each) were added. The brown precipitate that had formed was filtered off and stirred in 300 mL 
water for 15 min. The solid was filtered again and washed with water and cold ethanol. The 
solid was recrystallized from ethanol to obtain colorless crystals of 309 (18.4 g, 39%). 
1H NMR (250 MHz, CDCl3) δ 7.94–7.85 (m, 2H), 7.76–7.66 (m, 1H), 7.66–7.57 (m, 2H); 
13C NMR (101 MHz, CDCl3) δ 165.93, 135.68, 129.39, 121.02; M.p.: 65–67 °C. 
Analytical data are in agreement with the literature: S. M. Opalka, A. R. Longstreet, D. T. 
McQuade, Beilstein J. Org. Chem. 2011, 7, 1671–1679. 
 
(S)-7-Anilinoxy-1,4-dioxaspiro[4.5]decan-8-one (310): 
A solution of 309 (9.00 g, 84.0 mmol, 1.1 eq.) in DMF (100 mL) was added to 
a solution of 1,4-dioxaspiro[4.5]decan-8-one (307, 11.9 g, 76.4 mmol, 1.0 eq.) 
and D-proline (0.880 g, 7.64 mmol, 0.1 eq.) in DMF (150 mL) using a syringe 
pump over 26 h at 0 °C. Then the mixture was stirred for another 30 min at room 
temperature and quenched with pH 7 phosphate buffer solution. The mixture diluted with 
EtOAc and brine. Layers were separated and the aqueous layer was extracted with EtOAc. The 
combined organic layers were washed with brine, dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. The residue was purified by flash chromatography 
(pentane/EtOAc, 4:1–0:1) to obtain 310 as a yellow solid (15.2 g, 76%). 
[α]D25 = −45.1 (c = 0.48 in CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.22–7.12 (m, 2H), 6.92–
6.78 (m, 3H), 4.57 (dd, J = 12.9, 6.5 Hz, 1H), 4.16–3.77 (m, 4H), 2.68–2.52 (m, 1H), 2.48–2.26 
(m, 2H), 2.12 (t, J = 12.8 Hz, 1H), 2.02–1.79 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 208.87, 
148.11, 128.99, 122.26, 114.60, 107.70, 82.82, 65.00, 64.93, 39.78, 36.12, 34.49; M.p.: 60–64 
°C. 
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Analytical data are in agreement with the literature: M. Matsuzawa, H. Kakeya, J. Yamaguchi, 
M. Shoji, R. Onose, H. Osada, Y. Hayashi, Chem. Asian J. 2006, 1, 845–851. 
 
(7S,8R)-7-((Phenylamino)oxy)-1,4-dioxaspiro[4.5]decan-8-ol (S311): 
A solution of K-selectride (1 M in THF, 49.4 mL, 49.4 mmol, 2.0 eq.) was added 
to a solution of 310 (6.50 g, 24.7 mmol, 1.0 eq.) in THF (177 mL) at −78 °C and 
the reaction temperature was increased to −50 °C over 1.5 h. Sodium perborate 
tetrahydrate (12.2 g, 124 mmol, 5.0 eq.) and water (30 mL) were added and the 
reaction mixture was stirred for 30 min at room temperature. The organic layer was separated 
and the aqueous layer was extracted with Et2O. The combined organic layers were washed with 
brine, dried over Na2SO4 and the solvent was evaporated to obtain crude S311 (9.60 g) as a 
brown oil, which was used without further purification. 
 
(7S,8R)-1,4-Dioxaspiro[4.5]decane-7,8-diol (311): 
Crude S311 (1.00 g) was dissolved in methanol (8.3 mL) under argon atmosphere. 
Pd/C (10 wt% Pd, 7.4 mg, 69.4 µmol) was added. The reaction mixture was stirred 
under an H2 atmosphere (1 bar) at room temperature overnight. The mixture was 
filtered through diatomaceous earth and the solvent was evaporated. The residue 
was purified by flash chromatography (pentane/EtOAc, 3:1–1:3) to obtain 311 (425 mg, 72% 
over two steps) as a dark-red oil. 
[α]D25 = +4.4 (c = 0.39 in CHCl3); 1H NMR (250 MHz, CDCl3) δ 4.04–3.84 (m, 4H), 3.76–
3.57 (m, 1H), 2.68 (s, 2H), 2.05–1.89 (m, 1H), 1.88–1.68 (m, 4H), 1.63–1.47 (m, 1H); 
13C NMR (63 MHz, CDCl3) δ 108.75, 70.40, 69.71, 64.36, 63.79, 37.92, 31.03, 26.86. 
Analytical data are in agreement with the literature: M. Matsuzawa, H. Kakeya, J. Yamaguchi, 
M. Shoji, R. Onose, H. Osada, Y. Hayashi, Chem. Asian J. 2006, 1, 845–851. 
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(R)-4-Hydroxycyclohex-2-en-1-one (306): 
Amberlyst 15 (40.0 mg, 20 wt%, previously washed with THF) was added to a solution 
of 311 (200 mg, 1.05 mmol, 1.0 eq.) in THF (165 mL), H2O (16.5 mL) and acetone 
(16.5 mL), and the reaction mixture was stirred at 80 °C for 21 h. Amberlyst 15 was 
filtered off and washed with acetone. The filtrate was dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. The crude product was purified by flash chromatography 
(pentane/EtOAc, 1:4) to obtain 306 (103 mg, 68%) as a brown oil. 
[α]D25 = +108.1 (c = 0.26 in CHCl3); 1H NMR (250 MHz, CDCl3) δ 6.93 (ddd, J = 10.2, 2.4, 
1.6 Hz, 1H), 5.97 (ddd, J = 10.2, 2.0, 1.0 Hz, 1H), 4.64–4.52 (m, 1H), 2.65–2.51 (m, 1H), 2.46–
2.28 (m, 2H), 2.15 (s, 1H), 2.07–1.91 (m, 1H); 13C NMR (63 MHz, CDCl3) δ 198.88, 152.81, 
129.41, 66.51, 35.48, 32.63. 
Analytical data are in agreement with the literature: M. Matsuzawa, H. Kakeya, J. Yamaguchi, 
M. Shoji, R. Onose, H. Osada, Y. Hayashi, Chem. Asian J. 2006, 1, 845–851. 
 
(R)-4-((tert-Butyldiphenylsilyl)oxy)cyclohex-2-en-1-one (312): 
To a solution of 306 (1.49 g, 13.3 mmol, 1.0 eq.) in CH2Cl2 (135 mL), imidazole 
(924 mg, 13.6 mmol, 1.02 eq.) and DMAP (162 mg, 1.33 mmol, 0.1 eq.) were added 
at 0 °C. TBDPSCl (3.52 mL, 3.73 g, 13.6 mmol, 1.02 eq.) was added dropwise at 
0 °C and the resulting mixture was stirred at room temperature for 2.5 h. The mixture was 
quenched with sat. aq. NH4Cl, extracted with CH2Cl2 and the combined organic layers were 
dried over Na2SO4. The solvent was evaporated under reduced pressure. The crude product was 
purified by flash chromatography (pentane/EtOAc, 10:1–5:1) to obtain 312 (4.38 g, 94%) as a 
colorless oil. 
Rf = 0.1 (pentane/EtOAc, 10:1); [α]D25 = +63.7 (c = 0.12 in CHCl3); FTIR (neat): 𝜈 = 3070, 
2957, 2857, 1686, 1589, 1427, 1383, 1348, 1250, 1104, 987, 843 cm−1; 1H NMR (400 MHz, 
CDCl3) δ 7.67–7.56 (m, 4H), 7.45–7.26 (m, 6H), 6.71 (ddd, J = 10.3, 2.5, 1.2 Hz, 1H), 5.79 
(ddd, J = 10.3, 1.8, 1.0 Hz, 1H), 4.48–4.36 (m, 1H), 2.52–2.38 (m, 1H), 2.20–2.05 (m, 1H), 
2.05–1.91 (m, 2H), 1.01 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 199.05, 153.36, 135.89, 
135.87, 133.55, 133.52, 130.15, 130.13, 128.88, 127.98, 127.94, 67.71, 35.47, 32.73, 27.01, 
19.29; HRMS (ESI) calcd. for C22H29O2Si
+ [M+Na]+: 351.1775, found: 351.1776. 
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(4R,6R)-4-((tert-Butyldiphenylsilyl)oxy)-6-hydroxycyclohex-2-en-1-one (314): 
To a solution of 312 (380 mg, 1.08 mmol, 1.0 eq.) and Davis' oxaziridine 318 
(339 mg, 1.30 mmol, 1.2 eq.) in THF (5.6 mL) at −78 °C a solution of NaHMDS 
(1 M in THF, 1.3 mL, 1.30 mmol, 1.2 eq.) was added and the resulting yellow 
mixture was stirred at −78 °C for 1 h. The reaction mixture was quenched with sat. aq. NH4Cl 
and allowed to warm to room temperature. More sat. aq. NH4Cl was added and the mixture 
extracted with Et2O. The combined organic layers were thoroughly washed with 10% aq. 
NaHSO3, dried over Na2SO4 and evaporated under reduced pressure to give crude alcohol 314 
(524 mg) as a yellowish oil, which was used without further purification. 
Rf = 0.4 (pentane/Et2O, 3:1); 1H NMR (400 MHz, CDCl3) δ 7.72–7.62 (m, 4H), 7.51–7.35 (m, 
6H), 6.54 (ddd, J = 9.9, 5.2, 1.8 Hz, 1H), 5.98 (d, J = 9.9 Hz, 1H), 4.82 (dd, J = 12.3, 5.3 Hz, 
1H), 4.47 (ddd, J = 5.2, 3.8, 2.4 Hz, 1H), 3.39 (br s, 1H), 2.51 (ddt, J = 13.3, 5.4, 2.1 Hz, 1H), 
1.89 (ddd, J = 13.2, 12.3, 3.8 Hz, 1H), 1.08 (s, 9H); HRMS (ESI) Exact mass calcd. for 
C22H26NaO3Si
+ [M+Na]+: 389.1549, found: 389.1543. 
 
(6R,7aR)-6-((tert-Butyldiphenylsilyl)oxy)-7,7a-dihydrobenzofuran-2(6H)-one (288): 
The Bestmann ylide (323, 53.4 mg, 0.177 mmol, 1.3 eq.) was added to a solution 
of α-hydroxy ketone 314 (49.8 mg, 0.136 mmol, 1.0 eq.) in benzene (3.0 mL) 
and the mixture was heated to 85 °C for 3 h in a microwave reactor. The mixture 
was diluted with Et2O, washed with water, dried over Na2SO4 and solvents were 
removed under reduced pressure. The residue was purified by flash chromatography 
(pentane/Et2O, 10:1–3:1, 1% Et3N) to afford a diastereomeric mixture of the bicyclic product 
288 (17.0 mg, 43.5 μmol, 43% over two steps; d.r. = 3.3:1, calculated by NMR) as a yellow oil. 
Rf = 0.4 (pentane/Et2O, 3:1); FTIR (neat): 𝜈 = 3728, 3630, 2928, 2857, 1762, 1111, 1069, 
703 cm−1; 1H NMR (400 MHz, CDCl3, major isomer) δ 7.70–7.64 (m, 4H), 7.45–7.37 (m, 6H), 
6.48 (d, J = 9.6 Hz, 1H), 5.96 (ddd, J = 9.7, 5.2, 1.0 Hz, 1H), 5.78 (s, 1H), 5.46 (ddd, J = 12.5, 
5.0, 1.9 Hz, 1H), 4.50 (ddd, J = 5.6, 3.7, 2.2 Hz, 1H), 2.55 (dddt, J = 12.5, 5.0, 2.2, 1.0 Hz, 1H), 
1.61 (td, J = 12.5, 3.8 Hz, 1H), 1.08 (s, 9H); 13C NMR (101 MHz, CDCl3, major isomer) δ 
173.47, 163.15, 144.40, 135.86, 135.83, 133.55, 133.03, 130.29, 130.17, 128.08, 127.93, 
121.18, 112.29, 76.80, 65.82, 37.83, 27.01, 19.33. 
Analytical data are in agreement with the literature: H. Miyatake-Ondozabal, L. M. Bannwart, 
K. Gademann, Chem. Commun. 2013, 49, 1921–1923. 
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tert-Butyl (S)-2-((6R,7aS)-6-((tert-butyldiphenylsilyl)oxy)-2-oxo-6,7-dihydro-benzofuran-
7a(2H)- yl)piperidine-1-carboxylate (275): 
To a solution of the bicyclic compound 288 (139 mg, 0.356 mmol, 1.0 eq.) in 
Et2O (3.4 mL) at 0 °C, Et3N (0.10 mL, 0.712 mmol, 2.0 eq.) was added and the 
reaction mixture was stirred at 0 °C for 45 min. TIPSOTf (0.11 mL, 0.409 mmol, 
1.15 eq.) was added, and the reaction mixture stirred overnight at room 
temperature. A solution of tert-butyl 2-hydroxypiperidine-1-carboxylate (274, 161 mg, 
0.801 mmol, 2.25 eq.) in Et2O (3.4 mL) was added and the mixture was cooled to −78 °C. Then, 
n-Bu2BOTf (0.28 mL, 0.801 mmol, 2.25 eq.) was added dropwise during 5 min, and the mixture 
stirred at −78 °C for 5 min. The mixture was quenched with sat. aq. NH4Cl, allowed to warm 
to room temperature and extracted with Et2O. The combined organic layers were dried over 
Na2SO4 and the solvent was removed under reduced pressure. The crude material was purified 
by repeated flash chromatography (pentane/EtOAc, 6:1) to afford two diastereomers of 275 
((−)-275, 140 mg, 69%; (+)-275, 33 mg, 16%) as colorless oils. As previously reported in the 
literature, each isomer showed two sets of signals in the NMR spectra corresponding to 
rotamers. 
(−)-275: Rf = 0.15 (pentane/EtOAc, 10:1); [α]D25 = −59.4 (c = 1.0 in CHCl3); 1H NMR 
(400 MHz, CDCl3, major rotamer) δ 7.73–7.60 (m, 4H), 7.51–7.34 (m, 6H), 6.51 (dd, J = 10.0, 
2.2 Hz, 1H), 6.24 (dt, J = 10.0, 1.6 Hz, 1H), 5.63 (s, 1H), 4.47–4.39 (m, 1H), 3.87–3.80 (m, 
1H), 3.74 (dd, J = 14.2, 5.7 Hz, 1H), 2.92 (td, J = 13.3, 4.7 Hz, 1H), 2.39 (dd, J = 12.1, 5.3 Hz, 
1H), 1.80 (dd, J = 12.3, 10.3 Hz, 1H), 1.66–0.80 (m, 6H), 1.31 (s, 9H), 1.07 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ 172.48, 166.11, 155.61, 139.86, 136.00, 135.95, 133.41, 133.03, 130.22, 
128.07, 128.04, 121.81, 111.11, 89.69, 79.75, 67.21, 52.40, 41.60, 40.87, 28.26, 27.04, 23.74, 
23.34, 19.24, 18.62. 
Analytical data are in agreement with the literature: G. G. Bardají, M. Cantó, R. Alibés, P. 
Bayón, F. Busqué, P. de March, M. Figueredo, J. Font, J. Org. Chem. 2008, 73, 7657–7662. 
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(S)-2-((6R,7aS)-6-((tert-Butyldiphenylsilyl)oxy)-2-oxo-6,7-dihydrobenzofuran-7a(2H)-
yl)piperidin-1- ium chloride (325): 
Protected amine (−)-275 (72.0 mg, 0.125 mmol, 1.0 eq.) was dissolved in 2 M 
HCl in Et2O (5.0 mL) and stirred in a microwave reactor at 45 °C for 10 h. The 
reaction mixture was diluted with CH2Cl2 and filtered. Solvents were removed 
under reduced pressure giving hydrochloride 325 (62.0 mg, 97%) as a colorless 
solid. 
Rf = 0.0 (pentane/EtOAc, 2:1); M.p. = 179–181 °C (dec.); [α]D25 = −56.2 (c = 0.10 in CHCl3); 
FTIR (neat): 𝜈 = 3376, 3050, 2932, 2858, 1753, 1640, 1428, 1112, 1084, 1064, 1003, 849, 
703 cm−1; 1H NMR (400 MHz, CD3OD) δ 7.78–7.68 (m, 4H), 7.58–7.38 (m, 6H), 6.69 (dd, J = 
10.2, 2.2 Hz, 1H), 6.46 (d, J = 10.2 Hz, 1H), 6.07 (s, 1H), 4.48 (dq, J = 7.8, 2.7 Hz, 1H), 3.25–
3.07 (m, 2H), 2.85 (td, J = 13.4, 3.1 Hz, 1H), 2.37 (dd, J = 12.6, 5.0 Hz, 1H), 1.82–1.67 (m, 
3H), 1.59–1.44 (m, 1H), 1.41–1.16 (m, 4H), 1.09 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 
171.48, 164.41, 143.86, 137.14, 137.01, 134.13, 133.95, 131.54, 131.45, 129.19, 129.15, 
120.89, 114.97, 86.22, 68.16, 58.00, 47.05, 42.52, 27.34, 24.46, 22.95, 22.80, 19.84. HRMS 
(ESI) Exact mass calcd. for C29H36NO3Si
+ [M−Cl]+: 474.2459, found: 474.2465. 
 
(5R,10aS,12R)-12-((tert-Butyldiphenylsilyl)oxy)-4,5,8,9,10,10a-hexahydro-2H,7H-5,10b- 
ethanofuro[2,3-a]quinolizin-2-one (326): 
Hydrochloride 325 (92.8 mg, 0.182 mmol, 1.0 eq.) was dissolved in DMF 
(10 mL) and K2CO3 (126 mg, 0.910 mmol, 5.0 eq.) was added. The reaction 
mixture was heated to 75 °C and stirred for 3 h. Water was added and the 
mixture was extracted with EtOAc. The combined organic layers were 
washed with sat. aq. NaHCO3 and water, dried over Na2SO4 and the solvent was removed under 
reduced pressure. The residue was purified by flash chromatography (pentane/Et2O, 4:1) to 
yield tetracycle 326 (69.5 mg, 81%) as a colorless semisolid. 
Rf = 0.4 (pentane/Et2O, 4:1); [α]D25 = −48.8 (c = 0.10 in CHCl3); FTIR (neat): 𝜈 = 3072, 2932, 
2856, 1762, 1653, 1428, 1113, 1059, 1013, 840, 702 cm−1; 1H NMR (400 MHz, C6D6) δ 7.68–
7.54 (m, 4H), 7.26–7.17 (m, 6H), 5.42 (t, J = 1.8 Hz, 1H), 4.05 (dddd, J = 9.4, 4.7, 3.0, 1.5 Hz, 
1H), 2.77 (dt, J = 18.8, 2.2 Hz, 1H), 2.41–2.24 (m, 3H), 2.18–2.07 (m, 2H), 1.92 (td, J = 11.1, 
3.0 Hz, 1H), 1.50 (dd, J = 12.3, 4.8 Hz, 1H), 1.45 (d, J = 9.0 Hz, 2H), 1.43–0.98 (m, 4H), 1.10 
(s, 9H), 0.92–0.80 (m, 1H), 0.78–0.65 (m, 1H); 13C NMR (101 MHz, C6D6) δ 172.79, 172.52, 
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136.03, 135.99, 134.04, 133.76, 130.39, 130.33, 128.59, 112.07, 83.51, 66.55, 65.28, 59.17, 
52.35, 41.81, 29.31, 27.07, 26.90, 25.95, 24.24, 19.13; HRMS (ESI) Exact mass calcd. for 
C29H36NO3Si
+ [M+H]+: 474.2459, found: 474.2453. 
 
Secu’amamine E (296): 
In a centrifuge tube (polypropylene) silyl ether 326 (32.0 mg, 67.6 µmol, 1.0 eq.) 
was dissolved in THF (3.0 mL) and HF·pyridine (200 µL, excess) was added 
dropwise. The yellow mixture was stirred at room temperature for 24 h. The 
mixture was carefully quenched with sat. aq. NaHCO3 and extracted with EtOAc. 
The combined organic layers were washed with water, dried over Na2SO4 and the solvent was 
removed under reduced pressure. The residue was separated by flash chromatography 
(CH2Cl2/MeOH, 30:1) giving 296 (15.6 mg, 98%) as a colorless oil. 
Rf = 0.2 (CH2Cl2/MeOH, 30:1); [α]D25 = −45.7 (c = 0.10 in MeOH); FTIR (neat): 𝜈 = 3446, 
2936, 2852, 1756, 1737, 1651, 1150, 1000 cm−1; 1H NMR (500 MHz, CD3OD) δ 5.74 (t, J = 
1.9 Hz, 1H), 4.42–4.20 (m, 1H), 3.05–2.91 (m, 2H), 2.90–2.86 (m, 1H), 2.84–2.72 (m, 3H), 
2.67 (dd, J = 12.2, 9.6 Hz, 2H), 1.86–1.76 (m, 1H), 1.61–1.54 (m, 1H), 1.54–1.46 (m, 2H), 1.38 
(dd, J = 12.2, 4.9 Hz, 1H), 1.39–1.28 (m, 1H), 0.87 (qd, J = 11.8, 4.0 Hz, 1H); 13C NMR 
(101 MHz, CD3OD) δ 177.20, 176.25, 111.99, 86.23, 66.46, 65.30, 60.33, 53.51, 41.50, 30.28, 
27.66, 26.75, 25.07; HRMS (ESI) Exact mass calcd. for C13H18NO3
+ [M+H]+: 236.12812, 
found: 236.12750. 
Analytical data are in agreement with those reported for the authentic natural product: A. 
Ohsaki, T. Nagaoka, K. Yoneda, A. Kishida, Tetrahedron Lett. 2009, 50, 6965–6967. 
 
General Procedure 1 (GP1): 
Alkaloid (1.0 eq.) was dissolved in CH2Cl2 (30–40 mm). Et3N (2.0 eq.), DMAP (2.0 eq.) and 
MsCl (1.8 eq.) were added in this sequence and the mixture was stirred at rt. After 15 min 
volatiles were evaporated under high vacuum without heating. The residue was subjected to 
flash chromatography. 
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Allosecurinine (172): 
Secu'amamine E (296, 5 mg, 21.3 µmol) was reacted according to GP1 giving 172 
(4.3 mg, 93%) as a yellow semisolid. 
Rf = 0.5 (CH2Cl2/MeOH, 10:1); [α]D25 = −487.0 (c = 0.10 in EtOH); 1H NMR 
(300 MHz, CDCl3) δ 6.81 (dd, J = 9.1, 5.3 Hz, 1H), 6.65 (dd, J = 9.1, 1.1 Hz, 1H), 5.73 (s, 1H), 
3.92 (t, J = 4.9 Hz, 1H), 3.67 (dd, J = 13.1, 3.4 Hz, 1H), 2.81–2.72 (m, 2H), 2.69 (dd, J = 9.9, 
4.4 Hz, 1H), 1.92 (d, J = 9.8 Hz, 1H), 1.76–1.61 (m, 3H), 1.52–1.05 (m, 3H); 13C NMR 
(101 MHz, CDCl3) δ 172.72, 167.48, 148.44, 122.97, 109.31, 91.78, 60.89, 58.98, 43.78, 42.75, 
22.19, 21.20, 18.55. 
Analytical data are in agreement with the literature: A. B. Leduc, M. A. Kerr, Angew. Chem. 
Int. Ed. 2008, 47, 7945–7948. 
 
(−)-Allonorsecurinine (329): 
Bubbialidine (292, 4.0 mg, 18.1 µmol) was reacted according to GP1 giving 329 
(2.3 mg, 63%) as a yellow semisolid. 
Rf = 0.4 (CH2Cl2/MeOH, 10:1); [α]D25 = −618.6 (c = 0.10 in EtOH); 1H NMR 
(400 MHz, CDCl3) δ 6.85 (dd, J = 9.1, 5.4 Hz, 1H), 6.71 (dd, J = 9.1, 1.1 Hz, 1H), 5.79 (s, 1H), 
4.16 (t, J = 7.4 Hz, 1H), 3.99 (t, J = 4.8 Hz, 1H), 2.96–2.81 (m, 3H), 2.03 (d, J = 10.0 Hz, 1H), 
1.95–1.72 (m, 2H), 1.72–1.61 (m, 1H), 1.33–1.20 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 
172.34, 166.99, 148.92, 124.09, 110.20, 90.80, 69.18, 57.89, 49.39, 46.95, 27.94, 25.52. 
Analytical data are in agreement with the literature: A. S. Reddy, P. Srihari, Tetrahedron Lett. 
2012, 53, 5926–5928. 
 
Bubbialine mesylate (330): 
Bubbialine (327, 10.5 mg, 47.5 µmol) was reacted according to GP1 giving 330 
(14.0 mg, 99%) as a pale yellow solid. 
Rf = 0.3 (CH2Cl2/MeOH, 30:1); [α]D25 = +141.3 (c = 0.10 in CHCl3); FTIR 
(neat): 𝜈 = 2931, 2844, 1765, 1657, 1366, 1169, 967, 952, 899, 848, 532, 498 cm−1; 1H NMR 
(400 MHz, CDCl3) δ 5.85 (t, J = 2.1 Hz, 1H), 5.02 (ddd, J = 10.1, 3.5, 2.8 Hz, 1H), 3.74 (dd, 
J = 9.4, 6.3 Hz, 1H), 3.52 (p, J = 1.8 Hz, 1H), 3.21 (ddd, J = 20.2, 3.6, 2.0 Hz, 1H), 3.15–3.09 
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(m, 1H), 3.13 (s, 3H), 2.68 (td, J = 9.3, 7.6 Hz, 1H), 2.44 (dt, J = 20.2, 1.8 Hz, 1H), 2.37 (dd, 
J = 13.7, 3.5 Hz, 1H), 2.23 (dd, J = 13.7, 10.1 Hz, 1H), 1.91–1.74 (m, 3H), 1.16–1.03 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 172.73, 168.29, 114.39, 83.54, 75.89, 63.70, 54.34, 51.13, 
39.35, 37.66, 27.29, 24.64, 24.24; HRMS (ESI) Exact mass calcd. for C13H18NO5S [M+H]
+: 
300.09002, found: 300.08945. 
 
(+)-Allonorsecurinine (331): 
Mesylate 330 (9.0 mg, 30.1 µmol, 1.0 eq.) was dissolved in CH2Cl2 (0.8 mL) and 
Et3N (6 µL, 42.1 µmol, 1.4 eq.) was added. The mixture was heated to 100 °C for 
6 h in a microwave reactor. Volatiles were removed under high vacuum and the 
residue was subjected to flash chromatography and preparative TLC (CH2Cl2/MeOH, 20:1, 1% 
Et3N) to obtain 331 (1.3 mg, 6.40 µmol, 21%) of moderate purity as an orange oil. 
Rf = 0.2 (CH2Cl2/MeOH, 20:1); [α]D25 = +365.6 (c = 0.064 in EtOH); 1H NMR (500 MHz, 
CDCl3) δ 6.81 (dd, J = 9.0, 5.4 Hz, 1H), 6.75 (d, J = 9.0 Hz, 1H), 5.83 (s, 1H), 4.27–4.22 (m, 
1H), 4.09 (s, 1H), 3.08–2.93 (m, 2H), 2.87 (dt, J = 10.5, 7.4 Hz, 1H), 2.07 (d, J = 10.2 Hz, 1H), 
1.96–1.79 (m, 2H), 1.77–1.67 (m, 1H), 1.37–1.16 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 
172.17, 166.90, 148.74, 124.14, 110.33, 90.81, 69.22, 57.96, 49.40, 46.97, 27.93, 25.56. 
Analytical data are in agreement with the literature: M. R. Medeiros, J. L. Wood, Tetrahedron 
2010, 66, 4701–4709. 
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7 Appendix 
NMR Spectra 
5-Ethyl-2,2-dimethylbenzo[d][1,3]dioxole (48) 
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5-Ethyl-2,2-dimethyl-6-nitrobenzo[d][1,3]dioxole (49) 
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2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propan-1-ol (50) 
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5-(1-(Benzyloxy)propan-2-yl)-2,2-dimethyl-6-nitrobenzo[d][1,3]dioxole (55) 
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4-(1-(Benzyloxy)propan-2-yl)-5-nitrobenzene-1,2-diol (56) 
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2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propanal (57) 
 
 
  
Appendix 
169 
N-Benzyl-2-(2,2-dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propan-1-amine (58) 
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4-(1-(Benzylamino)propan-2-yl)-5-nitrobenzene-1,2-diol (59) 
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5-(1-Bromopropan-2-yl)-2,2-dimethyl-6-nitrobenzo[d][1,3]dioxole (62) 
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Benzyl (2-(2,2-dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propyl)carbonate (65) 
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Benzyl (2-(4,5-dihydroxy-2-nitrophenyl)propyl) carbonate (66) 
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2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propyl benzylcarbamate (67) 
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2-(4,5-Dihydroxy-2-nitrophenyl)propyl benzylcarbamate (68) 
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2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propyl 2-phenylacetate (69) 
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2-(2,2-Dimethyl-6-nitrobenzo[d][1,3]dioxol-5-yl)propyl 2,2-diphenylacetate (71) 
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2-(4,5-Dihydroxy-2-nitrophenyl)propyl 2,2-diphenylacetate (72) 
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5-Bromo-6-ethyl-2,2-dimethylbenzo[d][1,3]dioxole (86) 
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Methyl 2-(6-chloro-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetate (97) 
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Methyl 2-(6-bromo-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetate (98) 
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Methyl 2-(6-iodo-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetate (99) 
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Methyl 2-(2,2-dimethyl-6-(trifluoromethyl)benzo[d][1,3]dioxol-5-yl)acetate (100) 
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Methyl 2-(2,2-dimethyl-6-(methylsulfonyl)benzo[d][1,3]dioxol-5-yl)acetate (101) 
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2-(6-Chloro-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetic acid (102) 
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2-(6-Bromo-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetic acid (103) 
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2-(6-Iodo-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)acetic acid (104) 
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2-(2,2-Dimethyl-6-(trifluoromethyl)benzo[d][1,3]dioxol-5-yl)acetic acid (105) 
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2-(2,2-Dimethyl-6-(methylsulfonyl)benzo[d][1,3]dioxol-5-yl)acetic acid (106) 
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Methyl 2-(2-bromo-4,5-dihydroxyphenyl)acetate (108) 
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Methyl 2-(4,5-dihydroxy-2-iodophenyl)acetate (109) 
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Methyl 2-(4,5-dihydroxy-2-(trifluoromethyl)phenyl)acetate (110) 
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Methyl 2-(4,5-dihydroxy-2-(methylsulfonyl)phenyl)acetate (111) 
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2,2-Dimethylnaphtho[1,8-de][1,3]dioxine (137) 
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2,2-Dimethyl-6,7-dinitronaphtho[1,8-de][1,3]dioxine (138) 
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1-(2,2-Dimethylnaphtho[1,8-de][1,3]dioxin-6-yl)ethan-1-one (139) 
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1-(2,2-Dimethyl-7-nitronaphtho[1,8-de][1,3]dioxin-6-yl)ethan-1-one (140) 
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tert-Butyl (6-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)¬pentan-
amido)¬hexyl) carbamate (154) 
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N-Biotinyl-1,6-hexanediamine (155) 
 
N-Biotinyl-N’-Boc-cystamine (159) 
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Cystaminyl biotinate hydrochloride (160) 
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tert-Butyl (15,18,27-trioxo-31-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)-4,7,10-trioxa-22,23-dithia-14,19,26-triazahentriacontyl)carbamate (163) 
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(R)-4-((tert-Butyldiphenylsilyl)oxy)cyclohex-2-en-1-one (312) 
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(6R,7aR)-6-((tert-Butyldiphenylsilyl)oxy)-7,7a-dihydrobenzofuran-2(6H)-one (288) 
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tert-Butyl (S)-2-((6R,7aS)-6-((tert-butyldiphenylsilyl)oxy)-2-oxo-6,7-dihydro-benzofuran-
7a(2H)- yl)piperidine-1-carboxylate (275) 
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(S)-2-((6R,7aS)-6-((tert-Butyldiphenylsilyl)oxy)-2-oxo-6,7-dihydrobenzofuran-7a(2H)-
yl)piperidin-1- ium chloride (325) 
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(5R,10aS,12R)-12-((tert-Butyldiphenylsilyl)oxy)-4,5,8,9,10,10a-hexahydro-2H,7H-5,10b-
ethanofuro[2,3-a]quinolizin-2-one (326) 
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Secu’amamine E (296) 
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Allosecurinine (172) 
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(−)-Allonorsecurinine (329) 
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Bubbialine mesylate (330) 
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(+)-Allonorsecurinine (331) 
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